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ABSTRACT 
 
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that is universally 
fatal.  The only drug that is currently FDA approved for the treatment of ALS is Riluzole 
(Figure 1), which improves life expectancy by a few months via an unknown mechanism. 
 
Figure 1: Riluzole 
 
This thesis describes the preparation of novel Riluzole analogues with the overall aim of 
improving neuroprotective activity against ALS.  Two libraries are reported based respectively 
on the incorporation of tetrahydropyridine and 1,4-substituted-1,2,3-triazole functionality to the 
benzothiazole ring.  Both of these functional groups have been reported in pharmaceutically 
active drugs either already on the market or in late clinical trials related to the treatment 
towards motor neuron diseases.  Tetrahydropyridine analogues were synthesised in a five 
step process by the generation of a diamine intermediate, followed by reaction with Zincke 
salt, cyclisation and reduction (Scheme 1).   
 
Scheme 1: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 
1.0 equiv. N-(2,4-dinitrophenyl)pyridinium chloride, MeOH, RT - reflux, 20 h; (c) 1.0 equiv. Sodium p-
toluenesulfonate, EtOAc, reflux, 12 h, 78 % (over two steps); (d) 12.0 equiv. KSCN, 1.0 equiv. Br2, 
AcOH, RT, 16 h; (e) 2.8 equiv. NaBH4, MeOH, 0 °C - RT, 16 h, 69 % (over two steps) 
 
1,4-Substituted-1,2,3-triazole analogues were synthesised by reaction of a terminal alkyne 
with an azide Riluzole analogue with substoichiometric amounts of CuI (Scheme 2).  The 
azide analogue was generated by carrying out a diazotransfer reaction on the diamine 
intermediate followed by cyclisation with KSCN and Br2.    
 
Scheme 2: Reagents and conditions: (a) 1.0 equiv. Br(CH2)NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 1.2 
equiv. Imidazole-1-sulfonyl azide hydrochloride, 2.3 equiv. K2CO3, 0.001 equiv. CuSO4.5H2O, MeOH, 
RT, 2 h, 63 %; (c) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 2 h, 63 %; (d) 1.5 equiv. Terminal 
Alkyne, THF/H2O, 1M CuSO4, 1M NaAsc, 20 °C, 2 h, 35 - 98 % 
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CHAPTER 1: INTRODUCTION 
 
1.1 Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic Lateral Sclerosis (ALS) was first described in 1869.1  It is also referred to as ʻLou 
Gehrigʼs Diseaseʼ in memory of the baseball player who died from ALS in 1941.2 ALS along 
with other neurodegenerative diseases, including Alzheimerʼs, Parkinsonʼs and Huntingtonʼs 
Disease are caused by a combination of events impairing normal neuronal functions (Figure 
2).3,4   
Figure 2: Different factors associated with neurodegenerative disease (Reproduced with permission, 
from Sheikh (2013))
4 
 
ALS is the degeneration of motor neurons, which leads to respiratory failure after three to five 
years through a combination of muscle weakness and wasting of upper and lower voluntary 
muscles.5,6  The exact mechanism by which disease progresses manifests for ALS is not 
known: a number of theories, which have been put forth will be outlined below.  
 
(1) Autoimmune Considerations in ALS Patients 
Over the last two decades a number of autoimmune considerations have been proposed as 
the underlying cause of ALS.7  There is growing evidence that unusual antibodies may be 
present in a significant number of patients with motor neuron disease (MND) and ALS, which 
are indicative of a pathogenic humoral effect.
7,8  MND is a class of neurodegenerative disease 
which selectively affects upper and lower motor neurons.  The following five disorders are 
grouped under this classification: ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular 
CHAPTER 1: INTRODUCTION 
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Atrophy (PMA), Progressive Bulbar Palsy (PBP) and Pseudobulbar Palsy.  Conventional 
autoimmune symptoms/disorders, inflammation and/or antibodies are observed within 
affected cells, whereas in regards to ALS patients increased serum levels of antibodies are 
not recorded.  Instead an increase of antibodies is reported within the nerves.  It has been 
hypothesised that antibodies interact with the ganglioside-rich motor nerve terminals, which 
act as antigens, allowing antibodies to enter the motor neurons where they can then inflict 
damage.7 Additionally, the presence of IgG, a type of antibody in ALS motor neurons provides 
further evidence that these are autoimmune considerations to the pathenogenesis of the 
disease.  In ALS model systems IgG is found to enhance calcium currents, either by 
antibodies directly interacting with voltage-dependent calcium channels (VDCC) or by 
modifying calcium currents, which will both result in cell death due to increased cellular 
calcium levels.8  The higher concentrations of these antibodies leads to an increased number 
of T-cells, which leads to ALS patients generating T-cell-independent B-cell responses.  
These are generally harder to suppress than T-dependant responses, and could result in 
cellular degeneration without signs of inflammation. 
 
Identification of the auto-antigens involved will help elucidate the mechanism further and also 
help in the development of designing rational therapies for molecular targets.9 
 
(2) Excessive activation of Glutamate in ALS Patients 
ALS patients have been reported to have a three-fold higher concentration of cerebrospinal 
fluid (CSF), which can lead to cell death through excitotoxicity (Figure 3), which is an over 
activation of glutamate, aspartate, N-acetyl-aspartyl glutamate and N-acetylaspartate.1   
 
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and is 
responsible for cell communication.  Glutamate is synthesised from the reductive deamination 
of α-ketoglutarate by glutamate dehydrogenase and from the activation of amino-transferase 
on amino acids. Approximately 20 % of the glutamate pool is found in the presynaptic nerve 
terminal.1   
 
Neurotransmission is initiated by the presynaptic neuron being depolarised by the influx of 
Ca2+, which then causes glutamate to diffuse across the synaptic cleft and activate the post-
synaptic glutamatergic receptors.  Excitatory signals are terminated by the removal of 
glutamate from the synaptic cleft with the help of Na+-dependant glutamate transporters such 
as the excitatory amino acid transporter-2 (EAAT-2), which are present in astrocytic 
processes that envelop the synapse.10,11,12  These transporters are responsible for removing 
up to 94 % of glutamate from the synaptic cleft.1  Within the astrocytes, glutamate is 
converted to glutamine by glutamine synthetase and is subsequently returned to the neuron 
for glutamate re-synthesis. 
CHAPTER 1: INTRODUCTION 
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Therefore an excessive activation of glutamatergic receptors located on the post-synaptic 
neuron due to an increase in glutamate increases the concentration of Ca2+ in the post-
synaptic neuron.  This in turn causes the activation of degenerative enzymes, for example 
phospholipase A, proteases and nitric oxide synthase.12  An increase in Ca2+ also causes 
mitochondrial function to be altered, resulting in the production of free radicals and impairing 
the production of adenosine triphosphate (ATP).  Depletion of ATP combined with the 
production of nitric oxide and other free radical species results in the deactivation of the 
Na+/K+ pump, raising intracellular Na+ concentrations, and subsequently results in neuronal 
depolarisation.  The reverse operation of Na+/Ca2+ exchange required to normalise 
intracellular Na+ concentrations further increases Ca2+ uptake, elevating already high levels of 
Ca2+ and increasing the likelihood of cell death.   
Figure 3: The pathogenic process that triggers motor neuron degeneration in ALS patients (Reproduced 
with permission, from Pasinelli (2006))
 13
  
 
(3) Misfolding of Superoxide Dismutase Type-1 (SOD1) in ALS Patients 
Superoxide dismutase type-1 (SOD1), also known as Cu/Zn superoxide dismutase is a free 
radical scavenger.  Its function is the detoxification or dismutation of the superoxide anion to 
form hydrogen peroxide, which then in turn is converted to water through the action of 
catalase and glutathione peroxidase (Scheme 3).14  The activity of SOD1 plays a crucial role 
in the regulation of oxidative stress and in the protection against oxygen radical-induced 
cellular damage. 
CHAPTER 1: INTRODUCTION 
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Scheme 3: Conversion of superoxide anion to water 
14
  
 
Misfolding of SOD1 can arise from mutations in the gene.  The first mutations of SOD1 linked 
to ALS were reported in 1993.5  To date, 20 % of familial ALS (fALS) and 1 - 4 % of sporadic 
ALS (sALS) cases are likely to be caused by mutations in the SOD1 gene.5  The exact 
mechanism of how mutated SOD1 is linked to motor neuron death and ALS is unknown, but 
over the years a number of hypotheses have been proposed and investigated (Figure 4).   
 
Figure 4: Molecular mechanisms of motor neuron injury in ALS caused by mutated SOD1 (Reproduced 
with permission, from Ferraiuolo (2011)) 
15
 
 
Protein misfolding of the SOD1 gene has resulted in the formation of mutated SOD1 genes.  
Mutations in the SOD1 gene has resulted in the reduction of cellular activity due to diminished 
stability, reducing the proteins half-life by 30 - 75 %.14  Misfolded proteins cause an 
endoplasmic reticulum (ER) stress response (Figure 4) that attempts to correct the protein 
folding.  If this ER correction process is not successful it can result in cell death.  Mutations in 
the SOD1 gene can also lead to oxidative stress from an imbalance between the generation 
and removal of reactive oxygen species (ROS) as a result of the SOD1 gene being 
structurally damaged protein misfolding.  It has been reported that the CSF of people with 
O2-
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H2O2 H2O
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ALS have higher levels of free radicals, which can impair cellular ability to cope with a toxic 
insult in cellular injury and neuronal death in non-replicating neurons during aging.15,16 
Aggregates of mutant SOD1 found in the neuronal cell lines or in cultured primary motor 
neurons depolarise mitochondria, impairing calcium homeostasis and reducing ATP 
production, which as a result will result in apoptosis.13  Raised levels of intracellular Ca2+, 
more ROS,  perturbation of mitochondria function and ATP production caused by mutant 
SOD1 can cause excitotoxicity, which will result in neuronal injury from excessive activation of 
glutamate receptors.  Excess glutamate release can be counteracted by increased uptake by 
astrocytes, but when in the presence of mutated SOD1 there function is reduced and they 
secrete inflammatory mediators due to neuroinflammation.           
 
(4) Accumulation of Transactive Response DNA Binding Protein 43 (TDP-43) in ALS 
Patients 
TDP-43 is a cellular protein, encoded by the TARDBP gene, which is a modular DNA/RNA 
binding protein.  TDP-43 is localised to the cytosol and the nucleus, and is involved in RNA 
splicing, gene transcription, microRNA processing, stabilisation and the transport of RNA.17  
In 2008 mutations were identified in the TARDBP gene encoding TDP-43, the result of which 
is believed to be the accumulation of the protein in cyctoplasmic inclusions, where it can take 
refuge in cyctoplasmic RNAs in stress granules (SG).6,18  Therefore, neurons of ALS sufferers 
have decreased levels of TDP-43.  The dysfunction of TDP-43 has been established as 
contributing towards up to 6.5 % of fALS cases, but the exact mechanism of how TDP-43 
causes neurotoxicity in neurons is currently not fully understood.17 
 
1.2 Therapeutic Targets for the Treatment of ALS 
As described previously, there are several proposed mechanisms towards the understanding 
of ALS.  To date, there is no single definitive mechanism for understanding how ALS 
manifests, which therefore widens the scope in finding a suitable drug target.  There have 
been several drugs tested at phase III clinical trials in regards to their potent properties 
against ALS.19  Phase III clinical trials are performed on a large number of patients and all 
new treatments are compared against the best treatment currently available, which for ALS 
this is Riluzole (1, Figure 5).  The following drugs shown in Figure 5 have all been subjected 
to phase III clinical trials;19  
(1) Dexpramipexole (2) is highly related to Pramipexole, which is a treatment for Parkinsonʼs 
Disease (PD).  Dexpramipexole has been shown to slow the progression of ALS by 
maintaining mitochondrial function in deteriorating motor neurons.  However, in 2012 phase III 
trials completed on Dexpramipexole showed no statistically significant evidence with regards 
to Dexpramipexole slowing ALS disease progression.20 
(2) Arimoclomol (3) is hypothesised to reduce the levels of protein aggregates identified as a 
possible cause of ALS in motor neurons.  Arimoclomol is understood to boost the expression 
CHAPTER 1: INTRODUCTION 
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of chaperones Hsp70 and Hsp90, which help newly synthesised proteins to fold properly.  
Phase II/III clinical trials are still ongoing.21 
(3) Olesoxime (4) is understood to protect mitochondria in the motor neurons of ALS patients 
via putative mitochondrial permeability transition pore modulators, which will result in the 
slowing of disease progression.22  Phase III clinical trails for Olesoxime were dropped due to 
a statistically insignificant increase in survival vs. placebo.23 
(4) Ceftriaxone (5) is an antibiotic that protects cultured neurons from glutamate-induced 
excitotoxicity, brought about by reducing glutamate levels and increasing the expression of 
glutamate transporter EAAT-2.  Phase III trials reported that this particular antibiotic had no 
effect on disease progression.24 
(5) Edaravone (6) is a neuroprotective agent, which acts as a potent antioxidant and is also a 
strong scavenger of free radicals.  These activities protect against oxidative stress and 
neuronal apoptosis.25  Treatment of patients with Edaravone has shown a reduction in CSF 
levels of 3-nitrotyrosine, a marker of oxidative stress. Edaravone is showing promising results 
in the slowing down of disease progression.  Phase III trials are ongoing. 
 
Figure 5: A number of small molecules tested for their properties against ALS at phase III
 19 
 
(1) Targeting Reduction in Glutamate Toxicity 
Riluzole (1) is an FDA approved drug, which is currently the only approved treatment for 
attenuating disease progression in ALS patients.  Riluzole is hypothesised to inhibit the 
release of glutamate and to non-competitively inhibit postsynaptic N-methyl-D-aspartate 
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.26  The 
modest success of Riluzole against ALS has highlighted the role of glutamate excitotoxicity in 
numerous disease states, which has put focus on further developing drugs which will target 
the modulation of glutamate signalling. 
 
A potential approach in preventing excitotoxicity is to enhance glutamate reuptake, via EAAT-
2.  EAAT-2 is a major glutamate transporter that removes glutamate from the synapse.  An 
approach in increasing EAAT-2 activity is the development of a library of small molecules, 
which could enhance EAAT-2 expression.  Colton et al. developed and used a cell based 
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ELISA for EAAT-2 protein expression to screen a library of 140,000 small molecules: 
including compounds approved by the FDA, a purified natural products library, and 
compounds purchased from Peakdale, Maybridge Plc, Cerep, Bionet Research Ltd, 
Prestwick, Specs and Biospecs, ENAMINE, Life Chemicals, Inc, MicroSource Diversity 
Systemʼs NINDS customs collection, Chemical Diversity Labs, Chembridge, and small 
molecules obtained from various academic institutions.26  This screen found 293 hits with 61 
compounds showing a dose dependent increase in EAAT-2 expression.  Three out of the 61 
compounds tested were selected for further optimisation based on their low potency (EC50 < 1 
µM), lack of toxicity and chemical traceability.  It should be noted that the structures of these 
compounds has not been disclosed.19,26   
 
Xing et al. performed chemical optimisation on the identified three lead compounds to develop 
additional analogues for potential use as therapeutic agents.27  It was found through structure-
activity relationship (SAR) studies that the thioether and pyridazine functionality are essential 
molecular components for increasing EAAT-2 protein levels.  Thiopyridazine analogues can 
be synthesised via a four-step process (Scheme 4).  Firstly, a known ketone in the presence 
of K2CO3 is reacted with glyoxylic acid to generate an aldol addition product.  This is then 
directly reacted with hydrazine to yield pyridazinone 10.  Reacting pyridazinone 10 with P2S5 
and pyridine at 120 °C yields pyridazinethione 11, which is further converted to thiopyridazine 
12 via alkylation.27   
 
Scheme 4: Reagents and conditions: (a) 2.0 equiv. K2CO3, H2O, RT, 20 h; (b) 1.2 equiv. NH2NH2, 
AcOH, 100 °C, 2.5 h, 20 % (over two steps); (c) 1.9 equiv. P2S5, Py. 120 °C, 3 h, 80 %; (d) 2.0 equiv. 
R
2
Br, 2.0 equiv. K2CO3, DMF, RT, 1 h, ~ 90 % 
27
 
 
Of the analogues synthesised in this study, several thiopyridazine derivatives (Figure 6) were 
found to exhibit an increase in EAAT-2 levels.  The thiopyridazine derivatives were found to 
increase EAAT-2 levels greater than six-fold over endogenous levels in primary astrocytes at 
concentrations of less than 5 µM.19  Additionally, thiopyridazine derivative 15 was found to 
increase EAAT-2 levels three- to four-fold at a low EC50 value, 0.5 µM.  These compounds will 
prove useful for determining the biological mechanism for regulating EAAT-2 levels and also 
for further assessing the role of glutamate excitotoxicity in cellular systems, potentially in 
animal models of acute and chronic neurodegeneration.27  
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Figure 6: Thiopyridazines developed to increase EAAT-2 protein levels 
27
 
 
In addition to finding small molecules which will enhance glutamate uptake through the 
increase of EAAT-2 levels, other studies have also reported that elevated levels of D-serine 
can also contribute to glutamate excitotoxicity.19  D-Serine serves as a co-agonist at the 
glycine site of the NMDA glutamate receptor.  An increase in D-serine has been reported in 
the spinal cord of ALS patients.28  Usually excess D-serine is removed by D-amine acid 
oxidase (DAO) via metabolism, but ALS patients have been reported to have a reduction in 
DAO, which could account for these high levels of D-serine.19  Recently, a new mutation in 
DAO has been reported to contribute to fALS.  This new mutation - R199W DAO is 
understood to inhibit DAOʼs original function by increasing small protein-containing 
aggregates and reducing cell viability when expressed in neuroblastoma-spinal cord (NSC)-
34 cells, a motor neuron cell line.29,30  Therefore, finding small molecules which will contribute 
towards the reduction of D-serine either by enhancing the activation of DAO or the reduction 
of serine racemase (SR), which is responsible for D-serine synthesis, may be therapeutically 
beneficial.31   
 
(2) Targeting SOD1 Mutation 
Developing a library of drugs which reduces SOD1 protein levels in ALS patients will reduce 
the levels of the mutated SOD1 gene, therefore resulting in cells building up a resistance to 
ALS-induced cellular death.  Murakami et al. developed a high-throughput screen (HTS), 
which screened a total of 9600 small molecules.32  From this screen, 325 compounds were 
identified as hits, with only two compounds demonstrating selectivity in downregulating SOD1 
protein levels without apparent cellular toxicity following secondary assays.  One of the two 
compounds, 3-(1H-benzo[d]imidazol-2-yl)-6-chloro-4H-chromen-4-one, 052C9 (17, Figure 7), 
was put forward for further analysis due to its considerably lower EC50 and was also found to 
reduce phosphorylation of the transcription factor Nrf2, a known activator of cellular stress 
gene as well as an upregulator of SOD1 transcription.19,32  
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Figure 7: Compounds shown to reduce SOD1 expression 
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Similarly, Wright et al. performed a HTS on 30,000 small molecules focusing on repressing 
SOD1 transcription.  From this HTS 20 compounds were identified as hits.  Compound  
7687685 (18, Figure 7) from this HTS demonstrated both reduction in endogenous SOD1 
protein levels in human cells and also repressed several other genes implicated in ALS.  
However, when in vivo studies of compound 18 were performed in SOD1 G93A transgenic 
mice, only a small reduction of SOD1 protein levels in spinal-cord extracts were recorded, 
suggesting that this would not be a useful treatment for ALS patients.19  
 
As previously stated, mutation in SOD1 has also been reported to lead to cellular toxicity 
through loss of function of the SOD1 protein whereby mutant proteins in intercellular inclusion 
lead to cellular dysfunction.  Therefore compounds, which reduce the aggregation of SOD1 
protein, could be found beneficial in protecting cells from neuronal damage.  Benmohamed et 
al. performed a HTS on 50,000 small molecule compounds focusing on their ability to reduce 
mutant SOD1 aggregates in a cell-culture model.33  Hits from this HTS were then subjected to 
further screens and from this, three distinct chemical series were identified for further 
optimisation based on their ability to reduce both cellular toxicity and mutant SOD1 protein 
aggregation: arylsulfanyl pyrazolones (ASP) 21, cyclohexane-1,3-diones (CHD) 22 and 
pyrimidine-2,4,6-triones (PYT) 23.19 
 
The general method to generate ASP 21 is achieved in two-steps (Scheme 5).  Thiophenol 19 
and ethyl 4-chloroacetate 20 react via an SN2 nucleophilic displacement to give β-ketoester, 
which is further treated with hydrazine to generate ASP 21.33 
  
Scheme 5: Reagents and conditions for the general synthesis of ASP compounds: (a) 1.0 equiv. ethyl 
4-chloroacetoacetate, 1.1 equiv. Et3N, DCM, 0 °C, 30 mins; (b) 1.0 equiv. NH2NH2, EtOH, RT, overnight, 
67 % (over two steps) 
33
 
 
A number of ASP analogues were synthesised as shown in Scheme 5 with different 
functionalised aromatic rings within the ASP scaffold.  The first set of SAR studies carried out 
looked at para substitution on the aryl ring with electron-withdrawing and electron-donating 
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substituents of varying size.  From this first study the only ASP compound that showed 
promising reduction in mutant SOD1 was an ASP analogue containing a chloro group at the 
para position of the aromatic ring with an EC50 of 1.93 µM.  Further studies focused on 
multiple substitutions on the aromatic ring, which included chloride as one of the substituents.  
These studies identified two promising compounds 24 and 25, which showed potent activity 
towards the reduction of mutant SOD1 (Figure 8).33      
 
Figure 8: Two ASP hit compounds 24 and 25 
33
 
 
Both of these ASP compounds 24 and 25 have shown promising properties with good 
potency and the capability of the ASP scaffold to permeate into the brain.  Penetration across 
the BBB is achievable with a minimum number of polar groups on a pharmaceutical 
compound, or the polar groups are temporarily masked.  Even though compounds 24 and 25 
exhibit good potency and the capability to cross the blood brain barrier (BBB), which is 
required for a drug targeting neurodegenerative diseases they have been report to have poor 
metabolic stability.   It has been reported that the sulfur linker when in the presence of either 
microsomal or plasma enzymes is oxidised to the sulfoxide 29 hindering its ability to reduce 
SOD1 aggregation.34  The synthesis of compound 29 was confirmed by analysis of mass 
spectroscopy between compound 27 and nicotinamide adenine dinucleotide phosphate 
(NADPH), which reported the rate of formation of 29 in relation to the loss of 27.  As 
metabolism of the sulfide linker is fast ASP compounds require microsomal and plasma 
enzyme protection.  This was achieved by replacing the sulfur linker with either a sulfoxide, 
sulfone or ether linker.  Potency of these different linkers increased (EC50 decreases) in the 
order of ether > sulfide > sulfone >> sulfoxide (Figure 9).34   
 
Figure 9: Structures for the Ether, Sulfide Sulfone and Sulfoxide Linkers 
 
Replacement of the sulfur linker with an ether linker enhanced the reduction of SOD1 protein 
aggregates.  Chen and co-workers investigated and reported the synthesis and activity of a 
number of aryloxanyl pyrazolones (AOP).34  Initial preparation of AOP 32 was achieved in a 
two-step process (Scheme 6, Pathway A).  Phenol was reacted with ethyl 4-
chloroacetoacetate to give intermediate β-hydroxyester 31 via an SN2 nucleophilic 
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displacement.  Intermediate 31 was then treated with hydrazine to give AOP 32.  This two-
step synthetic pathway was simple and direct, but was not efficient due to the instability of the 
enolate intermediates obtained.  These issues were overcome by generating AOP 32 in a 
four-step process (Scheme 6, Pathway B).  Phenol and 2-bromo-N-methoxy-N-
methylacetamide were reacted together to generate hydroxamide 35.  The hydroxamide 
intermediate was then reacted with ethyl acetate to generate intermediate β-hydroxyester 31, 
which was then further reacted with hydrazine to give AOP 32.    
 
Scheme 6: Reagents and conditions for general synthesis of AOP compounds: Pathway A (a) 1.5 
equiv. ethyl 4-chloroacetoacetate, 2.5 equiv. NaH, THF, DMF, -20 °C - 70 °C; (b) 1.0 equiv. NH2NH2, 
EtOH, RT, overnight, 2 - 30 % (over two steps); 
 Pathway B (c) 1.0 equiv. N,O-dimethylhydroxylamine hydrochloride, 2.2 equiv. K2CO3, Et2O, H2O, RT, 
30 mins, 74 %; (d) 1.0 equiv. NaOEt, EtOH, 70 °C, overnight; (e) 1.0 equiv. EtOAc, 2.3 equiv. LiHMDS, 
THF, -78 °C, overnight;  (f) 1.0 equiv. NH2NH2, EtOH, RT, overnight, 2 - 27 % (over three steps)  
 
After a number of AOP analogues containing mono or disubstituted functionality, such as aryl, 
alkyl or halide were successfully synthesised using Pathway B of Scheme 6 they were 
subjected to adsorption, distribution, metabolism and excretion (ADME) testing.  The following 
analogue 36 was found to be the most potent within this library of AOPs generated by Chen 
and co-workers (Figure 10).  Compound 36 showed promising results with good aqueous 
solubility, good BBB penetration, good metabolic stability and a life extension of G93A ALS 
mice of 13.3 % at 20 mg/kg.34  These initial findings show that AOP analogue 36 could be a 
novel drug candidate for the treatment of ALS.34  
 
Figure 10: AOP analogue 36 
34
 
 
Tripper and co-workers reported that if R2 on the pyrazolone ring 37 (Figure 11) is altered 
from a simple hydrogen bond AOP analogues become inactive, suggesting this position is 
essential for cellular activity.  Varying the functionality of R1 on the pyrazolone ring gave a 
number of active AOP analogues.  Addition of sterically demanding substituents at R1 had 
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little effect on the efficacy, suggesting the possibility of a large open pocket or corridor within 
the target structure.  Overall, this study identified that when R1 is a benzyl group, enhanced 
potency towards the reduction of mutant SOD1 is reported.35  
 
Figure 11: Varying R
1
 and R
2
 substituents on the pyrazolone ring 
 
CHD analogues are generated over two-steps using the general method shown below 
(Scheme 7).36  Commercially available or previously synthesised aldehydes were used as 
starting materials, which were converted to intermediate 39 via the Wittig reaction.  
Intermediate 39 was then converted to CHD analogues 22 after Michael addition, cyclisation, 
hydrolysis and decarboxylation.37 
 
Scheme 7: Reagents and conditions for the general synthesis of CHD compounds: (a) 1.0 equiv. 1-
(triphenylphosphoranylidene)-2-propanone, THF, RT, 12 h; (b) 1.0 equiv. diethyl malonate, 2.0 equiv. 
EtONa, EtOH, RT, 12 h; (b) 3N aq. NaOH, H2O, RT, 12 h; (c) 3N aq. HCl, Et2O, RT, 4 h, 80 % (over four 
steps) 
36
 
 
A number of CHD analogues synthesised by Zhang and co-workers containing functionality 
on the aromatic ring were found to be active candidates (Scheme 7, general procedure).36  All 
active CHD analogues were tested for their cell survival against the formation of mutant SOD1 
aggregates.  These mutant SOD1 aggregates are observed to be generated from treatment 
with proteasome inhibitor MG132.  SAR studies lead to several conclusions: (1) electronic 
properties of the substituted groups do not affect the activity of analogues; (2) the meta 
position is much more important than the other positions; (3) the size of the meta-substituent 
is crucial; and (4) trifluoromethyl is a favoured substituent to increase potency.  Over 120 
analogues were obtained using Scheme 7, which lead to the discovery of CHD analogue 40, 
which has an EC50 of 0.70 µM (Figure 12).
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Figure 12: CHD analogue 40 
 
Even though CHD analogue 40 showed favourable pharmacokinetics (PK), demonstrating 
high plasma stability, oral bioavailability and brain accumulation, it did not show any beneficial 
effects when tested in SOD1 G93A transgenic mice.  Additional studies demonstrated that 
CHD analogue 40 exhibited minimal activity in primary cortical neurons due to low penetration 
of neuronal cells.19  Due to the poor therapeutic benefits demonstrated by compound 40 
further SAR studies around this series were investigated, which lead to new chiral CHD 
analogues, such as 41.  CHD analogue 41 exhibited enhanced activity of cortical neurons 
with good PK properties, whilst also retaining activity in the PC12 assay (Figure 13).   
Additionally this analogue was found to extend the life expectancy of an ALS mouse by 13 %, 
which is slightly longer than that previously reported for Riluzole using the same mouse 
model.37   
  
Figure 13:  CHD analogue 41 
 
PYT analogues, such as 23 are synthesised in two-steps (Scheme 8, general procedure).  
Firstly commercially available S,S-dimethyl carbonodithioate and amines are reacted together 
to generate a urea intermediate 43.  This urea intermediate is then further treated with 
malonic acid in an acetic acid/acetic anhydride medium generating PYT analogues 23.38  
 
Scheme 8: Reagents and conditions for the general synthesis of PYT compounds: (a) 2.1 equiv. RNH2, 
MeOH, 60 °C, 24 h; (b) 1.0 equiv. (substituted) malonic acid, AcOH/Ac2O (3:2), 60 °C - 90 °C, 4 h 
38 
 
PYT analogues were identified as novel potential drug candidates with good potency and 
ADME properties towards the reduction of SOD1 protein aggregation.  PYT analogue 44 
(Figure 14), was found to have a desirable combination of potency, ADME properties, low 
toxicity, brain penetration and oral bioavailability.38 
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Figure 14: PYT analogue 44 
 
Conclusions drawn from the above three distinct chemical series, ASP 21, CHD 22 and PYT 
23 identified initially from HTS preformed by Benmohamed et al. have all shown positive 
results towards the reduction of mutant SOD1 aggregation.  In particular compound 36, which 
is a modification of the ASP library and has been reported to display an increased lifespan 
compared to controls.34  Reduction in mutant SOD1 aggregation will result in normal cell 
function, therefore reducing the chances of excitotoxicity, which is a proposed mechanism in 
contributing to ALS.  Therefore, investigating these libraries further could help towards finding 
alternative methods in reducing disease progression for patients with ALS.       
 
An alternative method to prevent the aggregation of SOD1 was to design a compound that 
acts as a pharmaceutical chaperone stabilising the SOD1 native dimer.  Ray et al. tested a 
number of compounds from 15 commercially available libraries to find out their potential 
towards binding at the SOD1 dimer interface and stabilise the dimer.  From this initial in silico 
screening 100 compounds were found to be hits, of which were further screened in SOD1 
A4V aggregation assay.  From this screening 15 compounds were identified to inhibit the 
aggregation of SOD1 A4V (most common ALS-causing mutation) proteins and other SOD1 
mutants.19,39   
 
When the 15 hit compounds were tested for SOD1 protein-binding in the presence of human 
plasma, they showed poor binding affinity relative to other protein components in the plasma.  
Nowak et al. carried out a number of docking calculations on a database of small molecules 
to model the aggregation inhibitors at the dimer interface binding pocket.40  From these 
docking calculations 20 compounds were identified to have satisfactory docking constraints 
(hydrogen bonds).  These hits were further tested for their ability to block aggregation of 
SOD1 and specifically bind SOD1 over blood plasma components.  This screening resulted in 
at least six compounds (Figure 15) having high selectivity towards the blocking of SOD1 
aggregation and were found to perform significantly better than original azauracil-based 
molecules tested in blood plasma.  These six compounds indicate an excellent starting point 
towards the therapeutic development of ALS.19,40 
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Figure 15: Compounds that selectively bind SOD1 over human plasma and inhibit A4V-SOD1 
aggregation
 40
 
 
(3) Targeting TDP-43 
Mutation in the TARDBP gene encoding TDP-43 is estimated to be responsible for up to 6.5 
% of fALS cases.17  TDP-43 mutations are highly toxic to the cell.19,41  One approach to reduce 
the pathology caused by mutant TDP-43 is to identify small molecules that inhibit the binding 
of TDP-43 to nucleotides.  Cassel et al. developed a HTS assay to measure oligonucleotide 
binding to TDP-43.  A total of 7360 small molecules which are known to disrupt 
oligonucleotide binding to TDP-43 protein were screened.42  From the HTS a series of 4-
aminoquinoline derivatives (Figure 16) were tested for their ability to regulate TDP-43.  Cassel 
et al. hypothesised that this series would stimulate capase-7 mediated cleavage of TDP-43, 
affecting its cellular accumulation.43  Caspase-7 can mediate the reduction of TDP-43 protein 
levels via cleavage of the TDP-43 and subsequent clearance of the cleaved products by the 
proteasome.  The 4-aminoquinoline derivatives shown in Figure 16 were found to bind to 
TDP-43 decreasing its association with oligonucleotide and increasing caspase-mediated 
cleavage of the protein.  When these compounds were further tested in H4 cells they were 
found to modestly reduce intracellular levels of TDP-43 and proteins known to be regulated by 
TDP-43.41  Reduction of TDP-43 levels within motor neurons will prove to be beneficial 
towards ALS treatment as this will restore normal TDP-43 functions, including RNA transport.  
Therefore further development and validation of these small molecules could prove valuable 
for future therapeutic development. 
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Figure 16: 4-aminoquinolines developed for disruption of oligonucleotide/ TDP-43 binding 
43 
 
Another mechanism to diminish TDP-43 toxicity in cells is the reduction of intracellular 
inclusions.  Bis(thiosemicarbazonato)copperII complexes (CuII (btsc)s 56, Figure 17) were 
tested on treated SH-SY5Y cells with paraquat, which induces cellular stress through 
mitochondrial inhibition, leading to the formation of TDP-43 aggregates in the cytoplasm.18  
The TDP-43-containing cellular inclusions are dependent on the activation of stress-induced 
kinases such as c-Jun N-terminal kinase (JNK).  Results obtained for compound 56 and other 
copper complexes showed reduced stress-induced kinase activity and prevented TDP-43 
aggregation.  These copper complexes have previously demonstrated neuroprotective effects 
in mouse models of neurodegeneration, therefore making them beneficial in the treatment of 
ALS as they modulate kinase activity and reduce protein aggregation.19,44   
 
Figure 17: Cu
II
(atsm), an example of a Cu
II
(btsc) copper complex
 
 
Alternatively a way to reduce TDP-43-containing cytoplasmic inclusions (foreign substances 
contained within the cell membrane) is to induce autophagy, which can be achieved by using 
known pharmacological activators such as Tamoxifen (57), Carbamazepine (58), Spermidine 
(59), or Rapamycin (60, Figure 18).  Autophagy is a process in which dysfunctional proteins 
and organelles are removed from the cell and then degraded by lysosomes.  These 
compounds were trialled to see if they could enhance autophagy in disease models with TDP-
43 proteinopathies.  It was found that clearance of cytoplasmic TDP-43, along with a 
reduction in caspase activation and cellular death corresponded to an upregulation of these 
autophagic markers.45  The use of enhancing autophagy may reduce cellular death and 
behavioural dysfunction associated with TDP-43 mutations.19  
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Figure 18: Pharmaceutical inducers of autophagy 
 
(4) TARGETING REDUCTION IN OXIDATIVE STRESS AND INFLAMMATION 
Oxidative stress is the result of an imbalance between the production of ROS and cellular 
antioxidant defence systems, which play a crucial role towards neurodegenerative conditions.  
Several treatment strategies have focused on minimising the imbalance between the 
production of ROS and cellular antioxidant defence systems within cellular pathways.  One 
method of reducing oxidative stress in the neurons is the upregulation of signalling through 
the NF-E2 related factor 2/ antioxidant response element (Nrf2/ARE) pathway, which is 
responsible for the upregulation of antioxidants and prosurvival genes and reduction of cell 
apoptosis under cytotoxic conditions.  Neymotin et al. tested two triterpenoids, 2-cyano-3,12-
dioxoolean-1,9-diene-28-oic acid-ethylamide (CDDO-EA 61) and CDDO-trifluoroethylamide 
(CDDO-TFEA 62) for their ability to activate Nrf2/ARE signalling in cell culture and mouse 
models of ALS (Figure 19).  Treatment of NSC-34 cells expressing SOD1 G93A with CDDO-
TFEA (62) gave elevated levels of Nrf2 and Nrf2 regulated genes.  When (61) and (62) were 
orally administered to transgenic SOD1 G93A mice, results obtained showed an increase in 
Nrf2 expression and nuclear localisation.  Both of these triterpenoid compounds activated the 
Nrf2/ARE system, which results in the reduction of oxidative stress in cell cultures and mice 
models of ALS therefore resulting in a neuroprotective response.19,46  
   
Kanno et al. used a virtual screening system to discover oxidative-stress reducing agents, 
which identified N-(5-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethyl-phenoxy)acetamide (CPN-
9 63, Figure 19).  Initial testing of CPN-9 (63) gave highly cytoprotective properties against 
pharmacologically induced oxidative stress.  Further testing of CPN-9 (63) in a variety of cell-
stress inducers all showed protection against cellular death when induced by oxidative-stress 
pathways only.  Overall, CPN-9 (63) showed resistance to oxidative stress through 
upregulation of the Nrf2/ARE transcriptional pathway and inhibition of cellular death.  
Treatment of transgenic mice expressing the hDOD1 H46R mutant gene with CPN-9 (63) 
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showed an increase in motor neuron function within the spinal cord and extended survival 
following disease onset.19,47  
 
Figure 19: Compounds developed to reduce oxidative stress and inflammation 
 
Tanaka et al. performed further studies into the reduction of oxidative stress in ALS utilising 
dopamine D4 receptor antagonist, L-745,870 (64, Figure 19) to selectively inhibit oxidative 
stress induced cell death.  This compound was previously determined to upregulate neuronal 
apoptosis inhibitory protein (NAIP), BIRC1, a cytoprotective protein that improves oxidative 
stress induced cellular death.48  Treatment of (64) administered within the stomach of SOD1 
H46R mice before symptom onset was discovered to delay symptom onset as determined by 
limb movement, rearing activity and foot clasping behaviours.  It was also found that 
treatment with (64) delayed weight loss and motor dysfunction as examined by a balance-
beam test.19,49 
 
Further work within this group identified that dopamine D2 receptor agonist bromocriptine 
(65), an NAIP upregulating compound, reduced oxidative stress through the upregulation of 
antioxidant proteins, such as activating transcription factor 3 (ATF3) and heme oxygenase 
1(HO-1).  The delay in disease progression of compound (65) was identified by in vivo studies 
of compound (65) administered to SOD1 H46R mice following symptom presentation.  These 
studies indicate that the depletion of oxidative stress pathways through the upregulation of 
antioxidant genes can reduce disease progression in ALS models.19,50     
 
1.3 Riluzole 
2-Amino-6-trifluoromethyoxybenzothiazole also known as Riluzole and Rilutek (1), is a 
derivative of benzothiazole 66 (Figure 20).  Riluzole is bicyclic and comprises of a benzene 
ring, fused to a five-membered ring containing a nitrogen and sulfur atom.1  Benzothiazole 
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derivatives were first identified in the 1950s as potential muscle relaxants, but were later 
investigated as anticonvulsant and neuroprotective agents.  In 1995 Riluzole was approved 
by the FDA for the treatment of ALS and, to date, remains to be the only approved drug in 
suppressing ALS symptoms.51  Riluzole is taken twice a day with a fixed regimen of 50 mg 
dosages, prolonging life expectancy by approximately 3 - 6 months.52,53 
 
Figure 20: Benzothiazole 66 
   
In the 1960s Yagupolʼskii and Gandelʼsman reported the first synthetic method of generating 
Riluzole, which was then patented by Rhône-Poulenc Rorer.1  The original method and 
commercial production of Riluzole is done in one-pot by reacting 4-trifluoromethoxyaniline, 
ammonium thiocyanate and a source of bromine together (Scheme 9).       
 
Scheme 9: Synthesis of Riluzole via the Hugerschoff Reaction: 
Reagents and conditions (a) 1.0 equiv. NH4SCN, 1.0 equiv. PhCH2NMe3Br3, MeCN, 24 h, 80 % 
54
 
 
Most pharmaceutical drugs are designed to have a single molecular targets, however the 
neuroprotective effects shown by Riluzole are thought to exert their effects through a number 
of interdependent pathways.  The exact mechanism of action in which Riluzole slows disease 
progression is still unknown but it is understood that Riluzole both inhibits the release of 
glutamate and also non-competitively inhibits postsynaptic NMDA and AMPA receptors. 
Potential modes of action include (1) anti-glutamatergic actions (2) Ca2+ channel blockade (3) 
Na+ channel blockade and (4) GABAergic mechanisms.1  
 
PK studies of Riluzole have demonstrated variable drug exposure in addition to serum 
concentrations varying greatly for patients with ALS, following oral administration.19,53  This 
variation correlates to the concentrations of CYP isoform CYP1A2 found in ALS patients.  The 
enzyme CYP1A2 converts Riluzole to N-hydroxyriluzole, via oxidative metabolism making the 
drug inactive.52  Individual dosing of Riluzole may lead to an increased efficacy in patients 
who are fast metabolisers and a decrease of side-effects in others who are slow 
metabolisers.  This is not a feasible approach because, if a large variability exists within a 
group of individuals, it may be due to individual characteristics and variability.53  Studies have 
focused around creating Riluzole prodrugs that would exhibit higher stability in vivo.  Prodrugs 
are inactive pharmaceutical medications, which when administered are converted to active 
pharmaceutical medications through a normal metabolic process, such as hydrolysis of an 
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ester.  Prodrugs might be used over drug administration to improve ADME, bioavailability, 
selectivity and reduce undesirable side effects.   
 
McDonnell et al. identified and screened 23 Riluzole prodrugs against glutamate toxicity in 
ALS and other disorder models.19  Preparation of Riluzole prodrugs candidates are achieved 
by converting the endocyclic amine to single α-amino amide, carbamate, succinamide, and 
amide linkage from γ-aminobutyric acids (Scheme 10).55     
 
Scheme 10: Preparation of Riluzole prodrugs. Reagents and conditions: (a) 1.0 equiv. RCO2H, 1.5 
equiv. EDCl, DCM, RT, 4 days, 34 - 83 %; or 1.8 equiv. ROCOCl, 1.5 equiv. Et3N, DCM, RT, 24 h, 13 -
77 %; or 1.0 equiv. RCO2COR
1
, DMF, RT, 24 h then 1.0 equiv. R
1
R
2
NH, 1.0 equiv. HATU, 1.0 equiv. 
Et3N, DMF, RT, 24 h, 9 - 16 %; (b) 5.0 equiv. TFA, DCM, 2h if deprotection is required 
55
 
 
These Riluzole prodrugs would be cleaved in the plasma by esterase and amidase enzyme to 
regenerate Riluzole.  The stability of these analogues were tested in simulated gastric fluid, 
intestinal fluid and liver microsomes to determine whether the prodrugs would enter the 
plasma intact.  Further, the cleavage of the Riluzole prodrug to Riluzole was analysed in the 
plasma.  From this rigorous testing one compound was shown to be a Riluzole prodrug 
candidate for in vivo testing, the O-bezylserine derivative 69 (Figure 21).  This prodrug 
showed good stability in in vitro intestinal and microsomal assays and was also able to 
withstand metabolism by CYP1A2.  Development of this prodrug could help Riluzole to be a 
more effective treatment against ALS.19,55  
 
Figure 21: O-benzylserine Riluzole prodrug 69 
 
Both the 6- and 3-position of the core Riluzole structure offer attachment points for the 
incorporation of diversity generating substructures.  Jimonet et al. reported the synthesis of 
several analogues of Riluzole (1) showing the crucial importance of the 6-substitutent on 
benzothiazoles and the preparation of 3-substituted derivatives of Riluzole and their in vivo 
ʻantiglutamateʼ activity.  For all compounds synthesised in vivo antiglutamate activity was 
recorded as the median effective dosage (ED50), which was calculated by injecting 6- and 3-
substituted Riluzole derivatives (Table 1 and 2) into male rats that had been injected with 12.5 
µM mol/kg solution of L-glutamic acid in saline.  The ED50 values obtained for each compound 
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was evaluated together with reference drugs for their ability to protect against seizures 
induced by intracerebroventricular administration of glutamic acid in rats.56 
 
(1) 6-Substituted Riluzole Derivatives 
A number of 2-benzothiazolamines bearing various substituents in the 6-position were 
synthesised via a number of routes (Scheme 11), as one general method was not feasible.  
All 6-substituted Riluzole analogues generated are listed in Table 1.      
 
Pathway C (Scheme 11) is one of two versatile routes to prepare 6-substituted Riluzoles 
analogues.  This route generated analogues 1, 75, 76, 80, 82 - 95 (Table 1) via a one-pot 
reaction between an appropriate aniline and thiocyanogen, which is generated from bromine 
and an alkaline thiocyanate in an acetic acid medium.  Pathway D (Scheme 11) generated 
analogues 78 and 79 (Table 1), which were achieved via an alternative route.  This route went 
via intermediate phenythiourea.   Phenythiourea was generated by reacting an appropriate 
aniline and thiocyanate together and on addition of bromine resulted in ring cyclisation, which 
generated 6-substituted Riluzole analogues.  Pathways outlined in Scheme 11 did not 
generate Riluzole analogues 74 and 81 reported in Table 1.  These two analogues were 
generated via further reactions to previously generated Riluzole analogues.  Analogue 74 was 
generated by the reduction of analogue 77, which is commercially available and analogue 81 
was generated by reacting commercially available 6-bromo Riluzole analogue with n-
butyllithium and chlorotrimethylsilane, which was then followed by hydrolysis.  
 
Scheme 11: Reagents and conditions: Pathway C (a) 4.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 21 h, 
11 - 71 %; 
 Pathway D (b) 1.1 equiv. NH4SCN, 0.006 equiv. NaHSO3, 2.0 equiv. 20 % aq HCl, 90 °C, 14 h; (c) 2.0 
equiv. Br2, DCM, reflux, 2.5 h, RT, 18 h, 22 - 41 % (over two steps)  
 
All 6-substituted-2-benzothiazolamines analogues 73 - 82 (Table 1) displayed very weak 
activity compared to that of Riluzole.56  These results suggest that electronic factors are 
relatively unimportant, as substitutions with electron-donating and electron-withdrawing 
groups at the 6-position did not increase antiglutamate activity when compared to analogue 
72.  Both chloro and trifluoromethoxy groups are known to deactivate the aromatic ring by an 
inductive electron withdrawal and also donate electrons by resonance.  When the 
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trifluoromethoxy substituent of analogue 1 is replaced with a chloro substituent generating 
analogue 73 the activity is drastically reduced.57  This difference in activity has been seen in 
other medicinal drugs where a chloro substituent is replaced by such a ʻpseudohalogenʼ 
resulting in an active compound; for example when the 7-chloro substituent in Diazepam is 
replaced with a trifluoromethoxy group.58  Therefore, Riluzoles in vivo activity depends 
essentially on non-electronic factors such as lipophilicity, which is the ability for a compound 
to dissolve in fats, oils, lipids and non-polar solvents. 
 
All active 6-substituted Riluzole analogues fell into two sets: (a) analogues bearing large alkyl 
substituents or (b) analogues bearing a polyfluoroalkyl or a polyfluoroalkoxy substituents 
similar to that of Riluzole.  A variety of alkyl chains varying in length and size were 
investigated to determine an optimum chain length related to antiglutamate activity.  For linear 
substituents it was found that the most potent analogue was 86 and shortening or lengthening 
of this chain decreased the potency of Riluzole analogues.  Altering the butyl chain with a 
branched chain such as 81 and 87 did not affect activity, but when the branched chain was 
shortened or lengthened this led to compounds with weaker activity 85 and 89.  Analogues 93 
- 95 contained a polyfluoroalkyl or a polyfluoroalkoxy substituents and showed strong 
antiglutamate activity, but when one or more of the fluorine groups were replaced with 
hydrogen, the activity decreased.  These results are consistent with lipophilicity of the 
substituent at the 6-position being a major contributing factor for antiglutamate activity.   
 
Table 1: Antiglutamate activity of 6-substituted-2-benzothiazolamines 
 
Compound R Reaction Pathway ED50, mg/kg i.p. 
1 OCF3 C 3.2 
72
a
 H  >10 
73
a
 Cl  > 10 
74
b
 NH2  > 10 
75 CN C > 10 
76 CO2Et C > 10 
77
a
 NO2  > 10 
78 SO2Me D > 10 
79 OMe D > 10 
80 O-t-Bu C > 10 
81
b
 SiMe3  5 
82 Me C > 10 
83 Et C 7 
N
S
NH2
R
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84 n-Pr C 6 
85 i-Pr C > 10 
86 n-Bu C 4 
87 t-Bu C 4 
88 n-Pen C 7.5 
89 t-Pen C > 10 
90 n-Hex C 7 
91 n-Hep C > 10 
92 COCF3 C > 10 
93 OC2F5 C 2.5 
94 C2F5 C 2.5 
95 CF3 C 2.5 
a commercially available product from Aldrich; b obtained via further reactions to existing Riluzole 
analogues 
 
(2) 3-Substituted Riluzole Derivatives 
Alkylation of 6-trifluoromethoxy-2-benzothiazolamine 1 occurred exclusively at the endocyclic 
nitrogen.59  Jimonet et al. published four different reaction pathways in which functionalisation 
was introduced to the endocyclic nitrogen of Riluzole (Scheme 12) generating a library of 3-
substituted Riluzole analogues (Table 2).56,60   
 
Pathway E (Scheme 12) generates 3-substituted Riluzole derivatives via simple alkylation of 
Riluzole with commercially available alkylating reagents, in either an alcohol, methylethyl 
ketone, or dimethylformamide solution under reflux for several hours.  The simplicity of this 
reaction and the availability of many alkylating agents allowed rapid synthesis of a large 
number of analogues 105 - 111, 113, 116 - 118, 121 and 124 - 126 (Table 2).  Pathway F 
(Scheme 12) generates thiolate and amine functionalised 3-substituted Riluzole derivatives, 
such as 122 and 130 (Table 2), which cannot be generated via simple alkylation reaction of 
Riluzole.  Riluzole is firstly alkylated with hydroxylethyl bromide.  This is then followed by 
protection of the imine with a suitable electron-withdrawing group such as trifluoroacetyl.  The 
hydroxyethyl chain is then activated with p-toluenesulfonyl chloride and reacted with either a 
thiolate or amine, generating either a thiolate or amine functionalised 3-substituted Riluzole 
analogue via an SN2 displacement reaction.  Protection of the imine is essential otherwise 
intramolecular nucleophilic attack occurs between the nucleophilic imino and tosylate group 
forming an unwanted tricyclic derivative 97.  Pathway G (Scheme 12) introduces functionality 
at the N-3 position before cyclisation, therefore reducing the generation of unwanted cyclised 
side-products experienced in other pathways.   4-Trifluoromethoxyaniline and 2-bromoethanol 
are reacted together generating an amino alcohol compound.  This amino alcohol compound 
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is then reacted with two equivalents of p-toluenesulfonyl chloride giving the ditosylate salt 
101.  Nucleophilic displacement of 101 with an appropriate amine, followed by hydrolysis and 
cyclisation gives analogues 127 - 130 (Table 2).  Pathway H (Scheme 12) also adds 
functionality before cyclisation.  Firstly ethenesulfonyl fluoride is reacted with 4-
trifluoromethoxyaniline via a Michael addition to give 103.  This is then converted to either a 
sulfonamide or sulfonic acid compound, such as 104, which is achieved via an SN2 
displacement between the sulfonyl fluoride compound and an appropriate amine or sulfonic 
acid.  The final step in the pathway is ring-cyclisation yielding either a sulfonamide or sulfonic 
acid functionalised 3-substituted Riluzole analogue, such as analogues 114 and 115. 
 
Scheme 12: Reagents and conditions: (a) 1.2 equiv. RX, EtOH, MEK or DMF, reflux, 24 h; (b) 1.0 eq. 
Br(CH2)2OH, EtOH, reflux, 1.5 h; (c) 1.1 equiv. TsCl, excess Py. 0 °C - RT, 90 % (over two steps); (d) 
1.2 equiv. CF3CO2Et, 1.1 equiv. Et3N, EtOH, RT, 18 h, 85 %; (e) 1.1 equiv. R
1
R
2
NH, 1.0 equiv. 
NaHCO3, DMF, 80 °C, 18 h or 1.1 equiv, R
1
SNa, DMF, 80 °C, 18 h; (f) aq K2CO3, MeOH, RT, 5 h; (g) 
1.0 equiv. Br(CH2)2OH, 160 °C, 1.5 h, 49 %; (h) 2.0 equiv. TsCl, 2.0 equiv. Et3N, DCM, 0 °C - RT, 1.5 h, 
55 %; (i) 2.1 equiv. R
1
R
2
NH, 2.1 equiv. NaHCO3, DMF, 80 °C, 18 h (j) HCl, aq AcOH, reflux; (k) 1.0 
equiv. Br2, 4.0 equiv. KSCN, AcOH, RT, 18 h; (l) 1.0 equiv. CH2CHSO2F, DMF, RT, 2 h, 75 %; (m) 8.0 
equiv. R
1
R
2
NH, acetone, reflux, 1 h or 8.0 equiv. AcOH, reflux, 1 h. 
 
Riluzole analogues generated with N-3 functionality being small aliphatic chains, such as 
methyl 105, ethyl 106 and propyl 107 showed good antiglutamate activity, but the small 
variation in chain length did not drastically affect antiglutamate activity overall.  When bulky 
alkyl and aromatic substituents were introduced, for example derivatives 108 and 109, 
potency decreased dramatically.  N-3 Riluzole derivatives containing esters 111, amides 113, 
sulfonamides 114, carboxylic acid 112, sulfonic acid 115, and alcohol 116, functionality did 
not show improved potency compared to Riluzole.  
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Antiglutamate activity was shown to significantly increase when nitrogen or sulfur functionality 
was introduced to the N-3 position of Riluzole.  For the sulfur substituents the most potent 
derivative was methylthioethyl 118, which gave an ED50 of 1 mg/kg i.p.  Two other sulfur 
substituents similar to 118 were sulfoxide 119 and sulfone 120 all of which suggest that the 
active molecule in vivo is in fact a common metabolite.56  When the chain length to the thio 
group was increased or decreased or altered from the methythio group to thiol or something 
bulkier, such as a phenyl ring (117, 121 and 122) this resulted in a loss of anticonvulsant 
activity.  From the N-3 amino Riluzole substituents generated it was found that 
dimethylaminoethyl 124 and cyclic 125 substituted benzothiazoline analogues demonstrated 
good anticonvulsant potency over monoethylated substituents 123.  Increasing the chain 
length from a two-carbon chain to a three-carbon chain for dimethylaminoethyl substituted 
benzothiazoline 126 or changing one of the methyl groups for an aromatic substituent 127 
reduced potency.  The last three entries of Table 2, 4-phenylpiperidinyl 128, 4-phenyl-1,2,3,6-
tetrahydropyridyl 129, and 4-phenyl-piperazinyl 130 all show unexpectedly high levels of 
antiglutamate activity. 
 
Table 2: Antiglutamate activity of 3-substituted-2-imino-benzothiazolamines 
 
Compound R Reaction pathway ED50, mg/kg i.p. 
1
a
 H  3.2 
105 Me E 5.0 
106 Et E 5.0 
107 n-Pr E 4.5 
108 n-Bu E 10.0 
109 CH2Ph E > 10 
110 (CH2)2Ph E > 10 
111 CH2CO2Me E > 10 
112
b
 CH2CO2H  > 10 
113 CH2CONH2 E 7.0 
114 (CH2)2SO2NH2 H 6.0 
115 (CH2)2SO3H H > 10 
116 (CH2)2OH E 8.0 
117 CH2SMe E 3.0 
118 (CH2)2SMe E 1.0 
N
S
NH
R
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119
c
 (CH2)2SOMe  1.1 
120
c
 (CH2)2SO2Me  1.8 
121 (CH2)2SPh E 4.5 
122 (CH2)3SMe F 4.2 
123 (CH2)2NHMe  > 10 
124 (CH2)2NMe2 E 2.3 
125 
 
E 2.0 
126 (CH2)3NMe2 E 9.0 
127  (CH2)2N(Me)CH2Ph G 7.0 
128 
 
G 3.0 
129 
 
G 2.2 
130 
 
F 3.5 
a commercially available product from Aldrich; b could not be obtained directly from Riluzole thus 
compound 112 was prepared in two-steps after acidic hydrolysis of the benzothiazoline precursor 111; c 
sulfoxide 119 and sulfone 120 were prepared from their respective thioethers via oxidation with mCPBA.  
 
In conclusion a library of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-
benzothiazolines were successfully evaluated for their antiglutamate properties against 
seizures induced by intracerebroventricular administration of glutamic acid in rats.  For the 6-
substituted-2-benzothiazolamine library two sets of products were found to be active, 
compounds bearing a large but not too large alkyl substituent 86 and compounds bearing a 
polyfluoroalkyl or a polyfluoroalkoxy substituent 93 - 95.  Active analogues from this library 
suggest that 6-substituted-2-benzothiazolamine possess excitatory amino acid antagonist 
activity, which could result in some of the analogues synthesised from this library exhibiting 
interesting anticonvulsive and neuroprotective properties similar to Riluzole.  For the 3-
substituted-2-imino-benzothiazolines it was shown that a variety of analogues could be 
synthesised via a number of pathways (Scheme 12) and a number of these analogues 
showed similar or elevated activity compared to Riluzole.  Benzothiazoline analogues 
exhibiting strong antiglutamate activity were found to bear heteroatoms in the β-position of the 
alkyl substituent, which included the cycloalkylamino- 125, ethylamino- 124, and uncharged or 
oxidised alkylthioethyl-benzothiazoline analogues 118.     
 
Other methods investigated towards enhancing Riluzoles antiglutamate activity included a 
combination therapy with Neramexane in which both active ingredients are administered as a 
single pharmaceutical composition.  Neramexane is categorised as either an NMDA 
N
N
N
N N
CHAPTER 1: INTRODUCTION 
34 
antagonist or an NMDA receptor antagonist, therefore containing neuroprotective properties 
which inhibit the effects of excessive glutamate at the NMDA receptors to nerve cells.  Initial 
studies were carried out on mice with an overexpression of the SOD1 gene mutation present 
in ALS patients.  Initial results from this study showed that a combination therapy containing 
both Riluzole and Neramexane retarded disease progression.  This study was carried forward 
and tested in 150 patients suffering from ALS.  Results obtained from this study concluded 
that a combination therapy containing both Riluzole and Neramexane reduced disease 
progression to a greater extent then Riluzole.61    
       
1.4 1,2,3,6-Tetrahydropyridine  
One of the first reported synthesis of a tetrahydropyridine (THPy) was of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP 132), which was discovered in the late 1970s as a trace 
impurity in a synthetic fentanyl derivative known as meperidine.62 It is a potent neurotoxin in 
the domaminergic system, which produced Parkinson-like symptoms amongst other side 
effects.63  MPTP is generated through the rearrangement of 3,6-dimethyl-6-phenyl-tetrahydro-
1,3-oxazine (131) using either sulphuric or hydrochloric acid (Scheme 13).  Under relatively 
mild conditions 1-methyl-4-phenyl-4-piperidinol 133 was also obtained as a minor product.64,65   
 
Scheme 13: Synthesis of MPTP 
 
The reduction of N-alkylpyridiniums with sodium borohydride is a widely used method for the 
synthesis of pharmacologically interesting THPys 136.64,66  Unfunctionalised N-
alkylpyridiniums 135 can be synthesised either via SN2 nucleophilic displacement between 
pyridine and an alkyl or aryl halide or via the Zincke reaction (Scheme 14).67,68 
 
Scheme 14: Synthesis of THPy Conditions and reagents: Pathway I (a) excess Py. reflux, 24 h; (b) 2.8 
equiv NaBH4, MeOH, RT, 18 h;  
Pathway J (c) MeOH, RT - reflux, 24 h; (d) 2.8 equiv. NaBH4, MeOH, RT, 18 h 
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The Zincke reaction is a versatile method that allows the synthesis of pyridinium salts that 
cannot be made by direct N-functionalisation of pyridines.69  Zincke reported the preparation 
of pyridinium salts and their reactions with primary amines in a series of papers between 
1903 and 1905.68,69  The mechanism by which the Zincke reaction occurs is, that a primary 
amine reacts with a highly electrophilic N-2,4-dinitrophenylpyridinium salt 138, resulting in the 
ring-opening of 138 to afford dianil salts 141 and 142.  Reacting dianil salt 142 with another 
equivalent of primary amine generates 143 alongside the release of 2,4-dinitroaniline.  
Cyclisation of 139 results in the generation of pyridinium salt 135 (Scheme 15).70  
 
Scheme 15: Mechanism for the Zincke reaction 
 
The THPy moiety is present in a variety of pharmaceutical compounds, including dopamine 
autoreceptor agonists, GABA uptake inhibitors as anticonvulsant and sedatives, muscarinic 
agonists in the treatment of AD and non-steroidal anti-inflammatory drugs (NSAIDs).64  
Dopamine autoreceptor agonists, GABA uptake inhibitors and Muscarinic agonists which 
contain THPy moiety were reported to maintain healthy neurotransmission, which had 
previously been damaged by a dysfunction within the nervous system through excessive 
neurotransmission, which can lead to a variety of neurodegenerative diseases such as, AD, 
PD and ALS.  NSAIDs containing THPy functionality report the reduction of inflammation from 
a biological response by protecting the body from infection and reducing tissue damage 
through injury.  As stated early the exact mechanism in which ALS progresses in unknown, 
but through a number of proposed theories it is thought to be a combination of pathways 
including autoimmune, excitotoxicity, misfolding of the SOD1 gene and accumulation of TDP-
43.  Therefore tetrahydropyridine moiety incorporated with Riluzole could potentially enhance 
antiglutamate activity as both have been reported to reduce inflammation and regulate 
neurotransmission to a healthy level. 
 
1.5 1,4-Substituted-1,2,3-Triazole Moiety in a Variety of Drug Candidates  
The term ʻclick chemistryʼ was first conceived by Sharpless and co-workers in 2001, who laid 
out a set of high benchmarks which needed to be met if a reaction was to be termed a ʻclickʼ 
reaction.71  These benchmarks were; ʻthe reaction must be modular, wide in scope, give very 
high yields, and be stereospecific (but not necessarily enantioselective).  The required 
N
DNP
Cl
NH2 +R
138
N NH2R
DNP
Cl
RNH2 RNH3
+Cl-
N
DNP
NHR NH NR
DNP
141
HNN
RDNP
DNPNH2
+ RNH2NRHN
R
142143
N
R
RHN
RNH3
+Cl-RNH2
NRH2N
R
- RNH2
N
R
Cl
135
137 139 140
144145
CHAPTER 1: INTRODUCTION 
36 
process characteristics include simple reaction conditions, readily available starting materials 
and reagents, the use of no solvents or a solvent that is benign (such as water) or easily 
removed, and simple product isolation.72 
 
The Huisgen cycloaddition, also known, as the 1,3-dipolar cycloaddition, is a reaction 
between an azide and a terminal alkyne, which generates 1,4- and 1,5-substituted-1,2,3-
triazoles (Scheme 16).  This reaction was first described in the 1960s.73  The Huisgen 
cycloaddition reaction does not quite fit the ʻclickʼ reaction criteria as for the past 40 years this 
reaction has suffered from a lack of selectively yielding a mixture of 1,4- and 1,5-regioisomers 
due to activation energies of the two triazoles being very similar in energy 25.7 kcal/mol and 
26.0 kcal/mol.74  Furthermore, this transformation required heating and long reaction times to 
achieve completion, and the resulting regioisomers obtained require the use of potentially 
laborious separation techniques.73  In 2002 Medal, then Sharpless, discovered that CuI salts 
could be used to catalyse the Huisgen cycloaddition, which allowed the reaction to be 
regioselective and also eliminated the harsh reaction conditions previously reported.75  The 
reaction could also now be performed at room temperature (RT) with very short reaction times 
(Scheme 16).  The copperI catalysed azide-alkyne cycloaddition (CuAAC) is a close fit to the 
definition of ʻclick chemistryʼ.75    
 
Scheme 16: The 1,3-dipolar cycloaddition between azides and alkynes 
 
The CuAAC reaction to generate 1,4-substituted-1,2,3-triazoles tolerates most organic 
functional groups and shows a wide scope with respect to alkyne and azide reactants.  The 
reaction proceeds in a variety of solvents, tolerates a wide range of pH values, and performs 
well over a broad temperature range.76  The use of CuI in the 1,3-dipolar cycloaddition 
reaction lowers the activation barrier of the uncatalysed process by as much as 11 kcal/mol, 
which is sufficient to explain the incredible rate enhancement observed under CuI catalysis.76    
 
The CuAAC reaction proceeds via a stepwise sequence on the basis of calculation and 
kinetic studies.76  Although thermal cycloaddition of azides and alkynes occurs through a 
concerted [2+3] cycloaddition mechanism, DFT calculations on monomeric copper acetylide 
complexes indicate that the concerted mechanism is strongly disfavoured.  Overall a 
concerted mechanism is disfavoured as the calculated activation barrier for the cycloaddition 
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between an appropriate azide and copper-acetylene π complex is similar to the uncatalysed 
process, 25.7 kcal/mol.74,76  The stepwise catalytic cycle compared to the uncatalysed 
process lowers the activation energy by as much as 11 kcal/mol.76  The catalytic sequence 
begins with the coordination of the alkyne to the CuI species, forming a copper acetylide 
intermediate 151.  CuI is generated from an in situ reduction of CuII, such as CuSO4.5H2O 
with sodium ascorbate or ascorbic acid.  Introduction of the azide to this copper acetylide 
intermediate 151 generates an acetylide-azide complex 152.  The terminal nitrogen on the 
azide of the acetylide-azide complex 152 attacks the C-2 carbon of acetylide forming a six-
membered CuIII metallocycle 153.  This is followed by ring contraction, which results in the 
generation of a copper triazolide intermediate 154 which on elimination yields the 1,4-
substituted-1,2,3-triazole 148 upon protonation (Scheme 17).76  Formation of 1,4-substtuted-
1,2,3-triazoles is confirmed by nuclear overhauser effect (NOE) data as only the 1,4-
substituted-1,2,3-triazole gives NOE interactions to both substituents for the triazole proton 
and no NOE between the substituents.  NOE is the transfer of nuclear spin polarization from 
one nuclear spin population to another via cross-relaxation 
 
Scheme 17: Proposed catalytic cycle for the Cu
I
-catalysed ligation 
 
There are a few 1,2,3-triazole containing molecules on the market or in the last stages of 
clinical trials, which include the anti-cancer compound carboxyamidotriazole (CAI 155), the 
nucleoside derivative non-nucleoside reverse transcriptase inhibitor tert-
butyldimethylsilylspiroaminooxathioledioxide (TSAO 156), β-lactam antibiotic tazobactum 
(157) and the cephalosporine cefatrizine (158, Figure 22).77  Triazole moiety has been 
incorporated into a wide variety of therapeutically interesting drug candidates to date, which 
includes anti-inflammatory agents, CNS stimulants, sedatives, anti-anxiety and antimicrobial 
agents as well as showing anti-fungal activity.78  Compounds containing 1,2,3-triazole moiety 
have also shown a wide range of pharmacological uses such as anti-malarial, analgesic, anti-
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inflammatory, anti-convulsant, anti-neoplastic, anti-malarial, anti-viral, anti-proliferative and 
anti-cancer activities.78 
 
Figure 22: Potential pharmaceuticals based on 1,2,3-triazoles 
 
1,2,3-Triazole functionality is an attractive connectivity unit in drug discovery because of its 
stability against metabolic degradation and capable hydrogen bond acceptors from the N(2) 
and N(3) of the triazole ring (Figure 23).79  Hydrogen bonding is a favourable property in 
relation to the binding of biomolecular targets and can also improve the overall solubility of the 
pharmaceutically active compound.77   
 
Figure 23: 1,4-substituted-1,2,3-triazole 
 
In conclusion, click chemistry has had a dramatic and diverse impact on drug discovery and 
development in generating novel 1,4-substituted-1,2,3-triazole, which can be achieved via 
combinational chemistry.  Triazole moiety can be found in a range of pharmaceutically active 
compounds including CNS treatments.   
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To date Riluzole (1) is the only approved neuroprotective drug on the market, which prolongs 
the life expectancy of ALS patients via an unknown mechanism.  While Riluzole is the only 
neuroprotective compound against ALS it has relatively low efficacy.  This low efficacy means 
better therapies need to be investigated, which this thesis will do by modifying the chemical 
structure of Riluzole in the aim of producing a compound that has beneficial properties of 
Riluzole, but is predicted to be more effective in people living with ALS.  This will be achieved 
by looking into designing two novel synthetic routes incorporating tetrahydropyridine 159 and 
1,4-substituted-1,2,3-triazole 160 moiety at the N-3 position of Riluzole (Figure 24).  Once 
simple synthetic methods have been developed for these two N-3 Riluzole libraries all pure N-
3 Riluzole derivatives generated will be tested at Bradford University for their antiglutamate 
activity and compared to Riluzole.  
 
Figure 24: N-3 Riluzole Derivatives containing tetrahydropyridine and 1,4-substituted-1,2,3-triazole 
moiety 
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All N-3 Riluzole compounds synthesised were synthesised in accordance with Lipinskiʼs rule 
of five, which are as follows; (1) the molecule being synthesised does not exceed a molecular 
weight of 500 g/mol-1, (2) there are no more than five hydrogen bond donor groups, (3) there 
are no more than ten hydrogen bond acceptors, and (4) there is a calculated log P value of 
less than +5 (log P is a measure of drugʼs lipophilicity).80  Pure N-3 Riluzole compounds 
obtained were then biological tested for their antiglutamate activity compared to Riluzole by 
Victoria Pugh who is carrying out a PhD at the University of Bradford, ʻEvaluation and 
Mechanism of Novel Neuroprotective Compounds for the Treatment of Motor Neurone 
Diseaseʼ. 
  
3.1 Tetrahydropyridine Synthesis 
The addition of tetrahydropyridine functionality to the N-3 position of Riluzole as reported by 
Jimonet and co-workers compound 129 has shown an increase of antiglutamate activity 
compared to Riluzole by approximately an EC50 of 1.0 mg/kg.  Therefore synthesising a 
library of N-3 Riluzole analogues containing tetrahydropyridine moiety could result in an 
increase in antiglutamate activity reducing motor neuron damage, which could potentially lead 
to an increase in life expectancy for ALS patients.  
 
3.1.1 Synthesis of Tetrahydropyridines without Functionality on the 
Tetrahydropyridine Ring 
In 1999 Jimonet and co-workers reported the synthesis of a number of N-3 substituted 
Riluzole compounds, including 2-imino-3-[2-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)-ethyl]-6-
trifluoromethoxy-benzothiazoline 129 with higher antiglutamate activity than Riluzole (Scheme 
18).56  Scheme 18 shows a direct route to generating N-3 Riluzole analogues with 
tetrahydropyridine moiety, which can be further adopted to generating 3-(2-(4,5-
dihydropyridin-1-yl)ethyl)-6-trifluoromethoxy)benzothiazole-2-imine 159, which is the starting 
point towards generating a library of N-3 Riluzole analogues with the aim of enhancing 
Riluzoles antiglutamate activity. 
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Scheme 18: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2OH, 160 °C, 1.5 h, 49 %; (b) 2.0 equiv. 
TsCl, 2.0 equiv. Et3N, DCM, 0 °C, 1.5 h, 55 %; (c) 2.1 equiv. 4-phenyl-1,2,3,6-tetrahydropyridine 
hydrochloride, 2.1 equiv. NaHCO3, DMF, 80 °C, 18 h; (d) HCl, aq. AcOH, reflux, 3 h; (e) 1.0 equiv. Br2, 
4.0 equiv. KSCN, AcOH, RT, 18 h
56
 
 
Compound 129 was synthesised in four-steps starting from 4-trifluoromethoxyanilne 67.  
Reacting 4-trifluoromethoxyaniline with 2-bromoethanol generated amino alcohol 100 via an 
SN2 reaction.  Compound 100 was further reacted with two equivalents of p-toluenesulfonyl 
chloride to give the ditosylated amino alcohol 101.  Reacting compound 101 with 4-phenyl-
1,2,3,6-tetrahydropyridine resulted in the displacement of -OTs, which followed by acidic 
desulfonylation gave compound 161.  The final step in the generation of compound 129 was 
achieved by reacting compound 161 with KSCN and Br2.   
 
Cyclisation of compound 161 was achieved by firstly reacting a secondary amine with KSCN 
to form the thiourea intermediate 162, which then in the presence of Br2 underwent an 
electrophilic addition at sulfur to afford 163 as an intermediate.   This intermediate is then 
attacked by the π system of the aromatic ring to give 164, which is followed by rapid re-
aromatisation to form the benzothiazole ring (Scheme 19).81  
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Scheme 19: Proposed bromine mediated cyclisation to afford the benzothiazole core. Reagents and 
conditions: (a) 4.0 equiv. KSCN, AcOH, RT, 14 h; (b) 1.0 equiv. Br2, AcOH, RT, 18 h  
 
In generating compound 159 the first two-steps of Jimonet and co-workers pathway (Scheme 
18) were repeatable, but nucleophilic displacement between -OTs and pyridine to generate 
the pyridinium intermediate was unsuccessful with only starting material being recovered from 
the reaction between compound 101 and pyridine, the nucleophile.  Altering the -OTs for an 
iodide leaving group via the Finklestein reaction generated compound 165 in high yield 
(Scheme 21). 
 
The first-halogen exchange was reported in the mid 1800s by Perkin.82  However, the process 
became known as the Finklestein reaction after a number of systematic studies on the 
reaction were conducted by Finklestein several decades later, in 1910.82  The reaction 
proceeds by SN2 substitution of the leaving group, typically bromide or chloride, with an iodide 
(Scheme 20).  The reaction exploits the differing solubilities of sodium halide salts in acetone.  
Sodium chloride and sodium bromide are not soluble in acetone, so therefore precipitate out 
of the reaction mixture, thus driving the reaction to completion. 
 
Scheme 20: The mechanism of the Finklestein reaction 
 
The pyridinium intermediate was then reduced with sodium borohydride to generate 
tetrahydropyridine intermediate 166 via a double iminium reduction.  Desulfonylation of the 
secondary amine with strong acid to yield 167 was unsuccessful with only starting material 
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being recovered (Scheme 21).  Despite repeating this reaction, the desulfonylation was 
unsuccessful, which precluded the cyclisation pathway required to prepare an N-3 
unsubstituted tetrahydropyridine derivative of Riluzole.   
 
Scheme 21: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2OH, 160 °C, 1.5 h, 36 %; (b) 2.0 equiv. 
TsCl, 2.0 equiv. Et3N, DCM, 0 °C, 1.5 h, 48 %; (c) 2.0 equiv. NaI, acetone, reflux, 60 h, 97 %; (d) excess 
Py. reflux, 20 h, (e) 2.8 equiv. NaBH4, MeOH, 0 °C - RT, 42 h, 71 % (over two steps); (f) HCl, aq. AcOH, 
reflux, 3 h, 0 % 
  
Repetition of Jimonet and co-workers methodology to generate N-3 Riluzole analogues with 
tetrahydropyridine moiety was unsuccessful as desulfonylation of compound 167 was found 
to retard this synthetic pathway, even though Jimonet and co-workers have reported the 
generation of a number Riluzole analogues using this route.  Therefore alternative routes, 
which donʼt require protecting groups within the reaction pathway, should be investigated, 
such as the generation of sulfamidate and aziridine intermediates.   
 
3.1.1.1 Synthesis of Unfunctionalised Tetrahydropyridine Riluzole Derivatives via 
Sulfamidate Chemistry 
Cyclic sulfamidates are synthetically versatile electrophiles, which can be directly synthesised 
from readily available 1,2- and 1,3-amino alcohols.  Generating these cyclic sulfamidate 
intermediates in the generation of N-3 Riluzole tetrahydropyridines will remove previous 
problems highlighted by Jimonet and co-workers experimental procedure.  Pyridine then 
reacts at the C-O bond of the sulfamidate, which followed by desulfonylation and re-
aromatisation yields an N-3 Riluzole tetrahydropyridine. 
 
Constrained 1,2-amino alcohols, such as prolinol, are directly reacted with sulfuryl chloride to 
yield cyclic sulfamidates.83  Using this as a generalised method for the synthesis of cyclic 
sulfamidates from 1,2- and 1,3-amino alcohols is not feasible as this process can result in 
competitive chlorination and aziridination.83  A two-step approach is preferred instead.  Firstly 
1,2- and 1,3-amino alcohols are treated with thionyl chloride in the presence of imidazole 
generating 1,2- and 1,3-cyclic sulfamidites 169 in a highly efficient manner.  Cyclic sulfamidite 
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169 then undergoes oxidation with RuO4 or RuCl3 and NaIO4 in aqueous solvent to yield the 
cyclic sulfamidate 170.  A number of alternative oxidising agents reported in the literature, 
such as m-CPBA and KMnO4 have been tested previously, but reagents RuO4 or RuCl3 and 
NaIO4 have been reported as the most effective systems giving yields greater than 80 % 
(Scheme 22).83,84     
 
Scheme 22: Reagents and conditions: (a) 1.1 equiv. SOCl2, 2.2 equiv. Et3N, 4.0 equiv. imidazole, DCM, 
RT, 12 h; (b) 0.1 mol % RuCl3, 1.1 equiv. NaIO4, MeCN/H2O, RT, 12 h 
 
Nucleophilic attack directed towards cyclic sulfamidates occurs exclusively at the oxygen-
bearing carbon via an SN2 nucleophilic substitution (Scheme 23).
84  The reactivity of cyclic 
sulfamidates is similar to activated aziridines and azetidines, but not through ring strain.  
Cyclic sulfamidates can undergo ring-opening with a variety of nucleophiles, such as sulfur, 
oxygen, nitrogen, carbon and halogen nucleophiles.83  From here on in, this thesis will focus 
solely on the ring-opening of cyclic sulfamidates with nitrogen nucleophiles.   
 
Zhang and co-workers reported the facile synthesis of functionalised chiral ionic liquids via 
ring-opening of sulfamidates with pyridine (Scheme 23).85  This reaction is of relevance to 
generating 3-(2-(4,5-dihydropyridinin-1-yl)ethyl)-6-trifluoromethoxy)benzothiazole-2-imine 159 
as an uncyclised pyridinium ionic liquid will be generated as one of the intermediate 
compounds in the synthesis towards obtaining compound 159.  The generation of an 
uncyclised pyridinium compound can be obtained by generating a sulfamidate compound 
from compound 100, which is then ring-opened with pyridine.  This uncyclised pyridinium 
intermediate will then undergo re-aromatisation and reduction to yield compound 159.  
Pyridine behaves like a tertiary aliphatic or aromatic amine in reactions that involve bond 
formation through the lone pair of electrons on the nitrogen ring.  Pyridine attacks the C-O 
bond of the sulfamidate generating the desired pyridinium cation.86    
 
Scheme 23: Reagents and conditions (a) toluene, 80 °C, 10 h, 72 %; (b) excess HCl, EtOH, 80 °C, 6 h, 
88 % 
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The synthesis of cyclic sulfamidates with 1,2-amino alcohols followed by ring-opening with 
pyridine was adopted as a route for preparing Riluzole derivatives with tetrahydropyridine 
substituents at the N-3 position.  Compound 100 was treated with thionyl chloride in the 
presence of pyridine to generate cyclic sulfamidite intermediate 174 (Scheme 24).87  This 
reaction was attempted numerous times but only starting material was recovered from the 
reaction. 
 
Scheme 24: Reagents and conditions: (a) 3.3 equiv. SOCl2, excess Py. DCM, 0 °C - RT, 1.5 h, 0 % 
 
Reasoning behind why this reaction was unsuccessful could be due to the trifluoromethoxy 
group having electron deficient characteristics, which will in turn result in the lone pair of the 
nitrogen delocalising within the electron deficient aromatic ring.  Delocalisation of the nitrogen 
lone pair within the electron deficient ring will in turn retard cyclisation and sulfamidite 
generation, as nucleophilic attack between the nitrogen and the sulfurochloridite is less likely 
to occur.    
 
3.1.1.2 Synthesis of N-3 Riluzole Derivatives with Tetrahydropyridine Functionality via 
Aziridine Chemistry 
Aziridine functionality represents one of the most valuable three-membered ring systems in 
modern synthetic chemistry due to its widely recognised versatility as a significant building 
block for chemical bond elaborations and functional group transformations.88  Synthesising 
aziridine intermediates in the generation of N-3 Riluzole tetrahydropyridine will remove the 
use of protecting groups and also the number of steps required to get to the desired 
tetrahydropyridine product.  Also, aziridines are very constrained three-membered rings, 
which readily ring-open with a variety of nucleophiles, which include carbon, oxygen, sulfur, 
and nitrogen heteroatoms.  Over the years a number of different synthetic methods have 
been published regarding the synthesis of aziridines and this thesis focuses on three.  
 
3.1.1.2.1 Ring-opening of Aziridines via O-Diphenylphosphinyl Protection to Generate 
Unfunctionalised Tetrahydropyridine Riluzole Derivatives  
In 1993 Sweeney and co-workers first reported the preparation of N-phosphinylated aziridine 
176, which was efficiently prepared from 1,2-hydroxyamines via a three-step process 
(Scheme 25).89  
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Scheme 25: Reagents and conditions: (a) 1.0 equiv. Ph2POCl, 1.0 equiv Et3N, DCM, 0 °C - RT, 4 h; (b) 
1.1 equiv. TsCl, 3.0 equiv Et3N, 0 °C - RT, 18 h; (c) 2.0 equiv. NaH, THF, 0 °C - RT, 24 h, 52 % (over 
three steps) 
 
N-phosphinylated aziridines 176 are generated from 1,2-amino alcohols 175.  1,2-Amino 
alcohols 175 was reacted with one equivalent of p-toluenesulfonyl chloride, and then one 
equivalent of diphenylphosphonic chloride to give 2-((diphenylphosphoryl)amino)ethyl-4-
methylbenzenesulfonate.  This was further treated with NaH resulting in the cyclisation of 2-
((diphenylphosphoryl)amino)ethyl-4-methylbenzenesulfonate to yield N-phosphinylated 
aziridine 176 in good yield.  Small quantities of N-tosylaziridine 177 are also generated as a 
byproduct of this reaction.  This byproduct 177 is speculated to have been generated by 
incomplete phosphinylation generating N,O-ditosylated compounds which upon treatment 
with base yields the undesired aziridine 177.  Alternatively the phosphinyl group migrates 
from the nitrogen to the oxygen during tosylation, which then upon cyclisation with base will 
yield the undesired aziridine 177.89   
 
Sulfonyl groups are commonly used as activating groups for aziridines due to their excellent 
activation properties for ring-opening reactions with a variety of nucleophiles.  When these N-
tosylaziridnes are ring-opened they yield sulfonamides, which then require harsh conditions to 
achieve desulfonylation.  However as discussed earlier desulfonylation of the nitrogen on 
compound 177 has proven to be unsuccessful, which is what this chemistry will be applied to.  
Diphenylphosphinyl groups have similar activating effects to toluenesulfonyl group as the 
P=O bond is highly polar and compared to sulfonyl groups diphenylphosphonic groups can be 
easily removed because there is a smaller interaction between the phosphorus and lone pair 
on the nitrogen. Therefore, N-P bonds can be cleaved under much milder conditions (Scheme 
26).90   
 
Scheme 26: Reagents and conditions: (a) 2.0 equiv. Ph2POCl, 3.0 equiv. Et3N, THF, 0 °C - RT, 5 h; (b) 
excess NaH, THF, 0 °C - RT, 24 h, 99 % (over three steps) (c) Nu; (d) excess BF3OEt2, MeOH, DCM, 
RT, 18 h, 68 - 92 % (over two steps) 
91
 
 
Scheme 25 shows a plausible experimental procedure to generate O-
diphenylphosphinoylated compounds with 1,2-amino alcohols, which can then be cyclised via 
nucleophilic attack with a nucleophilic amine generated by using a strong base, such as NaH 
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to generate aziridines.  Scheme 26 reports a repeatable deprotection procedure to regenerate 
free amines.  These experimental procedures were applied to amino alcohol 100 in the aim of 
generating Riluzole derivatives with tetrahydropyridine substituents at the N-3 position from a 
secondary amine instead of a primary amine, which has been reported in the above schemes 
25 and 26.  Reacting compound 100 with one equivalent of diphenylphosphonic chloride 
successfully gave compound 182 in moderate yield (Scheme 27).  Further reacting compound 
182 with two equivalents of NaH did not generate the desired N-aryl aziridine 183 only 
starting material was recovered (Scheme 27).  After numerous attempts this method was 
sidelined.   
 
Scheme 27: Reagents and conditions: (a) 1.0 eq Ph2POCl, Et3N, DCM, 0 °C - RT, 94 %; (b) 2.0 equiv. 
NaH, THF, 0 °C - RT, 24 h, 0 % 
 
As discussed in section 3.1.1.1 the generation of a sulfamidate intermediate 174 in the 
preparation of generating N-3 Riluzole analogues with tetrahydropyridine moiety was 
unsuccessful due to the nitrogen lone pair not being available for nucleophilic attack, as a 
result of the nitrogen being delocalised in the electron deficient ring.  The reasoning provide 
for compound 174 is also true for aziridine 183 not being generated.   
 
3.1.1.2.2 Ring-opening of Aziridines via Buchwald-Hartwig Cross-Coupling to Generate 
Unfunctionalised Tetrahydropyridine Riluzole Derivatives 
Palladium-catalysed carbon-nitrogen bond-forming reactions have received considerable 
attention in recent years, with the first reported synthesis of palladium-catalysed amination of 
aryl halides being published by Kosugi et al. in 1983.92  Using this methodology to generate a 
Riluzole aziridine intermediate 183 between an aryl halide and aziridine will remove previous 
issues experienced in which cyclisation has not occurred due to the nitrogen lone pair being 
delocalised within the electron deficient ring preventing nucleophilic attack.   
 
Buchwald and Hartwig concurrently investigated both the mechanistic and synthetic process 
of the palladium-catalysed amination of aryl halides 10 years after it was first reported.  In 
1995 both Hartwig and Buchwald separately reported the replacement of tin reagents for 
either alkoxide or silylamide bases as the generation of tin amides, are known to be toxic, 
thermally unstable, air-sensitive and can only be applied to electron-neutral aryl halides.92  
Exploration of alkoxide bases, such as NaOtBu, K2CO3 and Cs2CO3 by Buchwald and co-
workers reported that they could be applied to the palladium-catalysed amination between a 
variety of electron-withdrawing and electron-donating aryl bromides with either primary or 
secondary amines.93  In 1996 Hartwig and Buchwald published a number of back-to-back 
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papers in which the palladium catalyst is complexed with chelating phosphine type ligands 
such as BINAP and DPPF.92  It was reported that these palladium complexes catalysed the 
amination of aryl bromides and iodides with primary alkyl amines, cyclic secondary amines, 
and anilines.  Overall, BINAP is the preferred ligand of choice as amination between either 
alkyl amines or alkyl halides can be applied to a number of electron-rich, electron-poor, 
hindered, unhindered or neutral aryl bromides, iodides or amines and will give high yields.   
 
Buchwald proposed the catalytic cycle by which palladium-catalysed cross-coupling amination 
generates new C-N bonds between suitable amines and aryl halides.94  Firstly, Pd(0) 
undergoes oxidative addition with a suitable aryl halide to generate 189, which is followed by 
amine addition to give 191.  The introduction of an alkoxide base generates 192 a Pd(II)-aryl 
amide, which is then reductively eliminated to generate a new C-N bond and also the 
regeneration of the Pd(0) catalyst (Scheme 28). 
 
Scheme 28: The catalytic cyclic for the formation of C-N bonds 
 
Palladium-catalysed amination reactions between aryl halides and aziridines were not 
reported until 2003 where Yudin and co-workers described the reaction between 
cyclohexeneimine 194 and a variety of electron-withdrawing and electron-donating groups at 
the para and ortho potion of the aryl halide (Scheme 29).95,96  Palladium cross-coupling 
conditions reported by Yudin and co-workers are of interest towards the synthesis of 
compound 183 as electron-withdrawing aryl halides can be reacted with aziridines.   
 
Scheme 29: Reagents and conditions: (a) 2 mol % Pd2(dba)3, 2 mol % BINAP, 1.4 equiv. 
t
BuONa, 
toluene, 50 °C - 80 °C, 2 - 24 h, 76 - 96 %  
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The experimental procedure reported by Yudin and co-workers was adapted to synthesising 
N-3 tetrahydropyridine Riluzole analogue.  As previously discussed the generation of a 
Riluzole aziridine intermediate via intramolecular cyclisation has not been successful due to 
the nitrogen lone being delocalised within the electron deficient aromatic ring.  The generation 
of a Riluzole aziridine intermediate using Yudin and co-workers methodology removes 
intramolecular cyclisation and instead palladium catalysed cross-coupling between 4-
trifluoromethoxy bromobenzene and aziridine will be attempted.  Palladium cross-coupling 
between 4-trifluoromethoxy bromobenzene and aziridine, which was generated in situ by 
reacting 2-chloroethylammonium hydrochloride with 0.02 M sodium hydroxide solution did not 
generate compound 183 (Scheme 30).97  4-Trifluoromethoxy bromobenzene was seen to be 
fully consumed, but product peaks were not observed in the crude 1H NMR.  Overall the 1H 
NMR obtained was inconclusive.   
 
Scheme 30: Reagents and conditions: (a) 2.0 equiv. 0.02 M aq NaOH, H2O, 50 °C, 45 mins
97
; (b) 2 mol 
%, Pd2(dba)3, 2 mol % rac-BINAP, 1.4 equiv. Na
t
OBu, toluene, 50 °C, 12 h, 0 % 
 
Reasoning for the lack of success with this reaction could be related to the conditions used to 
cross-couple aziridine with 4-trifluoromethoxy bromobenzene, as Yudin and co-workers only 
reported palladium cross-coupling with substituted or kinetically stable aziridines, such as 
cyclohexeneimine 194.  Cross-coupling with aziridine has proven to be problematic firstly due 
to its low basicity (the pKa of the aziridinium ion is 8.0, whereas that of a secondary amine is 
ca. 11) and secondly its inherent ring strain of approximately 111 kJ mol-1.98  Low basicity of 
the aziridine results in weak bond formation of the amine within the aziridine and activated 
palladium catalyst, which means the generation of palladium mediated N-arylated compounds 
are less likely to be generated.  Palladium mediated N-arylated products are less likely to be 
generated from aziridines having low basicity instead of aziridines being ring-opened because 
of the ring strain associated which results in the generation of unwanted ring-opened 
products.  Ring-opening of aziridines can be induced by either nucleophilic attack at the 
carbon or Lewis acid coordination at the nitrogen.  In general, ring-opening reactions of 
aziridines and N-arylaziridines can be achieved under relatively mild conditions.99   
 
3.1.1.2.3 Generation of Aziridines via the Mitsunobu Reaction Followed by Ring-
Opening to Generate Unfunctionalised Tetrahydropyridine Riluzole Derivatives 
Mitsunobu conditions have been widely reported for the synthesis of aziridines from 1,2-
amino alcohols.100  In 1984 Pfister reported the synthesis of aziridines via intramolecular 
dehydrogenation of 2-aminoethanol using a combination of DEAD and triphenylphosphine 
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(Scheme 31).101  Since then a number of aziridines have been generated from 1,2-amino 
alcohols using this methodology.102   
 
Scheme 31: Reagents and conditions: (a) 1.5 equiv. DEAD, 1.5 equiv. PPh3, THF/Et2O, 0 °C - RT, 2 h, 
18 % 
 
Using Mitsunobu reaction conditions to generate a Riluzole aziridine intermediate will remove 
issues previously experienced with protecting groups reported by Jimonet and co-workers 
methodology, which did not successfully generate an N-3 Riluzole analogue with 
tetrahydropyridine moiety as desulfonylation was not repeatable.  Applying the following 
methodology to compound 100 did not yield a Riluzole aziridine intermediate 183 only starting 
material was recovered (Scheme 32). 
 
Scheme 32: Reagents and conditions: (a) 1.4 equiv. DEAD, 2.0 equiv. PPh3, THF/Et2O, 0 °C - RT, 24 h, 
0 % 
 
The three-step intramolecular Mitsunobu reaction in which the amino alcohol 100 is converted 
to a Riluzole aziridine intermediate 183 was as stated above unsuccessful.  The recovery of 
starting material could be the result of the trifluoromethoxy group attached at the para position 
of aniline being electron withdrawing with a hammett value of σp = 0.35.
103  Having an electron 
deficient aromatic ring attached to the nitrogen will reduce intramolecular SN2 nucleophilic 
displacement between the nitrogen and the activated alcohol reducing the chances of 
generating a Riluzole aziridine intermediate.   
 
3.1.1.3 Zincke Reaction 
The Zincke reaction is an amine exchange process in which primary amines are converted to 
pyridinium salts using N-(2,4-dinitrophenyl) pyridinium chloride 138 (Scheme 33).104   
 
Scheme 33: Zincke Reaction Reagents and Conditions: (a) 2.0 equiv R-NH2, EtOH, reflux, 12 h 
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Incorporating the Zincke reaction into the synthesis of N-3 Riluzole with tetrahydropyridine 
moiety will remove focus from previous chemistry, which so far has focused on the secondary 
amine attached to an electron deficient aromatic ring.  All reaction pathways so far focusing 
on the secondary amine attached to an electron deficient ring have ended in failure therefore 
taking a new approach could result in success.  The aim is to generate a diamine compound 
which will react with N-(2,4-dintrophenyl) pyridinium chloride via Zincke reaction conditions 
generating an uncyclised pyridinium compound 204.  Once this intermediate has been 
generated it will then undergo cyclisation and reduction to generate an N-3 Riluzole 
tetrahydropyridine analogue (Scheme 34).   
 
Scheme 34: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 
1.0 equiv. N-(2,4-dintirophenyl) pyridinium chloride, MeOH, RT - reflux, 20 h; (c) 1.0 equiv. sodium p-
toluenesulfonate, EtOAc, reflux 12 h, 78 % (over two steps); (d) 12.0 equiv. KSCN, 1.0 equiv. Br2, 
AcOH, RT, 16 h; (e) 2.8 equiv. NaBH4, MeOH, 0 °C - RT, 16 h, 69 % (over two steps)  
 
Firstly 4-trifluoromethoxyaniline underwent an SN2 nucleophilic displacement with 2-
bromoethylamine hydrobromide to generate diamine 203.105  The diamine 203 is then reacted 
with N-(2,4-dinitrophenyl) pyridinium chloride 138 under Zincke reaction conditions to yield an 
uncyclised pyridinium salt 204, which proceeds via Scheme 15, found on pg. 36.  Reacting 
compounds 203 and 67 together generates a ring-opened dianil salt.  Reacting ring-opened 
dianil salt with another equivalent of compound 203 results in the generation of a diamine 
chain and the release of 2,4-dintiroanilne.  The diamine chain then undergoes cyclisation to 
yield compound 204 after counter-ion exchange.  Compound 204 then undergoes cyclisation 
with the following reagents KSCN and Br2 under acidic conditions to generate intermediate 
205, which is then reduced in situ with NaBH4 to yield compound 159 (Scheme 34).    
 
Uncyclised pyridinium 204 is generated over uncyclised tetrahydropyridine as cyclisation of 
the latter has been reported to yield a dibromopiperidine ring.  Optimisation studies of 
cyclising uncyclised pyridinium 204 to the crude intermediate 205 were investigated as 
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following the exact experimental procedure reported by Jimonet and co-workers gave a 1:1 
ratio of 204 and 205.  This optimisation study focused on varying the equivalents of KSCN 
and Br2, and also looked at using alternative bromine source (Table 3).  All other variables 
time, temperature and solvent were kept constant throughout this study.  
 
Table 3: Varying the equivalents of KSCN, Br2 or PhCH2NMe3Br3 source 
 
Reagents and conditions: (a) 4.0 - 12.0 equiv. KSCN, 1.0 - 2.0 equiv. Br2 or PhCH2NMe3Br3, AcOH, RT, 
24 h 
 
Entry KSCN Br2 PhCH2NMe3Br3 204:205 
a
 
1 4.0 eq 1.0 eq - 1:1 
2 8.0 eq 1.0 eq - 1:4 
3 12.0 eq 1.0 eq - 1:8 
4 4.0 eq 2.0 eq - 1:1 
5 8.0 eq 2.0 eq - 1:1 
6 12.0 eq 2.0 eq - 1:4 
7 4.0 eq - 1.0 eq 1:2 
8 8.0 eq - 1.0 eq 1:3 
9 12.0 eq - 1.0 eq 1:5 
10 4.0 eq - 2.0 eq 1:1 
11 8.0 eq - 2.0 eq 1:1 
12 12.0 eq - 2.0 eq 1:4 
a 1H NMR were run in CDCl3 after working up the reaction  
 
Entries 1-6 in Table 3 vary the equivalents of KSCN and Br2.  Ratios of starting material 204 
to crude intermediate 205 were determined by comparing proton integration corresponding to 
the two compounds after work-up with all 1H NMRs run in CDCl3.  The highest conversion of 
204 to 205 used twelve equivalents of KSCN and one equivalent of Br2, entry 3.  Entries 7-12 
of Table 3 vary the equivalents of KSCN and an alternative bromine source, 
trimethylphenylammonium tribromide (PhCH2NMe3Br3), which is an organic ammonium 
tribromide (OATB).  OATBs compared to liquid bromine have higher molecular weights so are 
found as crystalline solids.  Advantages of using OATBs over liquid bromine include higher 
stability and accurate masses as OATBs are less volatile and take solid forms.81  Overall for 
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all entries in Table 3 a trend can be observed, increasing the equivalents of KSCN from four 
to twelve equivalents increases the conversion of 204 to 205.  Altering the equivalents of 
bromine from one to two equivalents shows no enhanced improvement in conversion of 
compound 204 to crude intermediate 205.  Also altering the bromine source from Br2 liquid to 
an OATB showed no improvement in conversion from 204 to 205.  To conclude this 
optimisation study has reported that the reaction conditions required for a high conversion of 
compound 204 to intermediate 205 requires twelve equivalents of KSCN and one equivalent 
of Br2, entry 3. 
 
Riluzole derivative 159 was obtained in a four-stage synthesis from 4-trifluoromethoxyaniline 
with an overall yield of 13 %.  Biological testing on compound 159 was not conducted as 
standard column chromatography failed to give sufficiently pure compound.    
 
3.1.2 Synthesis of Functionalised Tetrahydropyridines  
3.1.2.1 Using the Zincke Reaction 
Generating an N-3 Riluzole tetrahydropyridine analogue was successful using Zincke reaction 
chemistry.  The synthesis of N-3 Riluzole tetrahydropyridine analogues with substitution on 
the tetrahydropyridine ring can be generated using the same method describe for compound 
159 but instead substituted Zincke salts are used.  Synthesising a variety of substituted N-3 
Riluzole tetrahydropyridine analogues will produce a variety of N-3 Riluzole substituted 
tetrahydropyridine analogues, which can be tested for their antiglutamate activity against 
Riluzole in the aim of generating an analogue with greater antiglutamate activity. 
 
Substituted Zincke salts are generated by reacting a substituted pyridine with 1-chloro-2,4-
dinitrobenzene (Scheme 35).  The substituted Zincke salt 208 is then reacted with a primary 
amine to yield a substituted pyridinium compound, which when reduced yields a substituted 
tetrahydropyridine.  When generating a substituted Zincke salts there are a few important 
aspects to consider: (1) pyridines with functionality at either the 2- or 6-position do not 
generate Zincke salts as this retards primary amine attack due to unfavourable steric effects, 
(2) generation of Zincke salts between 1-chloro-2,4-dinitrobenzene and pyridines with strongly 
electron deficient functionality, with R being CN, or NO2 or where R
1 is also CN or NO2 are not 
obtainable due to the pyridines lone pair being pulled towards the electron deficient functional 
group so therefore stopping SNAr substitution, and (3) Zincke salts with the following 
substituted pyridines having R as Br or COOEt or R1 as COOEt can be obtained but require 
elevated temperatures.68   
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Scheme 35: Generation of substituted N-(2,4-dinitrophenyl)pyridinium chloride salts; Reagents and 
conditions: (a) Acetone or MeOH, reflux, 48 h, 63 - 85 %
70
  
 
The rate in which pyridinium salts are generated via the nucleophilic substitution between a 
substituted Zincke salt and a primary amine are determined by the functionality on the Zincke 
salt 208.  It has been reported that the reaction between primary amines and mildly electron-
deficient Zincke salts generates pyridinium salts quickly as fast ring-opening of the Zincke salt 
has been recorded.  Whereas, reacting primary amines with electron-rich Zincke salts 
generates pyridinium slats slowly as slow ring-opening of the Zincke salt has been recorded.  
This sluggish reaction with electron-rich Zincke salts can be overcome by raising the reaction 
temperature, changing the solvent the reaction is run in, or changing the Zincke salts 
counteranion from chloride to dodecyl sulfate.  Altering the Zincke salts counter-ion will lower 
nucleophilic anion properties, which will then allow Zincke salts to dissolve in a broader range 
of organic solvents.68,106    
 
Zincke salts 209 entries 1-6 of Table 4 were generated via an SNAr substitution between 1-
chloro-2,4-dinitrobenzene and substituted pyridines giving moderate to high yield 49 - 92 %.  
These Zincke salts generated were then reacted with diamine 203 to give crude uncyclised 
substituted pyridinium salts, which then underwent counter-ion exchange with sodium p-
toluenesulfonate to yield pure uncyclised substituted pyridinium tosylate salts 210 a - f in low 
to good yields over two-steps.  Having substitution at the 3-position of the pyridinium tosylate 
salts decreased in yield as you increased the alkyl chain.  Whereas, substitution at the 4-
position of the pyridinium tosylate salt decreased in yield as the alkyl chain was increased 
and using bulkier groups increased the yield.  Overall compound 210 f gave the best yield of 
pyridinium tosylate salt 89 %.  
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Table 4: Results obtained from the reaction of compound 203 with substituted zincke salts 
 
Reagents and conditions: (a) 1.0 equiv. Zincke salt, solvent, RT - reflux, 18 h; (b) 1.0 equiv. sodium p-
toluenesulfonate, EtOAc, reflux, 12 h, 18 - 89 % (over two steps) 
 
Zincke Salt 209 
Entry 
R R
1
 
Solvent 
Time 
(hrs) 
Compound % Yield 
1 
107
 Me H n-butanol 18a 210a 41 
2 
108
 H Me n-butanol 18a 210b 73 
3
 107
 Et H MeOH 18b 210c 18 
4
 109 H Et MeOH 18b 210d 63 
5
 110
 Ph H EtOH 18a 210e 44 
6
 111
 t-Bu H n-butanol 18a 210f 89 
a = Refluxed; b = 2 hrs RT-16 hrs reflux 
 
All uncyclised pyridinium tosylate salts were subjected to ring cyclisation with KSCN and Br2 
under an acidic medium.  The following uncyclised pyridinium tosylate salts 210 a, d and e 
successfully yielded crude ring cyclised pyridinium salt 211 a - c.  These crude ring cyclised 
pyridinium salts were then subjected to in situ reduction with NaBH4 to yield crude N-3 
functionalised tetrahydropyridine Riluzole derivative 212 a - c as oils (Table 5).  Yields for 
compounds 212 a - c were calculated from crude mixtures after work-up.  Following on from 
observation observed for the uncyclised pyridinium tosylate salts similar trends were seen.  
For tetrahydropyridine Riluzole analogues containing substitution at the 4-position it was 
observed that compound 212 c gave a higher crude yield than 212 a with a crude yield of 68 
% compared 30 %.  For the tetrahydropyridine Riluzole analogue containing substitution at 
the 3-position a crude yield of 69 % was obtained.  
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Table 5: Synthesis of N-3 substituted tetrahydropyridine derivatives of Riluzole 
 
Reagents and conditions: (a) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 16 h; (b) 2.8 equiv. NaBH4, 
MeOH, 0 °C - RT, 16 h, 30 - 69 % crude (over two steps) 
 
Uncyclised pyridinium tosylate 
210 Entry 
R R
1
 
Compound Yield (%)
a
 
1 Me H 212a 30 
2 H Et 212b 69 
3 Ph H 212c 68 
a
 isolated crude yield after reaction work-up 
 
Crude proton NMRs of compounds 212 a - c were obtained by running the sample in CDCl3 
after worked-up.  The crude proton NMR results obtained for compounds 212 a - c show that 
the ring cyclised pyridinium previously synthesised have successfully undergone reduction as 
a broad singlet is found in the region between 6.5 and 4.5 ppm, which corresponds to the 
alkene region (Figure 25).  Compound 212 c, which contains the phenyl substituent at the 
para position was observed further downfield compared to the other two analogues due to its 
aromatic functionality.  The other distinct region within these crude 1H NMRs is between 7.5 
and 6.5 ppm, which corresponds to the benzothiazole ring formation as prior to cyclisation 
this splitting pattern is not observed.  The 1H NMRs are going from two doublets in the 
aromatic region, which corresponds to the four aromatic protons attached to the 
trifluoromethoxy group of the uncyclised compound 210 a, d and e to two doublets and a 
singlet, which corresponds to the three protons of the benzothiazole ring.     
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Figure 25: Crude 
1
H NMR of 3- and 4-substituted tetrahydropyridines; 212 a, 212 b, 212 c 
 
N-3 functionalised tetrahydropyridine Riluzole derivatives were obtained via the Zincke 
reaction from 4-trifluoromethoxyaniline in moderate yields.  Biological testing of compounds 
212 a - c has not been reported because the following tetrahydropyridine Riluzole derivatives 
could not be purified via simple column chromatography.  Column chromatography was not a 
viable method of purification because of their polarity.  The following solvent, MeOH moved 
these compounds of the baseline, but in doing so this did not remove any possible impurities 
or improve the physical appearance of the compounds.   
 
3.1.2.2 Using Grignard Reagents 
The Zincke reaction method described in section 2.1.2.1 has provided a viable method to 
generating an N-3 Riluzole containing tetrahydropyridine functionality.  This synthetic pathway 
described, Scheme 34 can be modified to incorporate a Grignard reaction, which can then go 
on to generate a library of N-3 Riluzole tetrahydropyridine analogues with substitution at the 
2-position, which is not possible via substituted Zincke salts.  Having substitution at the 2-
position as well as the 3- and 4-position via substituted Zincke salt reactions will provide a 
variety of analogues to be tested for their antiglutamate activity compared to Riluzole and 
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having substitution at the ortho, para and meta position will highlight any possible trends 
observed when biologically tested.    
 
In 1909 Freund and Bode reported the formation of 1,2- and 1,4- dihydropyridines by reacting 
pyridine with a range of suitable Grignard reagents.112 Since this first report, a number of 
publications have described the addition of carbon nucleophiles to pyridinium salts at the 2-, 
4- and 6-position generating 2-, 4- and 6-functionalised dihydropyridine intermediates.  N-alkyl 
dihydropyridine intermediates are further reduced to tetrahydropyridines or piperidines due to 
the intermediate dihydropiperidines being unstable.113  Nucleophiles that have been reported 
to have undergone nucleophilic addition with pyridine and N-alkyl pyridinium salts, include 
alkyllithium reagents such as phenyllithium and tert-butyllithium which react exclusively at the 
2-position; Grignard reagents which, depending on the bulkiness of the Grignard reagent, 
react at either the 2- or 4-position; and lithium organocuperates which, react solely at the 4-
position.114  The remainder of this subchapter will focus on the reaction between N-alkyl 
pyridinium salts and Grignard reagents. 
 
Guillotea-Bertin and co-workers reported the synthesis of 2-functionalised tetrahydropyridines 
by reacting pyridinium salt 214 with suitable Grignard reagents (Scheme 36).115  This is 
achieved by firstly alkylating the pyridinium salt with a suitable Grignard reagent, which yields 
an unstable 1,2-dihydropyridine 215.  The unstable 1,2-dihydropyridine is then reduced with 
NaBH4 affording tetrahydropyridine 216 as the major product and 217 and 218 as the minor 
products.  Guillotea-Bertin and co-workers observed that regioselective attack at the 2-
position of the pyridinium ring decreases with relatively hindered Grignard reagents, such as 
benzyl and isopropylmagnesium bromide which attack predominately at the 4-position of the 
pyridinium ring, resulting in the formation of piperidines 218 as the major product, after 
reduction.115    
 
Scheme 36: Reagents and conditions: (a) DCM, 20 °C - Reflux, 36 h
116
; (b) 3.0 equiv. MeMgCl, 
THF/toluene, -20 °C - 0 °C, 3 h; (c) 6.0 equiv. NaBH4, aq. MeOH, reflux, 1 h, 46 % (over three steps)  
 
Guillotea-Bertin and co-workers methodology was applied to the synthesis of N-3 Riluzole 
analogues with 2-substituted tetrahydropyridines.  Firstly compound 204, which is generated 
by reacting diamine 203 with Zincke salt, 2,4-dinitrophenyl pyridinium chloride followed by a 
counter-ion exchange is ring cyclised generating N-3 Riluzole pyridinium salt 205.  Pyridinium 
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salt 205 is then alkylated with one of the following Grignard reagents, methylmagnesium 
bromide, ethylmagnesium chloride or phenylmagnesium chloride (Table 6).  This is followed 
by in-situ reduction to generate N-3 Riluzole 2-substituted tetrahydropyridine analogues.    
 
Table 6: Synthesis of 2-substituted tetrahydropyridines 
 
Reagents and conditions: (a) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 16 h; (b) 3.0 equiv. RMgX, 
THF, -20 °C - 0 °C, 3 h; (c) 6.0 equiv. NaBH4, 90 % aq MeOH, reflux, 1 h, 0 - 62 % (over three steps) 
 
Entry Grignard Reagent (R) Compound Yield  (%)
a
 
1 MeMgBr 220a 42 
2 EtMgCl 220b 62 
3 PhMgCl 220c 0 
a % yields are calculated as a whole from the crude reaction mixture after work and 1H NMR were run in 
CDCl3 
  
Running the reaction in THF/Toluene as reported by Guillotea-Bertin solely yielded compound 
205.  It was observed that compound 205 did not dissolve in this solvent system, which gives 
indication into why only compound 205 was recovered.  Running the reaction solely in THF 
rectified solubility issues previously experienced and successfully yielded crude N-3 Riluzole 
2-substituted tetrahydropyridines.  Alkylating compound 205 with methylmagnesium bromide 
and ethylmagnesium chloride successfully generated N-3 Riluzole analogues with 2-
substituted tetrahydropyridines.  Crude yields obtained indicate that increasing the alkyl chain 
of the Grignard reagent increases the percentage yield of 2-substituted tetrahydropyridines.  
Alkylating compound 205 with phenylmagnesium chloride does not yield N-3 Riluzole 2-
phenyl tetrahydropyridine and starting material is not recovered (Figure 26).  The crude 1H 
NMR for the alkylation of compound 205 with phenylmagnesium chloride followed by in-situ 
reduction does not show the two protons corresponding to the alkene region of the 
tetrahydropyridine ring.  This distinct alkene region of the tetrahydropyridine ring is observed 
for compounds 220 a and b, highlighted in the black box, Figure 26.  Guillotea-Bertin and co-
workers have previously discussed that the alkylation of pyridinium salts with hindered 
Grignard reagents, such a phenylmagnesium chloride do not yield 2-substituted 
tetrahydropyridines, but instead generate 4-substituted piperidine rings, which would highlight 
why an alkene region is not seen for compound 220 c.  Due to compound 220 c crude 1H 
NMR being unclear mass spectrometry was performed to determine whether one of these 
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products had been generated, however mass spectrometry analysis did not detect the mass 
of the N-3 4-substituted piperidine Riluzole or the masses for compound 205.  
 
Figure 28: Crude 
1
H NMR for compounds 159, 220 a, 220 b and 220 c 
 
In summary, crude 2-substituted tetrahydropyridine Riluzole derivatives can be generated in 
four-steps from 4-trifluoromethoxyaniline, with methyl and ethyl Grignard reagents.  
Purification of these crude 2-substituted tetrahydropyridine compounds via simple column 
chromatography has proven difficult, as pure samples for biological testing was not 
achievable.  Purifying compounds 220 a and b using HPLC successfully generated a pure 
sample of compound 220 a, but when compound 220 b was purified using the same HPLC 
solvent system the compound was found to break down on the column.  Overall this synthetic 
method to generate a library of novel N-3 substituted tetrahydropyridine Riluzole derivatives is 
not versatile as bulky Grignard reagents do not yield the desired tetrahydropyridine analogues 
and also a versatile purification method has not be achieved. 
 
3.2 Synthesis of N-3 1,4-Substituted-1,2,3-Triazole Derivatives of Riluzole Using Click 
Chemistry 
1,2,3-Triazoles generated to date have a lot of interest in drug discovery including 
combinational chemistry.  Therefore click chemistry will be investigated to generate a library 
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of N-3 Riluzole 1,4-substituted-1,2,3-triazole analogues.79  The 1,2,3-triazole nucleus has 
diverse biological activities including anticancer, antifungal, antibacterial, antiturberculosis and 
antivirus.  Triazoles exhibit both basic and acidic properties and are also found to be very 
stable to metabolic and chemical degradation making them rather inert to severe hydrolytic, 
oxidising and reducing conditions, even at high temperatures.79  All these properties 
described above for triazole moiety are favourable characteristics in designing novel 
pharmaceutically active compounds.  Triazole analogues synthesised within this thesis will be 
tested for their antiglutamate activity against Riluzole.  
 
1-4-Substituted-1,2,3-triazole derivatives of Riluzole 160 will be generated as follows firstly 4-
trifluoromethoxyaniline 67 will undergo SN2 nucleophilic displacement with 2-bromoethylamine 
hydrobromide to generate diamine 203.  Diamine 203 then undergoes diazotransfer with 
imidazole-1-sulfonyl azide hydrochloride to yield azide 222.  Imidazole-1-sulfonyl azide 
hydrochloride 221 is synthesised in two-steps.  Firstly equimolar amounts of sulfuryl chloride 
and sodium azide are reacted together to yield chlorosulfonyl azide, which is then reacted an 
excess of imidazole generating the diazotransfer reagent in moderate yield, 48 %.117  Azide 
222 is then ring cyclised in the presence of KSCN and Br2 to yield azide 223.  Azide 223 will 
then be reacted with a terminal alkyne in the presence of substoichiometric amounts of CuI, 
which is generated in situ to yield a 1,4-substituted-1,2,3-triazole Riluzole analogue 160 
(Scheme 37).118  The catalytic cycle by which 1,4-substituted-1,2,3-triazoles are synthesised 
is shown on pg. 38 Scheme 17. 
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Scheme 37: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 
1.2 equiv. Imidazole-1-sulfonyl azide hydrochloride, 2.3 equiv. K2CO3, 0.001 equiv. CuSO4.5H2O, 
MeOH, RT, 2 h, 25 %; (c) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 2 h, 63 %; (d) 1.5 equiv. 
Terminal Alkyne, THF/H2O, 1.0 equiv. 1M CuSO4, 2.0 equiv. 1M NaAsc, 20 °C, 2 h, 27 - 98 % 
105,117,118,119 
 
Conversion of diamine 203 to azide 222 is obtained via a diazotransfer instead of nucleophilic 
displacement with an azide anion because an azide anion could result in the formation of 
elimination products or products with the incorrect stereochemical configuration.117  Ruff120 
first described the conversion of primary amines to azides using the following diazotransfer 
reagent, trifluoromethanesulfonyl azide (TfN3) in the presence of catalytic amounts of Cu
II, 
which generates organic azides in high yields and preserves any existing 
stereochemistry.121,122  However, using TfN3 as a diazotransfer reagent in the conversion of 
primary amines to azides has some major drawbacks which include its explosive nature, 
relatively poor shelf life, difficulty in extraction from polar compounds and the expense of the 
starting material trifluoromethanesulfonic anhydride in generating TfN3.
117  Hanessian and 
Vatèle reported diazotransfer reactions with the diazotransfer reagent imidazole-1-sulfonyl 
azide hydrochloride, which resulted in the conversion of primary amines to azides.117,123  
Imidazole-1-sulfonyl azide hydrochloride is reported to have similar reactivity to that of 
trifluorosulfonates, but compared to TfN3, imiadazole-1-sulfonyl azide hydrochloride has a 
longer shelf live and is less expensive to prepare.    
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Azide 223 was successfully generated in three-steps starting from 4-trifluoromethoxyaniline 
67 (Scheme 37).  Reacting azide 223 with a number of terminal alkynes including alkyl 
chains, cyclic alkyls, alkyl esters, alkyl benzenes, heterocycles and electron-donating and 
electron-withdrawing aromatic rings in the presence of substoichiometric amounts of CuI 
generated in situ between copper sulfate and sodium ascorbate successfully generated 1,4-
substituted-1,2,3-triazole N-3 Riluzole analogues 160 (Table 7).  All reactions were run at 20 
°C and reactions were monitored by TLC. 
 
Table 7: Synthesis of N-3 1,4-substituted-1,2,3-triazole Riluzole compounds 
 
 Reagents and conditions: (a) 1.5 equiv. Terminal Alkyne, THF/H2O, 1.0 equiv. 1M CuSO4, 2.0 equiv. 
1M NaAsc, 20 °C, 2 h, 27 - 98 % 
 
Entry Alkyne (R) Compound Time (hrs)
a
 Yield (%)
b
 
7 
 
160a 3 39 
8 
 
160b 3 50 
9 
 
160c 2 47 
10 
 
160d 2 56 
11 
 
160e 2 59 
12 
 
160f 2 37 
13 
 
160g 2 64 
14 
 
160h 2 53 
15 
 
160i 2 46 
16 
 
160j 2 50 
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17 
 
160k 2 44 
18 
 
160l 2 41 
19 
 
160m 2 56 
20 
 
160n 2 44 
21 
 
160o 2 52 
22 
 
160p 2 61 
23 
 
160q 2 67 
24 
 
160r 2 47 
25 
 
160s 2 27 
26 
 
160t 2 45 
27 
 
160u 2 49 
28 
 
160v 2 55 
29 
 
160w 2 58 
30 
 
160x 2 53 
31 
 
160y 2 59 
32 
 
160z 2 63 
33 
 
160aa 2 72 
34 
 
160ab 2 68 
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35 
 
160ac 2 72 
36 
 
160ad 2 75 
37 
 
160ae 2 67 
38 
 
160af 2 61 
39 
 
160ag 2 73 
40 
 
160ah 2 53 
41 
 
160ai 2 55 
42  160aj 2 67 
43 
 
160ak 2 59 
44 
 
160al 2 55 
45 
 
160am 2 64 
46 
 
160an 2 61 
47 
 
160ao 2 63 
48 
 
160ap 2 35 
49 
 
160aq 2 66 
50 
 
160ar 2 59 
51 
 
160as 2 74 
52 
 
160at 2 87 
53 
 
160au 2 69 
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54 
 
160av 2 50 
55 
 
160aw 2 59 
56 
 
160ax 2 59 
57 
 
160ay 2 58 
58 
 
160az 2 67 
59 
 
160ba 2 98 
60  160bb 2 44 
a completion of reaction was monitored via TLC; b isolated yields after column chromatography 
 
All 1,4-substituted-1,2,3-triazole N-3 Riluzole analogues were generated in moderate to high 
yields.  Altering the alkyne chain length for the benzyl group analogues 160 a - c showed that 
the highest yielding analogue had a chain length of two with 50 %.  Percentage yields 
obtained between azide 223 and alkynes containing electron-withdrawing aromatic rings 
varied from 35 - 74 % with analogue 160 ap being the lowest and analogue 160 as being the 
highest yielding.  Compound 160 at was not included due to its molecular mass being greater 
than 500 g/mol-1.  Percentage yields obtained between azide 223 and alkynes containing 
electron-donating aromatic rings varied from 27 - 75 % with analogue 160 s being the lowest 
and analogue 160 ad being the highest yielding.  No major trends are observed between 
electron-withdrawing and electron-donating groups.  Analogues with the same functionality 
positioned at the para, meta or ortho position have shown higher yields at the meta position.  
Increasing the ring size of the cycloalkyl alkyne decreases percentage yield and increasing 
branched alkyne alkyl chains also decreases the percentage yield of 1,4-substituted-1,2,3-
trialozle N-3 Riluzole analogues obtained. 
 
All triazole compounds 160 a - bb were subjected to biological testing in primary cortical 
neurons cultured from E15 Swiss mouse embryos.  All compounds were made up to 1 µM 
concentrations in DMSO and after 30 mins alone on the cultivated cortical neuron cells a 100 
µM concentration of kainate in water was added.  This was left for 18 hrs at 37 °C in an 
incubator with 5 % CO2 levels.  Each compound was repeated four times generating a total of 
24 MAP2 images per experimental condition.  Measurement of the neuroprotective activity for 
each triazole compound was measured by all cells being incubated with a primary antibody, 
which selectively binds to MAP2 proteins in the neuron.  The cells were then further incubated 
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N
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with a fluorescent secondary antibody, which will selectively bind to primary antibodies.  
Therefore when fluorescent light is shone on the cell the fluorescent secondary antibodies will 
be visible in regards to parts of the cell where MAP2 is present.  The more fluorescence 
observed corresponds to less of the cell being damaged by kainate (Figure 27). 
 
                                            A                                                                          B 
Figure 27: (A) less fluorescents means more cell damage; (B) more fluorescents means less cell 
damage  
 
Figures 28 - 31 which present preliminary data obtained for subjecting compounds 160 a - bb 
to primary cortical neurons cultured from E15 Swiss mouse embryos, method described 
above were obtained from Bradford University.  The data is shown in two ways; (1) Figure 28 
and 29 focus on the raw averages of MAP2 fluorescence normalised to kainate, and (2) 
Figure 30 and 31 look at each drug treatment normalised to a cortical neuron cell treated with 
kainate.  All 1,4-substituted-1,2,3-triazole compounds 160 are compared to that of kainate 
because kainate has similar properties to glutamate in which they both act on the same post-
synaptic receptors and if either kainate or glutamate is generated in excess they will both 
cause a negative response known as excitotoxicity.   
 
Figure 28: Raw Averages Perimeters for Compounds 160 a - bb 
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Figure 29: Raw Averages Perimeters with Error Bars for Compounds 160 a - bb 
 
Figure 30: Normalised to Kainate Perimeter for Compounds 160 a - bb 
Figure 31: Normalised to Kainate Perimeter with Error Bars for Compounds 160 a - bb 
 
Figures 28 and 29 record the fluorescence emitted for each triazole compound treated with 
kainate on cortical neuron cells and are compared to a cortical neuron cell treated with only 
kainate.  Compounds emitting more fluorescence than kainate (Figure 28) are of potential 
interest as higher emissions of fluorescence recorded on cortical neuron cells means less of 
the cell has been damaged by an excess of kainate.  Figure 29 develops on Figure 30 by 
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stating that any compounds with fluorescent error bars overlaying the error bar of kainate, 
shown by the blue line are not of interest.  Overall these two Figures report the success of five 
compounds 160 g, i, r, ae and ah which have shown high fluorescence and cell protection in 
cortical neurons, so will therefore be considered for future biological testing.  Figures 30 and 
33 standardise kainate to one fluorescent unit (FU).  All compounds fluorescence is compared 
to the fluorescence emitted from a cortical neuron treated with only kainate standardised to 1 
FU.  Compounds emitting fluorescence below the red line of kainate (Figure 30) have low cell 
protection levels compared to kainate so are therefore not of interest for future biological 
testing.  Figure 31 includes fluorescent error bars for each compound treated with kainate and 
all results that have error bars that either overlay or are below the red line of kainate which 
has been standardised to 1 FU show cell protection similar to or worse than cortical neuron 
cells treated with kainate.  From theses two Figures the following compounds 160 g, i, u, ae, 
ah, au and ax have shown high fluorescence against kainate and will be put forward for future 
biological testing.   
 
In conclusion, a library of 1,4-substituted-1,2,3-triazole N-3 Riluzole compounds were 
successfully synthesised in four-steps using diazotransfer and click chemistry in moderate to 
high yields.  All analogues synthesised were biologically tested for their antiglutamate activity 
against Riluzole with eight analogues expressing higher antiglutamate activity over Riluzole 
(Figure 32).  These analogues range from heterocyclic compounds 3- and 4-pyridine and 2-
thiophene to aromatic rings with electron-donating groups 2-aniline, 4-anisole and 4-ethyl 
benzene and electron-withdrawing groups 4-bromo benzene and 4-benzoic acid.  There are 
no obvious trends, such as substitution observed at one position on the ring.  These hits show 
substitution at all positions and also a range of donating and withdrawing substitutions as well 
as heterocycles exhibiting antiglutamate activity greater than Riluzole.  
 
Figure 32: Hit 1,4-substituted-1,2,3-triazole N-3 Riluzole Analogues 
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The aim of this thesis was to generate two novel N-3 Riluzole libraries, one with 
tetrahydropyridine moiety and the other containing 1,4-substituted-1,2,3-triazole moiety.  
Once this had been achieved all pure N-3 analogues from the two novel libraries would be 
tested for their antiglutamate activity and compared to Riluzole.   
 
A number of routes were investigated in generating N-3 Riluzole analogues with 
tetrahydropyridine moiety.  Routes, which looked at nucleophilic displacement or attack with 
pyridine between a tosyl, sulfamidite or aziridine, were all unsuccessful (Schemes 21, 24, 27, 
30 and 32).  Attempts at generating the following azide 183 from 4-trifluoromethoxyaniline 67 
using Mitsunobu (Scheme 32), Buchwald-Hartwig cross-coupling (Scheme 30) or protection 
chemistry (Scheme 27) were unsuccessful therefore retarding nucleophilic attack to yield the 
uncyclised pyridinium compound 205.  The synthesis of a sulfamidite compound from the 
sulfamidate 174, which is generated from 4-trifluoromethoxyaniline 67 to yield the uncyclised 
pyridinium compound 205 after nucleophilic attack with pyridine was also unsuccessful 
(Scheme 24).  Reasoningʼs into why these synthetic routes were unsuccessful are due to the 
aromatic ring being electron-deficient which was hindering the nitrogenʼs lone pair from 
reacting with the necessary group to allow ring cyclisation to yield either the aziridine or 
sulfamidite intermediate after oxidation of the sulfamidate.  However, generating a diamine 
compound 203 from 4-trifluoromethoxyaniline 67 and then reacting it with a suitable Zincke 
salt overcame previous issues generating an N-3 Riluzole analogues with tetrahydropyridine 
moiety (Scheme 38).  This synthetic route generated tetrahydropyridine rings with 
functionality at the 3- and 4-position.  Limited functionality at the 2-position was achieved by 
reacting the ring-cyclised pyridinium salt generated by reacting diamine 203 with 2,4-
dinitrophenyl pyridinium chloride 138 with a suitable Grignard reagent followed by in-situ 
sodium borohydride reduction (Scheme 38).   
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Scheme 38: Reagents and conditions: (a) 1.0 equiv. Br(CH2)NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 
MeOH, RT - reflux, 20 h; (c) 1.0 equiv. Sodium p-toluenesulfonate, EtOAc, reflux, 12 h, 18 - 89 % (over 
two steps); (d) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 16 h; (e) 2.8 equiv. NaBH4, MeOH, 0 °C - 
RT, 16 h, 30 - 71 % (over two steps); (f) 3.0 equiv. MeMgBr, THF, -20 °C - 0 °C, 3 h; (g) 6.0 equiv. 
NaBH4, 90 % MeOH (aq), reflux, 1 h, 42 % 
 
Even though these synthetic routes were successful and could generate a range a 
tetrahydropyridine analogues with functionality at the 2,- 3- and 4-position these compounds 
proved difficult to purify to the standards required for biological testing.  Future purification into 
rectifying this problem could look at either improving the ring-cyclised pyridinium intermediate 
205, which could be achieved by improving its crystallinity.  This can be achieved by altering 
the bromine counter-ion for either a tosylate or tetraphenylborate counter-ion.  Or, 
alternatively looking at generating N-3 Riluzole tetrahydropyridine analogues as salts, which 
has been reported in the literature, such as Jimonet and co-workers synthesising 2-imino-3-
[2-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)-ethyl]-6-trifluoromethoxy-benzothiazoline 129 as the 
dihydrochloride salt.56 
 
A number of N-3 Riluzole triazole analogues were generated in a four-step process from 4-
trifluoromethoxyaniline 67 in moderate to high yields (Scheme 39).  All Riluzole analogues 
generated were biologically tested in cortical neuron cells at Bradford University and their 
antiglutamate activity was compared to Riluzole.  Compounds which expressed increased 
antiglutamate activity over Riluzole were triazole analogues 160 g, i, r, u, ae, ah, au and ax 
(Figure 32).   
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Scheme 39: Reagents and conditions: (a) 1.0 equiv. Br(CH2)2NH2.HBr, toluene, reflux, 24 h, 65 %; (b) 
1.2 equiv. Imidazole-1-sulfonyl azide hydrochloride, 2.3 equiv. K2CO3, 0.001 equiv. CuSO4.5H2O, 
MeOH, RT, 2 h, 25 %; (c) 12.0 equiv. KSCN, 1.0 equiv. Br2, AcOH, RT, 2 h, 63 %; (d) 1.5 equiv. 
Terminal Alkyne, THF/H2O, 1.0 equiv. 1M CuSO4, 2.0 equiv. 1M NaAsc, 20 °C, 2 h, 27 - 98 % 
 
Future work on these hit eight compounds will include optimisation studies looking at finding 
an optimum potency required for maximum neuron protection.  Concentrations that will be 
tested are 100 nM, 500 nM, 2 µM and 5 µM.  Once this has been achieved the hit compounds 
will be subjected to testing in primary spinal cord motor neurons cultured from E15 Swiss 
mouse embryos.  Alongside finding the optimum potency for N-3 Riluzole triazole analogues 
optimisation studies on the CuAAC reaction need to be investigated as well as generating 
more 1,4-substituted-1,2,3-traizole analogues derived from the existing hit compounds (Figure 
33). 
 
Figure 33: Potential 1,4-substituted-1,2,3-triazole derivatives of Riluzole, which could be of future 
interest 
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For hit compound 160 r a focus will be put into looking at whether varying the alkyl chain of 
the ether linkage at the para position of the aromatic ring will improve neuronal protection 160 
bc.  For the two pyridine analogues 160 g and 160 i a range of functional groups ranging from 
electron-withdrawing to electron-donating groups at the ortho, meta and para position 
attached to 3- and 4-pyridine will be investigated 160 bd and 160 be.  For hit compound 160 
ax carbonyl functionality of the benzoic acid will be altered to see if this improves neuron 
protection.  Changing benzoic acid to benzoate 160 aw has already been generated (Table 7) 
and was found to drastically reduced neuronal protection.  Alternative benzyl carbonyl 
functionality 160 bf generated will include a variety of benzyl alkyl ketones and benzaldehyde. 
 
Optimisation of the CuAAC reaction will look at removing column chromatography purification 
in the case of this reaction being scaled up.  This could either be achieved by finding a 
versatile crystallisation method that can be applied to all 1,4-substituted-1,2,3-triazole Riluzole 
analogues or varying the equivalents of terminal alkyne added to the reaction, until there isnʼt 
an excess observed in the crude 1H NMR.   
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Spectroscopy 
NMR spectra were recorded on either a Bruker 400 or 500 MHz Ultrashield Plus spectrometer 
with the stated deuterated solvent.  Chemical shifts (δ) in 1H NMR are reported in ppm, 
downfield from TMS, and as in 13C NMR, are referenced to the residual solvent peak.  
Multiplicities are reported as a singlet (s), doublet (d), triplet (t), quartet (q) and combinations 
thereof, or multiplet (m).  Coupling constants (J) are quoted in Hertz and rounded to the 
nearest 0.5 Hz.  All 13C resonances were assigned via distortionless enhancement by 
polarisation transfer (DEPT) experiments.  Melting points were recorded on a Stuart melting 
point apparatus, model smp10 and are uncorrected.  Infrared spectra were recorded using 
Nicolet 380 FTIR spectrometer.  Mass spectroscopy was performed using an Agilent 6210 
100SL-TOF LC/MS. 
 
Reagents 
Reagents were purchased from Sigma Aldrich, Fischer Scientific and TCI.  They were used 
as supplied or, purified in accordance with the procedures of Perrin and Armarego.124  
Acetonitrile and dichloromethane were distilled from CaH2 under an atmosphere of nitrogen.  
Tetrahydrofuran was distilled from sodium wire and benzophenone under an atmosphere of 
nitrogen. 
  
Chromatography 
Thin layer chromatography (TLC) was carried out using Merck silica gel 60 F254 aluminium 
sheets.  Visualisations of the developed plates were carried out by UV quenching at 254 nM.  
Column chromatography was carried out using silica gel 60Å, particle size 63-200 µM 
obtained from Fischer Scientific.  
 
 
 
 
 
Caution: When handling sodium azide or any organic azide use a blast screen, as these 
compounds are potentially explosive.  Also seek appropriate safety guidelines outlined from 
Sigma Aldrich or wherever purchased whenever handling.   
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5.1 Synthesis of N-3 Unfunctionalised and Functionalised Tetrahydropyridine 
Derivatives of Riluzole 
2-((4-(Trifluoromethoxy)-phenyl)amino) ethanol 100
56
 
 
A solution of 4-trifluoromethoxyaniline (0.8 mL, 5.65 mmol, 2.0 equiv.) and 2-bromoethanol 
(0.2 mL, 2.82 mmol, 1.0 equiv.) was stirred at 160 °C for 1.5 h.  Once cooled 20.0 mL DCM 
was added to the reaction mixture and the resulting precipitate was filtered off.  The filtrate 
was collected and concentrated under reduced pressure to yield a crude orange/brown oil.  
The crude oil was purified via column chromatography using 4:6 EtOAc:CY to yield 2-((4-
(trifluoromethoxy)-phenyl)amino) ethanol (100, 0.23 g, 1.02 mmol, 36 %) as a dark orange oil; 
Rf 0.22 (4:6 EtOAc:CY). 
 
IR νmax/cm
-1 3372, 2947, 2883, 1617, 1516, 1250; 1H NMR (400MHz, CDCl3) δ; 7.04 (2H, d, J 
= 8.0 Hz, H-3ʼ and H-5ʼ), 6.61 (2H, d, J = 8.0 Hz, H-2ʼ and H-6ʼ), 4.09 (1H, bs, NH), 3.85 (2H, 
t, J = 4.0 Hz, H-2), 3.30 (2H, t, J = 4.0 Hz, H-1), 1.65 (1H, bs, OH); 13C NMR (100MHz, 
CDCl3) δ; 46.2 (C-1), 61.2 (C-2), 113.4 (C-2ʼ and C-6ʼ), 122.5 (C-3ʼ and C-5ʼ), 140.7 (ArC), 
140.9 (ArC), 147.1 (Ar(OCF3)); MS m/z [M+H]
+ C9H11F3NO2 requires 222.07, found 220.07. 
 
2-(4-Methyl-N-(4-(trifluoromethoxy)phenyl)phenylsulfonamido)ethyl-4-
methylbenzenesulfonate 101
56
 
 
To a cooled solution amino alcohol 100 (2.00 g, 9.05 mmol, 1.0 equiv.) and Et3N (2.5 mL, 
18.09 mmol, 2.0 equiv.) in 40.0 mL DCM was added p-toluenesulfonyl chloride (3.45 g, 18.09 
mmol, 2.0 equiv.) portion-wise.  After 5 h of stirring at 0 °C the reaction mixture was warmed 
to RT, diluted with 40.0 mL DCM and washed with 40.0 mL H2O.  The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure to yield a 
crude orange oil.  The crude oil was recrystallised with 100 % EtOH to yield 2-(4-methyl-N-
(trifluoromethoxy) phenyl) phenylsulfonamido)ethyl-4-methylbenzenesulfonate (101, 2.28 g, 
4.30 mmol, 48 %) as a colourless solid; m.p. 92 - 95 °C (Lit.56 m.p. 88 °C) 
 
IR νmax/cm
-1 3026, 2952, 1502, 1350, 1251, 1160; 1H NMR (400MHz, CDCl3) δ; 7.69 (2H, d, J 
= 8.0 Hz, TsH-2 and TsH-6), 7.44 (2H, d, J = 8.0 Hz, TsH-2ʼ and TsH-6ʼ), 7.33 (2H, d, J = 8.0 
Hz, TsH-3 and TsH-5), 7.26 (2H, appd, J = 8.0 Hz, TsH-3ʼ and TsH-5ʼ), 7.09 (2H, d, J = 8.0 
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Hz, H-3ʼʼ and H-5ʼʼ), 6.96 (2H, d, J = 8.0 Hz, H-2ʼʼ and H-6ʼʼ), 4.13 (2H, t, J = 4.0 Hz, H-2), 
3.80 (2H, t, J = 4.0 Hz, H-1), 2.45 (6H, d, J = 12.0 Hz, Ts(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 
21.5 (Ts(CH3), 21.6 (Ts(CH3)), 49.9 (C-1), 67.4 (C-2), 119.0 (ArC), 121.4 (C-3ʼʼ and C-5ʼʼ), 
127.7 (TsC-2ʼ and TsC-6ʼ), 127.9 (TsC-2 and TsC-6), 129.7 (TsC-3ʼ and TsC-5ʼ), 129.9 (TsC-
3 and TsC-5), 130.4 (C-2ʼʼ and C-6ʼʼ), 132.5 (ArC), 134.5 (ArC), 137.6 (ArC), 144.2 (ArC), 
145.2 (ArC), 148.6 (Ar(OCF3)); MS m/z [M+H]
+ C23H23F3NO6S2 requires 530.08, found 530.09. 
 
N-(2-Iodoethyl)-4-methyl-N-(4-trifluoromethoxy)phenyl)benzenesulfonamide 165 
 
A solution of 101 (0.40 g, 0.76 mmol, 1.0 equiv.) and NaI (0.23 g, 1.51 mmol, 2.0 equiv.) in 
20.0 mL acetone stirred at reflux for 60 h.  This was then cooled and concentrated under 
reduced pressure to yield a crude pale yellow solid.  The crude solid was purified via column 
chromatography using 5:5 PE 40-60 °C:EtOAc to yield N-(2-iodoethyl)-4-methyl-N-(4-
(trifluoromethoxy)phenyl)benzenesulfonamide (165, 0.26 g, 0.54 mmol, 71 %) as a pale 
yellow solid; Rf 0.91 (5:5 PE 40-60 
oC:EtOAc), m.p. 97 - 99 °C  
 
IR νmax/cm
-1 3056, 2806, 1504, 1352, 1272, 1154; 1H NMR (400MHz, CDCl3) δ; 7.40 (2H, d, J 
= 8.0 Hz, TsH-2 and TsH-6), 7.21 (2H, d, J = 8.0 Hz, TsH-3 and TsH-5), 7.11 (2H, d, J = 8.0 
Hz, H-3ʼʼ and H-5ʼʼ), 7.03 (2H, d, J = 8.0 Hz, H-2ʼʼ and H-6ʼʼ), 3.77 (2H, t, J = 8.0 Hz, H-1ʼ), 
3.11 (2H, t, J = 8.0 Hz, H-2ʼ), 2.37 (3H, s, Ts(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 1.2 (C-2ʼ), 
21.6 (Ts(CH3)), 53.4 (C-1ʼ), 120.4 (C-3ʼʼ and C-5ʼʼ), 126.5 (TsC-2 and TsC-6), 128.6 (TsC-3 
and TsC-5), 129.3 (C-2ʼʼ and C-6ʼʼ), 134.8 (ArC), 137.2 (ArC), 144.1 (ArC), 146.0 (ArC), 148.8 
(Ar(OCF3)); MS m/z [M+Na]
+ C16H15F3INO3SNa requires 507.97, found 507.97. 
 
N-(2-(4,5-Dihydropyridinyl)ethyl)-4-methyl-N-(4-
(trifluoromethoxy)phenyl)benzenesulfonamide 166 
 
A solution of 165 (0.40 g, 0.82 mmol, 1.0 equiv.) in 5.0 mL pyridine was stirred at reflux for 20 
h.  This was then cooled and concentrated under reduced pressure to yield the crude 
pyridinium salt as a deep brown solid.  To a cooled solution of the crude pyridinium salt (0.48 
g, 0.93 mmol, 1.0 equiv.) in 12.5 mL MeOH at 0 °C was added NaBH4 (0.10 g, 2.60 mmol, 2.8 
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equiv.) portion-wise.  This was brought to RT and left to stir for a further 42 h.  The reaction 
mixture was then diluted with H2O and washed five times with DCM.  The organic layers were 
combined, dried over Na2SO4, filtered and concentrated under reduced pressure to yield N-(2-
(4,5-dihydropyridinyl)ethyl)-4-methyl-N-(4-(trifluoromethoxy)phenyl)benzenesulfonamide (166, 
0.29 g, 0.66 mmol, 71 %) as an orange oil.  
 
IR νmax/cm
-1 3038, 2920, 1660, 1505, 1349, 1258, 1155; 1H NMR (400MHz, CDCl3) δ; 7.50 
(2H, d, J = 8.0 Hz, TsH-2 and TsH-6), 7.37 (2H, d, J = 8.0 Hz, TsH-3 and TsH-5), 7.26 (2H, d, 
J = 8.0 Hz, H-3ʼʼʼ and H-5ʼʼʼ), 7.21 (2H, d, J = 8.0 Hz, H-2ʼʼʼ and H-6ʼʼʼ), 5.64 (1H, dt, J = 4.0 Hz 
and 8.0 Hz, H-5ʼʼ), 5.54 (1H, dt, J = 4.0 Hz and 8.0 Hz, H-4ʼʼ), 3.62 (2H, t, J = 4.0 Hz, H-1ʼ) 
2.87 (2H, appq, J = 4.0 Hz, H-6ʼʼ), 2.58 - 2.52 (4H, m, H-2ʼ and H-2ʼʼ), 2.35 (3H, s, Ts(CH3)), 
2.03 - 2.02 (2H, m, H-3ʼʼ); 13C NMR (100MHz, CDCl3) δ; 21.5 (Ts(CH3)), 26.0 (C-2ʼʼ), 48.5 (C-
1ʼ), 50.1 (C-2ʼ), 52.7 (C-3ʼʼ), 56.4 (C-6ʼʼ), 121.3 (C-3ʼʼʼ and C-5ʼʼʼ), 124.9 (C-5ʼʼ), 125.1 (C-4ʼʼ), 
127.7 (TsC-2 and TsC-6), 129.5 (TsC-3 and TsC-5), 130.3 (C-2ʼʼʼ and C-6ʼʼʼ), 135.0 (ArC), 
137.9 (ArC), 143.7 (ArC), 145.5 (ArC), 148.4 (Ar(OCF3)); MS m/z [M+H]
+ C21H24F3N2O3S 
requires 441.14, found 441.15. 
 
2-((4-(Trifluoromethoxy)phenyl)amino)ethyl Diphenylphosphinate 182 
 
To a cooled solution of 100 (0.25 g, 1.13 mmol, 1.0 equiv.) in 10.0 mL DCM was added 
diphenylphosphonic chloride (0.2 mL, 1.13 mmol, 1.0 equiv.) and Et3N (0.2 mL, 1.13 mmol, 
1.0 equiv.) dropwise.  After stirring at 0 °C for an hour the reaction mixture was warmed to RT 
and stirred for a further 4 h.  This was then diluted with H2O and washed twice with DCM.  
The organic layers were combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure to yield a crude orange oil.  The crude oil was purified via column 
chromatography using 1:1 EtOAc:Hex to yield 2-((4-trifluoromethoxy)phenylamino)ethyl 
diphenylphosphinate  (182, 0.45 g, 1.07 mmol, 94 %) as an off-white solid; Rf 0.13 (1:1 
EtOAc:Hex), m.p. 85 - 89 °C 
 
IR νmax/cm
-1 3280, 3051, 2974, 1614, 1532, 1506, 1273, 1024; 1H NMR (400MHz, CDCl3) δ; 
7.82 - 7.76 (4H, m, ArH), 7.55 - 7.51 (2H, m, ArH), 7.47 - 7.41 (4H, m, ArH), 7.01 (2H, d, J = 
7.5 Hz, H-3ʼ and H-5ʼ), 6.56 (2H, d, J = 7.5 Hz, H-2ʼ and H-6ʼ), 4.23 (2H, quin, J = 5.0 Hz, H-
2), 3.44 (2H, t, J = 5.0 Hz, H-1); 13C NMR (100MHz, CDCl3) δ; 44.4 (C-1), 64.0 (C-2), 113.1 
(C-2ʼ and C-6ʼ), 119.5 (ArC), 122.4 (C-3ʼ and C-5ʼ), 128.6 (ArCH), 130.1 (ArC), 131.6 (ArCH), 
132.5 (ArCH), 140.5 (Ar(OCF3)), 146.6 (ArC); MS m/z [M+H]
+ C21H20F3NO3P requires 422.11, 
found 422.11. 
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N-(4-Trifluoromethoxy)phenyl)ethane-1,2-diamine 203
105
 
 
A solution of 4-trifluoromethoxyaniline (2.7 mL, 20.00 mmol, 2.0 equiv.) and 2-
bromoethylamine hydrobromide (2.05 g, 10.00 mmol, 1.0 equiv.) in 10.0 mL toluene was 
stirred at reflux overnight.  Once cooled the reaction mixture was diluted with 13.0 mL 30 % 
NaOH solution and washed twice with toluene.  The organic layers were combined, dried over 
Na2SO4, filtered and concentrated under reduced pressure to yield a crude deep orange oil.  
The crude oil was purified via column chromatography using 9:1 DCM:MeOH with 1.25 % 
NH4OH to yield N-(4-trifluoromethoxy)phenyl)ethane-1,2-diamine (203, 1.43 g, 6.50 mmol, 65 
%) as a pale orange oil; Rf 0.42 (9:1 DCM:MeOH with 1.25 % NH4OH). 
 
IR νmax/cm
-1 3317, 3040, 2938, 1614, 1514, 1252; 1H NMR (400MHz, CDCl3) δ; 7.03 (2H, d, J 
= 9.0 Hz, H-3ʼ and H-5ʼ), 6.58 (2H, d, J = 9.0 Hz, H-2ʼ and H-6ʼ), 4.23 (1H, bs, NH), 3.16 (2H, 
t, J = 6.0 Hz, H-1), 2.97 (2H, t, J = 6.0 Hz, H-2), 1.70 (2H, bs, NH2); 
13
C NMR (100MHz, 
CDCl3) δ; 40.8 (C-2), 46.3 (C-1), 113.0 (C-2ʼ and C-6ʼ), 122.4 (C-3ʼ and C-5ʼ), 140.4 
(Ar(OCF3)), 147.2 (ArC), 147.5 (ArC); MS m/z [M+H]
+ C9H12F3N2O requires 221.08, found 
221.10.  
 
Formation of Zincke Salts 
N-(2,4-Dinitrophenyl)pyridinium Chloride 138
104
 
 
1-Chloro-2,4-dintirobenzene (10.01 g, 49.42 mmol, 1.0 equiv.) was added portion-wise to 
pyridine (4.0 mL, 49.42 mmol, 1.0 equiv.).  This was stirred at 95 °C for an hour.  Once cooled 
the precipitate was triturated with acetone and filtered to yield N-(2,4-dinitrophenyl)pyridinium 
chloride (138, 11.83 g, 42.09 mmol, 85 %) as an off-white powder; m.p. 212 - 216 °C (Lit.104 
m.p. 193 - 194 °C). 
 
IR νmax/cm
-1 3040, 1617, 1537, 1477, 1343; 1H NMR (400MHz, D2O) δ; 9.34 (2H, dd, J = 1.0 
Hz and 6.0 Hz, H-2 and H-6), 9.31 (1H, d, J= 5.0 Hz, H-3ʼ), 8.99 (1H, tt, J = 5.0 Hz and 10.0 
Hz, H-4), 8.95 (1H, dd, J = 5.0 Hz and 10.0 Hz, H-5ʼ), 8.44 (2H, dd, J = 7.0 Hz and 8.0 Hz, H-
3 and H-5), 8.34 (1H, d, J = 10 Hz, H-6ʼ); 13C NMR (100MHz, D2O) δ; 122.6 (C-3ʼ), 128.4 (C-3 
and C-5), 130.5 (C-5ʼ), 131.1 (C-6ʼ), 138.6 (ArC), 142.8 (ArC), 145.4 (C-2 and C-6), 149.1 (C-
4), 149.6 (ArC); MS m/z [M]+ C11H8N3O4
+ requires 246.05, found 246.05. 
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N-(2,4-Dinitrophenyl)-4-methylpyridinium Chloride 209a
107
 
 
To a solution of 4-picoline (1.0 mL, 9.87 mmol, 1.0 equiv.) in 20.0 mL MeOH was added 1-
chloro-2,4-dinitrobenzene (2.00 g, 9.87 mmol, 1.0 equiv.) portion-wise.  This was stirred at 
reflux for 96 h.  Once cooled the reaction mixture was concentrated under reduced pressure 
to yield a crude black tar.  The crude tar was purified via column chromatography via a 
gradient moving from 9:1 DCM:MeOH to 100% MeOH to yield N-(2,4-dinitrophenyl)-4-
methylpyridinium chloride (209a, 1.63 g, 5.51 mmol, 56 %) as a black solid; Rf 0.22 (9:1 
DCM:MeOH to 100% MeOH), m.p 82 - 84 °C (Lit.107 m.p. 142 - 145 °C). 
 
IR νmax/cm
-1 3002, 2942, 1609, 1537, 1467, 1339; 1H NMR (400MHz, MeOD) δ; 9.28 (1H, d, J 
= 2.5 Hz, H-3ʼ), 9.13 (2H, d, J = 7.0 Hz, H-2 and H-6), 8.93 (1H, dd, J = 3.0 Hz and 8.5 Hz, H-
5ʼ), 8.31 (1H, d, J = 8.5 Hz, H-6ʼ), 8.24 (2H, d, J = 6.5 Hz, H-3 and H-5), 2.89 (3H, s, 
CH3(Py.)); 
13
C NMR (100MHz, MeOD) δ; 21.4 (CH3(Py.)), 121.8 (C-3ʼ), 128.5 (C-3 and C-5), 
129.7 (C-5ʼ), 131.3 (C-6ʼ), 138.6 (ArC), 143.3 (ArC), 144.5 (C-2 and C-6), 149.7 (ArC), 164.1 
(ArC); MS m/z [M]+ C12H10N3O4
+ requires 260.07, found 260.07.  
 
N-(2,4-Dinitrophenyl)-3-methylpyridinium Chloride 209b
108
 
 
To a solution of 3-picoline (0.5 mL, 4.94 mmol, 1.0 equiv.) in 10.0 mL acetone was added 1-
chloro-2,4-dintirobenzene (1.00 g, 4.94 mmol, 1.0 equiv.) portion-wise.  This was stirred at 
reflux for 12 h.  Once cooled the reaction mixture was filter to yield N-(2,4-dinitrophenyl)-3-
methylpyridinium chloride (209b, 1.01 g, 3.90 mmol, 79 %) as an off-white solid; m.p. 221 - 
223 °C (Lit.108 m.p. 206 - 207 °C). 
 
IR νmax/cm
-1 3056, 2914, 1531, 1475, 1342; 1H NMR (400MHz, MeOD) δ; 9.30 (1H, bs, H-3ʼ), 
9.22 (1H, bs, H-2), 9.13 (1H, d, J = 6.0 Hz, H-6), 8.94 (1H, d, J = 8.5 Hz, H-5ʼ), 8.81 (1H, d, J 
= 8.0 Hz, H-4), 8.32 - 8.28 (2H, m, H-5 and H-6ʼ), 2.71 (3H, s, CH3(Py.)); 
13
C NMR (100MHz, 
MeOD) δ; 17.1 (CH3(Py.)), 121.8 (C-3ʼ), 127.4 (C-5), 129.7 (C-5ʼ), 131.2 (C-6ʼ), 138.8 (ArC), 
140.2 (ArC), 143.0 (C-6), 143.2 (ArC), 145.2 (C-2), 149.2 (C-4), 149.8 (ArC); MS m/z [M]+ 
C12H10N3O4
+ requires 260.07, found 260.07. 
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N-(2,4-Dinitrophenyl)-4-ethylpyridinium Chloride 209c
107 
 
To a solution of 4-ethylpyridine (0.6 mL, 5.43 mmol, 1.1 equiv.) in 5.0 mL PE 40-60 °C was 
added 1-chloro-2,4-dintirobenzene (1.00 g, 4.94 mmol, 1.0 equiv.) portion-wise.  This was 
stirred at reflux for 96 h.  Once cooled the reaction mixture was filter to yield N-(2,4-
dinitrophenyl)-4-ethylpyridinium chloride (209c, 1.06 g, 3.43 mmol, 75 %) as a black solid; 
m.p. 154 - 157 °C (Lit.107 m.p. 133 - 135 °C) 
 
IR νmax/cm
-1 3019, 2971, 1610, 1540, 1463, 1345; 1H NMR (400MHz, MeOD) δ; 9.29 (1H, d, J 
= 3.5 Hz, H-3ʼ), 9.16 (2H, d, J = 6.0 Hz, H-2 and H-6), 8.93 (1H, dd, J = 3.0 Hz and 8.5 Hz, H-
5ʼ), 8.31 (1H, d, J = 8.5 Hz, H-6ʼ), 8.28 (2H, d, J = 6.0 Hz, H-3 and H-5), 3.20 (2H, q, J = 8.5 
Hz, CH2CH3(Py.)), 1.50 (3H, t, J = 7.5 Hz, CH2CH3(Py.)); 
13
C NMR (100MHz, MeOD) δ; 12.5 
(CH2CH3(Py.)), 29.1 (CH2CH3(Py.)), 121.9 (C-3ʼ), 127.5 (C-3 and C-5), 129.8 (C-5ʼ), 131.3 (C-
6ʼ), 138.7 (ArC), 143.4 (ArC), 145.0 (C-2 and C-6), 149.9 (ArC), 169.1 (ArC); MS m/z [M]+ 
C13H12N3O4
+ requires 274.08, found 274.08. 
 
N-(2,4-Dinitrophenyl)-3-ethylpyridinium Chloride 209d
109
 
 
To a solution of 3-ethylpyridine (0.6 mL, 5.43 mmol, 1.1 equiv.) in 5.0 mL acetone was added 
1-chloro-2,4-dintirobenzene (1.00 g, 4.94 mmol, 1.0 equiv.) portion-wise.  This was stirred at 
reflux for 12 h.  Once cooled the reaction mixture was filter to yield N-(2,4-dinitrophenyl)-3-
ethylpyridinium chloride (209d, 0.92 g, 2.98 mmol, 61 %) as an off white powder; m.p. 197 - 
199 °C (Lit.109 m.p. 194 - 196 °C) 
 
IR νmax/cm
-1 3000, 2925, 1607, 1535, 1449, 1346; 1H NMR (400MHz, MeOD) δ; 9.31 (1H, d, J 
= 4.5 Hz, H-3ʼ), 9.25 (1H, bs, H-2), 9.15 (1H, bd, J = 6.0 Hz, H-6), 8.95 (1H, dd, J = 3.5 Hz 
and 9.0 Hz, H-5ʼ), 8.69 (1H, bd, J = 7.5 Hz, H-4), 8.24 (1H, t, J = 8.5 Hz, H-5), 8.31 (1H, d, J = 
9.0 Hz, H-6ʼ), 3.05 (2H, q, J = 7.5 Hz, CH2CH3(Py.)), 1.44 (3H, t, J = 7.5 Hz, CH2CH3(Py.)); 
13
C NMR (100MHz, MeOD) δ; 13.4 (CH2CH3(Py.)), 25.6 (CH2CH3(Py.)), 121.8 (C-3ʼ), 127.7 
(C-6ʼ), 129.8 (C-5ʼ), 131.1 (C-5), 138.8 (ArC), 143.2 (ArC), 143.3 (C-6), 144.8 (C-2), 145.7 
(ArC), 148.2 (C-4), 149.7 (ArC); MS m/z [M]+ C13H12N3O4
+ requires 274.08, found 274.08. 
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N-(2,4-Dinitrophenyl)-4-phenylpyridinium Chloride 209e
110 
 
To a solution of 4-phenylpyridine (0.77 g, 4.94 mmol, 1.0 equiv.) in 10.0 mL acetone was 
added 1-chloro-2,4-dintirobenzene (1.00 g, 4.94 mmol, 1.0 equiv.) portion-wise.  This was left 
to stir at reflux for 12 h.  Once cooled the reaction mixture was filter to yield N-(2,4-
dinitrophenyl)-4-phenylpyridinium chloride (209e, 0.86 g, 2.41 mmol, 49 %) as an off-white 
solid; m.p. 195 - 199 °C (Lit.110 m.p. 186 - 187 °C) 
 
IR νmax/cm
-1 3002, 1608, 1533, 1337; 1H NMR (400MHz, MeOD) δ; 9.31 (1H, bs, C-3ʼ), 9.26 
(2H, d, J =6.5 Hz, H-2 and H-6), 8.95 (1H, d, J = 8.5 Hz, H-5ʼ), 8.73 (2H, d, J = 6.5 Hz, H-3 
and H-5), 8.34 (1H, d, J = 8.5 Hz, H-6ʼ), 8.20 (2H, d, J = 7.5 Hz, ArH(Py.)), 7.80 - 7.72 (3H, m, 
ArH(Py.)); 13C NMR (100MHz, MeOD) δ; 121.8 (C-3ʼ), 124.4 (C-3 and C-5), 128.4 
(ArCH(Py.)), 129.7 (C-5ʼ), 129.8 (ArCH(Py.)), 131.4 (C-6ʼ), 133.1 (ArCH(Py.)), 133.4 (ArC), 
138.6 (ArC), 143.4 (ArC), 145.5 (C-2 and C-6), 149.7 (ArC), 159.4 (ArC); MS m/z [M]+ 
C17H12N3O4
+ requires 322.08, found 322.09. 
 
N-(2,4-Dinitrophenyl)-4-tert-butylpyridinium Chloride 209f
111 
 
To a solution of 4-tert-butylpyridine (0.7 mL, 4.94 mmol, 1.0 equiv.) in 20.0 mL MeOH was 
added 1-chloro-2,4-dinitrobenzene (1.00 g, 4.94 mmol, 1.0 equiv.) portion-wise.  This was 
stirred at reflux for 65 h.  Once cooled the reaction mixture was concentrated under reduced 
pressure to yield N-(2,4-dinitrophenyl)-4-tert-butylpyridinium chloride (209f, 1.37 g, 4.55 
mmol, 92 %) as a yellow solid; m.p. 137 - 150 °C (Lit.111 m.p. 154 -156 °C) 
 
IR νmax/cm
-1 3042, 2971, 1608, 1533, 1458, 1339; 1H NMR (400MHz, MeOD) δ; 9.29 (1H, d, J 
= 2.5 Hz, H-3ʼ), 9.16 (2H, d, J = 7.0 Hz, H-2 and H-6), 8.93 (1H, dd, J = 2.5 Hz and 8.5 Hz, H-
5ʼ), 8.44 (2H, d, J = 7.0 Hz, H-3 and H-5), 8.29 (1H, d, J = 8.5 Hz, H-6ʼ), 1.57 (9H, s, 
C(CH3)3(Py.)); 
13
C NMR (100MHz, MeOD) δ; 29.1 (C(CH3)3(Py.)), 122.6 (C-3ʼ), 124.5 (ArC), 
125.6 (C-3 and C-5), 130.5 (C-5ʼ), 131.3 (C-6ʼ), 138.5 (ArC), 142.8 (ArC), 144.3 (C-2 and C-
6), 149.4 (ArC), 175.7 (ArC); MS m/z [M]+ C15H16N3O4 requires 302.11, found 302.12. 
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Formation of Pyridinium Tosylates 
N-(2-((4-Trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 204 
 
To a solution of 203 (1.99 g, 9.06 mmol, 3.0 equiv.) in 30.0 mL MeOH was added Zincke salt 
138 (0.85 g, 3.02 mmol, 1.0 equiv.) portion-wise.   This was stirred at RT for 2 h and then 
refluxed for a further 18 h.  Once cooled the reaction mixture was, diluted with H2O and 
washed several times with DCM until no further colour was observed in the organic layer.  
The aqueous layer was concentrated under reduced pressure to yield uncyclised pyridinium 
chloride as a crude yellow oil.  To a solution of the crude uncyclised pyridinium chloride (0.96 
g, 3.02 mmol, 1.0 equiv.) in 30.0 mL EtOAc was added sodium p-toluenesulfonate (0.59 g, 
3.02 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 h then cooled and 
filtered.  The filtrate was concentrated under reduced pressure to yield a crude yellow slurry, 
which was purified via crystallisation with 100 % EtOAc to yield N-(2-((4-
trifluoromethoxy)phenyl)amino)ethyl)pyridinium tosylate (204, 1.07 g, 2.35 mmol, 78 %) as a 
fine pale yellow powder; m.p. 111 - 118 °C 
 
IR νmax/cm
-1 3291, 3060, 2855, 1609, 1506, 1251, 1160; 1H NMR (400MHz, MeOD) δ; 8.91 
(2H, d, J = 6.0 Hz, H-2 and H-6), 8.58 (1H, t, J = 8.0 Hz, H-4), 8.09 (2H, t, J = 7.0 Hz, H-3 and 
H-5), 7.72 (2H, d, J = 8.0 Hz, TsH), 7.25 (2H, d, J = 8.0 Hz, TsH), 7.03 (2H, d, J = 9.0 Hz, H-
3ʼʼ and H-5ʼʼ), 6.65 (2H, d, J = 9.0 Hz, H-2ʼʼ and H-6ʼʼ), 4.81 (2H, t, J = 5.0 Hz, H-2ʼ), 3.79 (2H, 
t, J = 5.0 Hz, H-1ʼ), 2.39 (3H, s, Ts(CH3)); 
13
C NMR (100MHz, MeOD) δ; 21.2 (Ts(CH3)), 44.4 
(C-1ʼ), 60.7 (C-2ʼ), 113.1 (C-2ʼʼ and C-6ʼʼ), 119.3 (ArC), 122.2 (C-3ʼʼ and C-5ʼʼ), 125.8 (TsCH), 
127.6 (C-3 and C-5), 129.0 (TsCH), 140.0 (ArC), 140.3 (Ar(OCF3)), 143.4 (ArC), 144.4 (ArC), 
145.7 (C-2 and C-6), 146.5 (C-4); MS m/z [M]+ C14H14F3N2O requires 283.11, found 283.10. 
 
4-Methyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 210a 
 
To a solution of 203 (0.30 g, 1.35 mmol, 1.1 equiv.) in 20.0 mL n-butanol was added Zincke 
salt 209a (0.36 g, 1.23 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 18 h.  
Once cooled the reaction mixture was diluted with H2O and washed several times with DCM 
until no further colour was observed in the organic layer.  The aqueous layer was 
concentrated under reduced pressure to yield uncyclised 4-methyl pyridinium chloride as a 
crude mustard yellow oil.  To a solution of the crude uncyclised 4-methyl pyridinium chloride 
(0.41 g, 1.23 mmol, 1.0 equiv.) in 20.0 mL EtOAc was added sodium p-toluenesulfonate (0.24 
g, 1.23 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 h then cooled and 
filtered.  The filtrate was concentrated under reduced pressure to yield a crude brown slurry, 
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which was purified via crystallisation with 100 % EtOAc to yield 4-methyl-N-(2-((4-
(trifluoromethoxy)phenyl)amino)ethyl pyridinium tosylate (210a, 0.24 g, 0.50 mmol, 41 %) as a 
fine pale yellow powder; m.p. 120 - 124 °C 
 
IR νmax/cm
-1 3302, 3053, 2913, 1610, 1476, 1518, 1255, 1141; 1H NMR (400MHz, CDCl3) δ; 
8.99 (2H, d, J = 6.5 Hz, H-2 and H-6), 7.78 (2H, d, J = 8.0 Hz, TsH), 7.48 (2H, d, J = 6.5 Hz, 
H-3 and H-5), 7.17 (2H, d, J = 8.0 Hz, TsH), 6.83 (2H, d, J = 8.5 Hz, H-3ʼʼ and H-5ʼʼ), 6.49 
(2H, d, J = 8.5 Hz, H-2ʼʼ and H-6ʼʼ), 4.98 (2H, t, J = 5.0 Hz, H-2ʼ), 3.68 (2H, t, J = 5.0 Hz, H-1ʼ), 
2.45 (3H, s, Ts(CH3)), 2.37 (3H, s, CH3(Py.)); 
13
C NMR (100MHz, CDCl3) δ; 21.2 (CH3(Py.)), 
21.9 (Ts(CH3)), 44.4 (C-1ʼ), 59.9 (C-2ʼ), 113.1 (C-2ʼʼ and C-6ʼʼ), 119.3 (ArC), 122.3 (C-3ʼʼ and 
C-5ʼʼ), 125.8 (TsCH), 128.2 (C-3 and C-5), 128.9 (TsCH), 140.0 (ArC), 140.3 (Ar(OCF3)), 
143.2 (ArC), 144.7 (C-2 and C-6), 146.5 (ArC), 158.5 (ArC); MS m/z [M]+ C15H16N2OF3 
requires 297.12, found 297.12. 
 
3-Methyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 210b 
 
To a solution of 203 (0.48 g, 2.19 mmol, 1.1 equiv.) in 10.0 mL n-butanol was added Zincke 
salt 209b (0.59 g, 2.19 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 18 h.  
Once cooled the reaction mixture was diluted with H2O and washed several times with DCM 
until no further colour was observed in the organic layer.  The aqueous layer was 
concentrated under reduced pressure to yield uncyclised 3-methyl pyridinium chloride as a 
crude yellow oil.  To a solution of the crude uncyclised 3-methyl pyridinium chloride (0.66 g, 
1.99 mmol, 1.0 equiv.) in 15.0 mL EtOAc was added sodium p-toluenesulfonate (0.38 g, 1.99 
mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 h then cooled and filtered.  
The filtrate was concentrated under reduced pressure to yield a crude brown slurry, which 
was purified via crystallisation with 100 % EtOAc to yield 3-methyl-N-(2-((4-
(trifluoromethoxy)phenyl)amino)ethyl)pyridinium tosylate (210b, 0.68 g, 1.45 mmol, 73 %) as 
a fine pale yellow powder; m.p. 221 - 223 °C 
 
IR νmax/cm
-1 3418, 3054, 2837, 1639, 1508, 1477, 1252, 1188; 1H NMR (400MHz, CDCl3) δ; 
9.10 (1H, s, H-2), 9.04 (1H, d, J = 6.0 Hz, H-6), 7.88 (1H, d, J = 8.0 Hz, H-4), 7.80 (2H, d, J = 
7.5 Hz, TsH), 7.59 (1H, t, J = 6.5 Hz, H-5), 7.18 (2H, d, J = 7.5 Hz, TsH), 6.80 (2H, d, J = 8.5 
Hz, H-3ʼʼ and H-5ʼʼ), 6.47 (2H, d, J = 8.5 Hz, H-2ʼʼ and H-6ʼʼ), 5.93 (1H, t, J = 6.0 Hz, NH), 5.04 
(2H, t, J = 4.5 Hz, H-2ʼ), 3.72 (2H, q, J = 5.0 Hz, H-1ʼ), 2.38 (3H, s, CH3(Py.)), 2.36 (3H, s, 
TsC(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 17.2 (CH3(Py.)), 20.2 (Ts(CH3)), 43.3 (C-1ʼ), 59.6 
(C-2ʼ), 112.9 (C-2ʼʼ and C-6ʼʼ), 119.2 (ArC), 122.1 (C-3ʼʼ and C-5ʼʼ), 125.7 (TsCH), 126.9 (C-5), 
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128.9 (TsCH), 139.0 (ArC), 140.0 (ArC), 140.1 (Ar(OCF3)), 142.8 (C-6), 143.3 (ArC), 145.0 
(C-4), 145.3 (C-2), 146.6 (ArC); MS m/z [M]+ C15H16N2OF3 requires 297.12, found 297.12. 
 
4-Ethyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridin-1-ium Tosylate 210c 
 
To a solution of 203 (1.02 g, 4.62 mmol, 3.0 equiv.) in 20.0 mL MeOH was added Zincke salt 
209c (0.48 g, 1.54 mmol, 1.0 equiv.) portion-wise.  This was stirred for 2 h at RT and then 
refluxed for a further 16 h.  Once cooled the reaction mixture was diluted with H2O and 
washed several times with DCM until no further colour was observed in the organic layer.  
The aqueous layer was concentrated under reduced pressure to yield uncyclised 4-ethyl 
pyridinium chloride as a crude orange slurry.  To a solution of the crude uncyclised 4-ethyl 
pyridinium chloride (0.53 g, 1.54 mmol, 1.0 equiv.) in 20.0 mL EtOAc was added sodium p-
toluenesulfonate (0.30 g, 1.54 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 
h then cooled and filtered.  The filtrate was concentrated under reduced pressure to yield a 
crude orange slurry, which was purified via crystallisation with 100 % EtOAc to yield 4-ethyl-1-
(2-((4-(trifluoromethoxy)phenyl)ethyl amino)ethyl pyridinium tosylate (210c, 0.13 g, 0.28 
mmol, 18 %) as a fine pale orange powder; m.p. 142 - 145 °C 
 
IR νmax/cm
-1 3301, 3055, 2957, 1609, 1518, 1476, 1255, 1185; 1H NMR (400MHz, CDCl3) δ; 
9.06 (2H, d, J = 6.0 Hz, H-2 and H-6), 7.80 (2H, d, J = 8.0 Hz, TsH), 7.55 (2H, d, J = 6.0 Hz, 
H-3 and H-5), 7.18 (2H, d, J = 8.0 Hz, TsH), 6.85 (2H, d, J = 8.5 Hz, H-3ʼʼand H-5ʼʼ), 6.51 (2H, 
d, J = 8.5 Hz, H-2ʼʼ and H-6ʼʼ), 5.95 (1H, bs, NH), 5.04 (2H, t, J = 5.0 Hz, H-2ʼ), 3.73 (2H, bs, 
H-1ʼ), 2.78 (2H, q, J = 7.5 Hz, CH2CH3(Py.)), 2.36 (3H, s, Ts(CH3)), 1.24 (3H, t, J = 7.5 Hz, 
CH2CH3(Py.)); 
13
C NMR (100MHz, CDCl3) δ; 13.0 (CH2CH3(Py.)), 21.3 (Ts(CH3)), 28.7 
(CH2CH3(Py.)), 44.4 (C-1ʼ), 60.2 (C-2ʼ), 113.0 (C-2ʼʼ and C-6ʼʼ), 119.3 (ArC), 122.2 (C-3ʼʼ and 
C-5ʼʼ), 125.8 (TsCH), 126.8 (C-3 and C-5), 129.0 (TsCH), 139.9 (ArC), 140.0 (ArC), 140.3 
(Ar(OCF3)), 144.8 (C-2 and C-6), 144.9 (ArC), 146.5 (ArC); MS m/z [M]
+ C16H18N2OF3 
requires 311.14, found 311.14. 
 
3-Ethyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 210d 
 
To a solution of 203 (1.01 g, 4.59 mmol, 3.0 equiv.) in 50.0 mL MeOH was added Zincke salt 
209d (0.47 g, 1.53 mmol, 1.0 equiv.) portion-wise.  This was stirred at RT for 2 h and then 
refluxed for a further 16 h.  Once cooled the reaction mixture was diluted with H2O and 
washed several times with DCM until no further colour was observed in the organic layer.  
The aqueous layer was concentrated under reduced pressure to yield uncyclised 3-ethyl 
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pyridinium chloride as a crude yellow oil.  To a solution of the crude uncyclised 3-ethyl 
pyridinium chloride (0.53 g, 1.53 mmol, 1.0 equiv.) in 25.0 mL EtOAc was added sodium p-
toluenesulfonate (0.30 g, 1.53 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 
h then cooled and filtered.  The filtrate collected was concentrated under reduced pressure to 
yield a crude yellow powder, which was purified via crystallisation with 100 % EtOAc to yield 
3-ethyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium tosylate (210d, 0.45 g, 0.94 
mmol, 63 %) as a fine pale yellow powder; m.p. 104 - 106 °C 
 
IR νmax/cm
-1 3287, 3054, 2974, 1613, 1509, 1476, 1248, 1154; 1H NMR (400MHz, CDCl3) δ; 
9.15 (1H, d, J = 6.0 Hz, H-6), 9.13 (1H, s, H-2), 7.91 (1H, d, J = 8.0 Hz, H-4), 7.80 (2H, d, J = 
8.0 Hz, TsH), 7.62 (1H, t, J = 6.5 Hz, H-5), 7.17 (2H, d, J = 8.0 Hz, TsH), 6.77 (2H, d, 8.5 Hz, 
H-3ʼʼ and H-5ʼʼ), 6.45 (2H, d, J = 8.5 Hz, H-2ʼʼ and H-6ʼʼ), 6.02 (1H, bt, J = 6.0 Hz, NH), 5.07 
(2H, bt, J = 4.5 Hz, H-2ʼ), 3.73 (2H, q, J = 5.0 Hz, H-1ʼ), 2.68 (2H, q, J = 7.5 Hz, 
CH2CH3(Py.)), 2.35 (3H, s, Ts(CH3)), 1.16 (3H, t, J = 7.5 Hz, CH2CH3(Py.)); 
13
C NMR 
(100MHz, CDCl3) δ; 14.1 (CH2CH3(Py.)), 21.2 (Ts(CH3)), 25.6 (CH2CH3(Py.)), 44.2 (C-1ʼ), 
60.7 (C-2ʼ), 112.8 (C-2ʼʼ and C-6ʼʼ), 119.3 (ArC), 121.8 (ArC), 122.1 (C-3ʼʼ and C-5ʼʼ), 125.8 
(TsCH), 127.1 (C-5), 128.9 (TsCH), 139.8 (ArC), 140.1 (ArC), 143.1 (C-6), 143.6 (Ar(OCF3)), 
144.8 (C-4), 145.0 (C-2), 146.7 (ArC); MS m/z [M]+ C16H18N2OF3 requires 311.14, found 
311.14. 
 
4-Phenyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 210e 
 
To a solution of 203 (0.19 g, 0.86 mmol, 2.0 equiv.) in 10.0 mL EtOH was added Zincke salt 
209e (0.15 g, 0.43 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 18 h.  Once 
cooled the reaction mixture was diluted with H2O and washed several times with DCM until no 
further colour was observed in the organic layer.  The aqueous layer was concentrated under 
reduced pressure to yield uncyclised 4-phenyl pyridinium chloride as a crude orange oil.  To a 
solution of the crude uncyclised 4-phenyl pyridinium chloride (0.17 g, 0.43 mmol, 1.0 equiv.) 
in 15.0 mL EtOAc was added sodium p-toluenesulfonate (0.08 g, 0.43 mmol, 1.0 equiv.) 
portion-wise.  This was stirred at reflux for 12 h then cooled and filtered.  The filtrate collected 
was concentrated under reduced pressure to yield a crude yellow powder, which was purified 
via crystallisation with 100 % EtOAc to yield 4-phenyl-N-(2-((4-
(trifluoromethoxy)phenyl)amino)ethyl)pyridinium tosylate (210e, 0.10 g, 0.19 mmol, 44 %) as 
a fine pale yellow powder; m.p. 161 - 164 °C 
 
IR νmax/cm
-1 3304, 3043, 1609, 1504, 1254, 1186; 1H NMR (400MHz, MeOD) δ; 8.84 (2H, d, J 
= 7.0 Hz, H-2 and H-6), 8.36 (2H, d, J = 7.0 Hz, H-3 and H-5), 7.98 (2H, dd, J = 2.0 Hz and 
4''
1''
N
H
1'
2'
N
1
4O
F3C
Ph
S
O
O
O
210 e
CHAPTER 5: EXPERIMENTAL 
86 
5.0 Hz, TsH), 7.72 (2H, d, J = 8.0 Hz, ArH(Py.)), 7.68 - 7.62 (3H, m, ArH(Py.)), 7.24 (2H, d, J 
= 8.0 Hz, TsH), 7.04 (2H, d, J = 8.0 Hz, H-3ʼʼ and H-5ʼʼ), 6.67 (2H, d, J = 8.0 Hz, H-2ʼʼ and H-
6ʼʼ), 4.79 (2H, t, J = 5.5 Hz H-2ʼ), 3.80 (2H, t, J = 5.5 Hz, H-1ʼ), 2.38 (3H, s, Ts(CH3)); 
13
C 
NMR (100MHz, MeOD) δ; 19.9 (Ts(CH3)), 43.6 (C-1ʼ), 59.7 (C-2ʼ), 112.6 (C-2ʼʼ and C-6ʼʼ), 
122.0 (ArC), 122.2 (C-3ʼʼ and C-5ʼʼ), 124.4 (C-3 and C-5), 125.5 (ArCH(Py.)), 127.7 (TsCH), 
128.4 (TsCH), 129.6 (ArCH(Py.)), 132.1 (ArCH(Py.)), 133.9 (ArC), 140.3 (ArC), 140.4 
(Ar(OCF3))), 142.1 (ArC), 144.9 (C-2 and C-6), 146.4 (ArC), 156.7 (ArC); MS m/z [M]
+ 
C20H18N2OF3 requires 359.14, found 359.14. 
 
4-tert-Butyl-N-(2-((4-(trifluoromethoxy)phenyl)amino)ethyl)pyridinium Tosylate 210f 
 
To a solution of 203 (0.16 g, 0.73 mmol, 1.1 equiv.) in 10.0 mL n-butanol was added Zincke 
salt 209f (0.22 g, 0.66 mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 18 h.  
Once cooled the reaction mixture was diluted with H2O and washed several times with DCM 
until no further colour was observed in the organic layer.  The aqueous layer was 
concentrated under reduced pressure to yield uncyclised 4-tert-butyl pyridinium chloride as a 
crude orange oil.  To a solution of the crude uncyclised 4-tert-butyl pyridinium chloride (0.25 g, 
0.66 mmol, 1.0 equiv.) in 20.0 mL EtOAc was added sodium p-toluenesulfonate (0.13 g, 0.66 
mmol, 1.0 equiv.) portion-wise.  This was stirred at reflux for 12 h then cooled and filtered.  
The filtrate collected was concentrated under reduced pressure to yield a crude yellow 
powder, which was purified via crystallisation with 100 % EtOAc to yield 4-tert-butyl-N-(2-((4-
(trifluoromethoxy)phenyl)amino)ethyl)pyridinium tosylate (210f, 0.30 g, 0.58 mmol, 89 %) as a 
fine pale yellow powder; m.p. 81 - 86 °C 
 
IR νmax/cm
-1 3304, 3053, 2972, 1644, 1516, 1476, 1248, 1186; 1H NMR (400MHz, CDCl3) δ; 
9.19 (2H, d, J = 6.5 Hz, H-2 and H-6), 7.82 (2H, d, J = 8.0 Hz, TsH), 7.62 (2H, d, J = 6.5 Hz, 
H-3 and H-5) 7.18 (2H, d, J = 8.0 Hz, TsH), 6.78 (2H, d, J = 8.5 Hz, H-3ʼʼ and H-5ʼʼ), 6.48 (2H, 
d, J = 8.5 Hz, H-2ʼʼ and H-6ʼʼ), 5.98 (1H, t, J = 6.0 Hz, NH), 5.05 (2H, t, J = 5.0 Hz, H-2ʼ), 3.70 
(2H, q, J = 4.5 Hz, H-1ʼ), 2.35 (9H, s, C(CH3)3(Py.)), 1.25 (3H, s, Ts(CH3)); 
13
C NMR 
(100MHz, CDCl3) δ; 21.3 (C(CH3)3(Py.)), 29.9 Ts(CH3)), 36.3 (ArC), 44.4 (C-1ʼ), 59.9 (C-2ʼ), 
113.0 (C-2ʼʼ and C-6ʼʼ), 122.2 (C-3ʼʼ and C-5ʼʼ), 124.6 (C-3 and C-5), 125.9 (TsCH), 128.9 
(TsCH), 132.2 (ArC) 140.0 (ArC), 140.3 (Ar(OCF3)), 143.2 (ArC), 145.1 (C-2 and C-6), 146.5 
(ArC), 170.8 (ArC); MS m/z [M]+C18H22N2OF3 requires 339.17, found 339.17. 
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Formation of N-3 Riluzole Tetrahydropyridines via the Zincke Pathway 
3-(2-(4,5-Dihydropyridin-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine 159 
 
To a solution of 204 (0.32 g, 0.70 mmol, 1.0 equiv.) and KSCN (0.82 g, 8.40 mmol, 12.0 
equiv.) in 6.0 mL AcOH was added a solution of Br2 (0.1 mL, 0.70 mmol, 1.0 equiv.) in 6.0 mL 
AcOH dropwise.  This was stirred at RT for 16 h then diluted with 36 mL H2O, neutralised with 
30 % NaOH solution and washed twice with 100 % EtOAc.  The organic layers were 
combined, dried over Na2SO4, filtered and concentrated under reduced pressure to yield ring-
cyclised pyridinium bromide as a crude oil.  To a cooled solution of the crude ring-cyclised 
pyridinium bromide (0.29 g, 0.70 mmol, 1.0 equiv.) in 30.0 mL MeOH at 0 °C was added 
NaBH4 (0.07 g, 0.96 mmol, 2.8 equiv.) portion-wise.  This was warmed to RT and stirred for a 
further 18 h.  This was then diluted with H2O and washed five times with DCM.  The organic 
layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure 
to yield 3-(2-(4,5-dihydropyridin-1-yl)-6-trifluoromethoxy)benzothiazol-2-imine (159, 0.16 g, 
0.48 mmol, 69 %) as a pale yellow oil. 
 
IR νmax/cm
-1 3054, 2917, 1645, 1503, 1485, 1257; 1H NMR (400MHz, CDCl3) δ; 7.15 (1H, d, J 
= 1.5 Hz, H-7), 7.09 (1H, dd, J = 2.0 Hz and 8.5 Hz, H-5), 6.89 (1H, d, J = 8.5 Hz, H-4), 5.80 - 
5.74 (1H, m, H-5ʼʼ), 5.70 - 5.65 (1H, m, H-4ʼʼ), 4.12 (2H, t, J = 7.5 Hz, H-2ʼ), 3.11 (2H, quin, J = 
3.0 Hz, H-6ʼʼ), 2.73 (2H, appt, J = 6.5 Hz, H-2ʼʼ), 2.70 (2H, appt, J = 6.0 Hz, H-1ʼ), 2.21 - 2.17 
(2H, m, J = 3.0 Hz, H-3ʼʼ); 13C NMR (100MHz, CDCl3) δ; 26.0 (C-3ʼʼ), 41.1 (C-2ʼ), 50.3 (C-1ʼ), 
52.9 (C-6ʼʼ), 54.1 (C-2ʼʼ), 109.4 (C-4), 115.2 (C-7), 119.6 (C-5), 121.8 (ArC), 123.8 (ArC), 
124.9 (C-4ʼʼ), 125.3 (C-5ʼʼ), 139.4 (ArC), 143.4 (Ar(OCF3)), 161.2 (ArC); MS m/z [M]
+ 
C15H17F3N3OS requires 344.10, found 344.10. 
 
3-(2-(4-Methyl-5,6-dihydropyridin-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
212a 
 
To a solution of 210a (0.17 g, 0.39 mmol, 1.0 equiv.) and KSCN (0.45 g, 4.68 mmol, 12.0 
equiv.) in 2.0 mL AcOH was added a solution of Br2 (0.02 mL, 0.39 mmol, 1.0 equiv.) in 2.0 
mL AcOH dropwise at RT and stirred for 16 h.  This was then diluted with 12.0 mL H2O, 
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neutralised with 30 % NaOH solution and washed twice with 100 % EtOAc.  The organic 
layers were combined, dried over Na2SO4, filter and concentrated under reduced pressure to 
yield ring-cyclised 4-methylpyridinium bromide as a crude oil.  To a cooled solution of the 
crude ring-cyclised 4-methylpyridinium bromide (0.17 g, 0.39 mmol, 1.0 equiv.) in 10.0 mL 
MeOH at 0 °C was added NaBH4 (0.04 g, 1.10 mmol, 2.8 equiv.) portion-wise.  This was 
warmed to RT and stirred for a further 18 h.  This was then diluted with H2O and washed five 
times with DCM.  The organic layers were combined, dried over Na2SO4, filtered and 
concentrated under reduced pressure to yield 3-(2-(4-methyl-5,6-dihydropyridin-1-yl)ethyl)-6-
trifluoromethoxy)benzothiazol-2-imine (212a, 0.04 g) as a crude red/brown oil. 
 
IR νmax/cm
-1 2911, 1650, 1585, 1485, 1255, 1160; 1H NMR (400MHz, CDCl3) δ; 7.14 (1H, s, 
H-7), 7.09 (1H, d, J = 9.0 Hz, H-5), 6.88 (1H, d, J = 9.0 Hz, H-4), 5.37 (1H, appquin, J = 1.5 
Hz, H-3ʼʼ), 4.12 (2H, t, J = 7.5 Hz, H-2ʼ), 3.07 (2H, bs, H-2ʼʼ), 2.71 - 2.68 (4H, m, H-1ʼ and H-
6ʼʼ), 2.01 (2H, bs, H-5ʼʼ), 1.69 (3H, s, CH3(THPy.)); MS m/z [M+H]
+ C16H19F3N3OS requires 
358.11, found 358.12. 
 
3-(2-(3-Ethyl-5,6-dihydropyridin-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
212b 
 
To a solution of 210d (0.20 g, 0.40 mmol, 1.0 equiv.) and KSCN (0.47 g, 4.80 mmol, 12.0 
equiv.) in 2.0 mL AcOH was added a solution of Br2 (0.02 mL, 0.40 mmol, 1.0 equiv.) in 2.0 
mL AcOH dropwise at RT and stirred for 16 h.  This was then diluted with 12.0 mL H2O, 
neutralised with 30 % NaOH solution and washed twice with 100 % EtOAc.  The organic 
layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure 
to yield ring-cyclised 3-ethylpyridinium bromide as a crude oil.  To a cooled solution of the 
crude ring-cyclised 3-ethyl pyridinium bromide (0.18 g, 0.40 mmol, 1.0 equiv.) in 10.0 mL 
MeOH at 0 °C was added NaBH4 (0.04 g, 1.12 mmol, 2.8 equiv.) portion-wise.  This was 
warmed to RT and stirred for a further 18 h.  This was then diluted with H2O and washed five 
times with DCM.  The organic layers were combined, dried over Na2SO4, filtered and 
concentrated under reduced pressure to yield 3-(2-(3-ethyl-5,6-dihydropyridin-1-yl)ethyl)-6-
trifluoromethoxy)benzothiazol-2-imine (212b, 0.08 g) as a crude orange oil. 
 
IR νmax/cm
-1 2934, 1648, 1486, 1257; 1H NMR (400MHz, CDCl3) δ; 7.15 (1H, bs, H-7), 7.09 
(1H, bd, J = 8.5 Hz, H-5), 6.91 (1H, d, J = 8.5 Hz, H-4), 5.47 (1H, appsept, J = 1.5 Hz, H-4ʼʼ), 
4.12 (2H, t, J = 7.5 Hz, H-2ʼ), 3.01 (2H, bs, H-2ʼʼ), 2.74 (2H, t, J = 7.5 Hz, H-1ʼ), 2.66 (2H, t, J 
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= 6.0 Hz, H-6ʼʼ), 2.19 - 2.17 (2H, m, H-5ʼʼ), 1.96 (2H, appq, J = 7.5 Hz, CH2CH3(THPy.)), 1.02 
(3H, t, J = 7.5 Hz, CH2CH3(THPy.)); MS m/z [M+H]
+ C17H21F3N3OS requires 372.13, found 
372.14.   
 
3-(2-(4-Phenyl-5,6-dihydropyridin-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
212c 
 
To a solution of 210e (0.10 g, 0.20 mmol, 1.0 equiv.) and KSCN (0.22 g, 2.30 mmol, 12.0 
equiv.) in 2.0 mL AcOH was added a solution of Br2 (0.01 mL, 0.20 mmol, 1.0 equiv.) in 2.0 
mL AcOH dropwise at RT and stirred for 16 h.  This was then diluted with 12.0 mL H2O, 
neutralised with 30 % NaOH solution and washed twice with 100 % EtOAc.  The organic 
layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure 
to yield ring-cyclised 4-phenyl pyridinium bromide as a crude oil.  To a cooled solution of the 
crude ring-cyclised 4-phenyl pyridinium bromide (0.10 g, 0.20 mmol, 1.0 equiv.) in 10.0 mL 
MeOH at 0 °C was added NaBH4 (0.02 g, 0.56 mmol, 2.8 equiv.) portion-wise.  This was 
warmed to RT and stirred for a further 18 h.  This was then diluted with H2O and washed five 
times with DCM.  The organic layers were combined, dried over Na2SO4, filtered and 
concentrated under reduced pressure to yield 3-(2-(4-phenyl-5,6-dihydropyridin-1-yl)ethyl)-6-
trifluoromethoxy)benzothiazol-2-imine (212c, 0.05 g) as a crude yellow oil. 
 
IR νmax/cm
-1 3058, 2923, 1654, 1485, 1257; 1H NMR (400MHz, CDCl3) δ; 7.40 - 7.24 (5H, m, 
ArH(THPy.)), 7.15 (1H, d, J = 1.5 Hz, H-7), 7.12 (1H, dd, J = 1.0 Hz and 8.5 Hz, H-5), 6.91 
(1H, d, J = 8.5 Hz, H-4), 6.07 (1H, quin, J = 2.0 Hz, H-3ʼʼ), 4.16 (2H, t, J = 7.5 Hz, H-2ʼ) 3.31 
(2H, appq, J = 2.5 Hz, H-2ʼʼ), 2.85 (2H, t, J = 6.0 Hz, H-6ʼʼ), 2.79 (2H, t, J = 7.5 Hz, H-1ʼ), 2.59 
- 2.58 (2H, m, H-5ʼʼ); MS m/z [M+H]+ C21H21F3N3OS requires 420.13, found 420.14.
 
 
Formation of N-3 Riluzole Tetrahydropyridines via the Grignard Pathway 
3-(2-(2-Methyl-3,4-dihydropyridin-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
220a 
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To a solution of 204 (0.35 g, 1.12 mmol, 1.0 equiv.) and KSCN (1.30 g, 13.44 mmol, 12.0 
equiv.) in 3.0 mL AcOH was added a solution of Br2 (0.06 mL, 1.12 mmol, 1.0 equiv.) in 3.0 
mL AcOH dropwise.  This was stirred at RT for 16 h.  The reaction mixture was then diluted 
with 18.0 mL H2O, neutralised with 30 % NaOH solution and washed twice with 100 % EtOAc.  
The organic layers were combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure to yield ring-cyclised pyridinium bromide as a crude oil.  To a solution of the 
crude ring-cyclised pyridinium bromide (0.51 g, 1.22 mmol, 1.0 equiv.) in 5.0 mL THF cooled 
to -20 °C under an atmosphere of N2 was added methylmagnesium bromide (1.2 mL) 
dropwise.  After 1 h at -20 °C the reaction mixture was warmed to 0 °C and stirred for a further 
2 h.  This was then diluted with 5.0 mL 90 % aq. MeOH and NaBH4 (0.28 g, 7.29 mmol, 6.0 
equiv.) was added portion-wise.  This was stirred at reflux for 1 h and then concentrated 
under reduced pressure, diluted with 10.0 mL H2O, and washed twice with 10.0 mL Et2O.  
The organic layers were combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure to yield 3-(2-(2-methyl-3,4-dihydropyridin-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (220a, 0.18 g) as a crude orange oil.     
 
IR νmax/cm
-1 2926, 1660, 1585, 1485, 1254, 1164; 1H NMR (400 MHz, CDCl3) δ; 7.14 (1H, s, 
H-7), 7.08 (1H, d, J = 9.0 Hz, H-5), 6.89 (1H, d, 9.0 Hz, H-4), 5.73 - 5.69 (1H, m, H-3ʼʼ), 5.00 
(1H, ddd, J = 2.0 Hz, 4.0 Hz and 8.0 Hz, H-4ʼʼ), 4.15 - 3.98 (2H, m, H-2ʼ), 3.12 - 3.09 (1H, m, 
H-2ʼʼ), 3.01 - 2.92 (2H, m, H-1ʼ), 2.68 - 2.56 (2H, m, H-6ʼʼ), 2.14 - 2.08 (2H, m, H-5ʼʼ), 1.09 (3H, 
d, J = 6.5 Hz, CH3(THPy.)); MS m/z [M+H]
+ C16H19F3N3OS requires 358.11, found 358.11. 
 
5.2 Triazole 
Imidazole-1-Sulfonyl Azide Hydrochloride 221
117
 
 
To a solution of NaN3 (1.30 g, 20.00 mmol, 1.0 equiv.) in 20.0 mL MeCN under an 
atmosphere of N2 cooled to 0 °C was added sulfuryl chloride (1.6 mL, 20.00 mmol, 1.0 equiv.) 
dropwise.  The reaction mixture was warmed to RT and left to stir overnight.  This was then 
cooled to 0 °C and imidazole (2.59 g, 38.00 mmol, 1.9 equiv.) was added portion-wise, and 
stirred for 3 h at RT.  The reaction mixture was then diluted with 40.0 mL EtOAC, washed 
twice with 40.0 mL H2O and then with 40.0 mL saturated NaHCO3.  The organic layer 
collected was dried over MgSO4 and filtered.  A solution of HCl in EtOH [obtained by the 
dropwise addition of AcCl (2.1 mL, 30.00 mmol, 1.5 equiv.) to 7.5 mL dry ethanol cooled to 0 
°C] was added dropwise to the cooled filtrate to give a colourless precipitate which when 
filtered and washed three times with 10.0 mL EtOAc yielded imidazole-1-sulfonyl azide 
N3
S
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hydrochloride (221, 1.64 g, 7.85 mmol, 48 %) as a colourless solid; m.p. 118 - 120 °C (Lit.117 
m.p. 100 - 102 °C)  
 
IR νmax/cm
-1 3054, 2169, 1322, 1159; 1H NMR (400MHz, D2O) δ; 9.05 (1H, bs, H-5), 7.84 (1H, 
bs, H-4), 7.42 (1H, bs, H-2); 13C NMR (100MHz, D2O) δ; 119.8 (C-4), 124.4 (C-2), 137.7 (C-
5); MS m/z [M+H]+ C3H4N5O2S requires 174.01, found 174.01. 
 
N-(2-Azidoethyl)-4-(trifluoromethoxy)aniline 222 
 
To a solution of 203 (0.83 g, 3.75 mmol, 1.0 equiv.), K2CO3 (1.21 g, 8.75 mmol, 2.3 equiv.) 
and CuSO4.5H2O (9 mg, 0.04 mmol, 0.001 equiv.) in 20.0 mL MeOH under an atmosphere of 
N2 was added imidazole-1-sulfonyl azide hydrochloride 221 (0.94 g, 4.50 mmol, 1.2 equiv.) 
portion-wise.  The reaction mixture was stirred at RT for 2 h and then diluted with 60.0 mL 
H2O, acidified with conc. HCl and washed three times with 40.0 mL EtOAc.  The organic 
layers were combined, dried over MgSO4, filtered and concentrated under reduced pressure 
to yield a crude orange oil. The crude oil was purified via column chromatography using 9:1 
PE 40-60 °C:EtOAC to yield N-(2-azidoethyl)-4-(trifluoromethoxy)aniline (222, 0.23 g, 0.93 
mmol, 25 %) as a pale yellow oil; Rf 0.38 (9:1 PE 40-60 °C:EtOAc) 
 
IR νmax/cm
-1 3411, 3029, 2926, 2102, 1613, 1448, 1515, 1250; 1H NMR (400MHz, CDCl3) δ; 
7.06 (2H, d, J = 8.0 Hz, H-3 and H-5), 6.61 (2H, d, J = 8.0 Hz, H-2 and H-6), 3.55 (2H, t, J = 
6.0 Hz, H-1ʼ), 3.34 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.3 (C-2ʼ), 50.4 (C-
1ʼ), 113.5 (C-2 and C-6), 119.4 (ArC), 122.6 (C-3 and C-5), 140.9 (Ar(OCF3)), 145.9 (ArC); 
MS m/z [M+H]+ C9H10N4F3O requires 247.08, found 247.08. 
 
3-(2-Azidioethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 223 
 
To a solution of uncyclised azide 222 (0.36 g, 1.46 mmol, 1.0 equiv.) and KSCN (1.70 g, 
17.52 mmol, 12.0 equiv.) in 4.0 mL AcOH was added a solution of Br2 (0.1 mL, 1.46 mmol, 
1.0 equiv.) in 4.0 mL AcOH dropwise.  This was stirred at RT for 2 h.  The reaction mixture 
was then diluted with 24.0 mL H2O, neutralised with 30 % NaOH solution and washed twice 
with EtOAc.  The organic layers were combined dried over MgSO4, filtered and concentrated 
under reduced pressure to yield a crude yellow oil.  The crude oil was purified via column 
chromatography using 100 % EtOAc to yield 3-(2-azidioethyl)-6-
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(trifluoromethoxy)benzothiazol-2-imine (223, 0.18 g, 0.59 mmol, 63 %) as a yellow oil; Rf 0.43 
(100 % EtOAc) 
 
IR νmax/cm
-1 3044, 2929, 2110, 1610, 1584, 1485, 1256; 1H NMR (400MHz, CDCl3) δ; 7.20 
(1H, bs, H-7), 7.14 (1H, bd, J = 9.0 Hz, H-5), 7.00 (1H, d, J = 9.0 Hz, H-4), 4.14 (2H, t, J = 6.0 
Hz, H-1ʼ), 3.73 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.7 (C-1ʼ), 48.5 (C-2ʼ), 
109.7 (C-4), 115.3 (C-7), 119.7 (C-5), 121.8 (ArC), 123.8 (ArC), 139.2 (ArC), 143.8 
(Ar(OCF3)), 161.2 (ArC); MS m/z [M+H]
+ C10H9N5F3OS requires 304.05, found 304.05. 
 
General Procedure for the [3 + 2] Cycloaddition of Azides and Terminal Alkynes 
 
To a solution of ring-cyclised azide 223 (1.0 equiv.) and alkyne (1.5 equiv.) in a 1:1 mixture of 
THF and H2O heated to 20 °C was added 1M CuSO4 (aq) (1.0 equiv.) and freshly prepared 
1M sodium ascorbate (aq) (2.0 equiv.).  The reaction was monitored by TLC.  After total 
consumption of azide 223 the reaction mixture was concentrated under reduced pressure, 
diluted with 2:1 DCM: conc. NH4OH and then left to stir for 30 mins at RT.  This was then 
washed twice with H2O and once with brine.  The organic layer collected was dried over 
MgSO4, filtered and concentrated under reduced pressure to yield the crude N-3 Riluzole 1,4-
substituted-1,2,3-triazole, which was further purified via flash column chromatography in a 
suitable solvent system. 
 
3-(2-(4-Phenyl-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160a 
 
Using the general procedure; to a solution of azide 223 (0.27 g, 0.89 mmol, 1.0 equiv.) and 
phenylacetylene (0.2 mL, 1.32 mmol, 1.5 equiv.) in 12.0 mL H2O and 12.0 mL THF heated to 
20 °C was added 0.9 mL 1M CuSO4 (aq) and 1.8 mL freshly prepared 1M sodium ascorbate 
(aq) dropwise.  This was stirred at 20 °C for 3 h.  After work-up the crude was column purified 
using 100 % EtOAc to yield 3-(2-(4-phenyl-1,2,3-triazolyl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160a, 0.14 g, 0.35 mmol, 39 %) as an off-white solid; 
Rf 0.21 (100 % EtOAc), m.p. 195 - 201 °C 
 
IR νmax/cm
-1 3250, 3085, 2954, 1615, 1584, 1483, 1259; 1H NMR (400MHz, CDCl3) δ; 7.65 
(2H, d, J =18.5 Hz, ArH), 7.61 (1H, s, H-5ʼʼ), 7.38 (2H, t, J = 7.0 Hz, ArH), 7.33 - 7.29 (1H, m, 
ArH), 7.09 (1H, bs, H-7), 6.94 (1H, bd, J = 8.5 Hz, H-5), 6.54 (1H, d, J = 9.0 Hz, H-4), 4.82 
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(2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.6 (C-
2ʼ), 46.9 (C-1ʼ), 109.0 (C-4), 115.3 (C-7), 119.8 (C-5), 120.8 (C-5ʼʼ), 121.7 (ArC), 123.2 (ArC), 
125.8 (ArCH), 128.3 (ArCH), 128.8 (ArCH), 130.2 (ArC), 138.6 (ArC), 143.9 (Ar(OCF3)), 148.2 
(ArC), 161.0 (ArC); MS m/z [M+H]+ C18H15F3N5OS requires 406.10, found 406.09. 
 
3-(2-(4-Benzyl-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160b 
 
Using the general procedure; to a solution of azide 223 (0.22 g, 0.72 mmol, 1.0 equiv.) and 3-
phenyl-1-propyne (0.1 mL, 1.07 mmol, 1.5 equiv.) in 8.6 mL H2O and 8.6 mL THF heated to 
20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 1M sodium ascorbate 
(aq) dropwise.  This was stirred at 20 °C for 3 h.  After work-up the crude was column purified 
using 100 % EtOAc to yield 3-(2-(4-benzyl-1,2,3-triazolyl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160b, 0.15 g, 0.34 mmol, 50 %) as a pale yellow 
solid; Rf 0.15 (100 % EtOAc), m.p. 103 - 106 °C 
 
IR νmax/cm
-1 3232, 3064, 2970, 1602, 1580, 1484, 1256; 1H NMR (400MHz, CDCl3); 7.24 - 
7.20 (3H, m, ArH), 7.10 (1H, bs, H-5ʼʼ), 7.00 - 6.99 (3H, m, ArH and NH), 6.96 (1H, s, H-7), 
6.91 (1H, bd, J = 9.0 Hz, H-5), 6.37 (1H, d, J = 9.0 Hz, H-4), 4.71 (2H, t, J = 6.0 Hz, H-1ʼ), 
4.37 (2H, t, J = 6.0 Hz, H-2ʼ), 3.92 (2H, s, H-1ʼʼʼ); 13C NMR (100MHz, CDCl3); 31.0 (C-1ʼʼʼ), 
42.8 (C-2ʼ), 45.7 (C-1ʼ), 107.8 (C-4), 114.0 (C-5ʼʼ), 118.1 (ArC) 118.7 (C-5), 120.7 (ArC), 121.7 
(ArC), 122.1 (C-7), 125.5 (ArCH), 127.5 (ArCH), 127.5 (ArCH), 137.6 (ArC), 142.7 (Ar(OCF3)), 
147.1 (ArC), 159.6 (ArC); MS m/z [M+H]+ C19H17F3N5OS requires 420.11, found 420.11. 
 
3-(2-(4-Phenylethyl-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160c 
 
Using the general procedure; to a solution of azide 223 (0.18 g, 0.59 mmol, 1.0 equiv.) and 4-
phenyl-1-butyne (0.1 mL, 0.89 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF heated to 
20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 1M sodium ascorbate 
(aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was column purified 
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using 100 % EtOAc to yield 3-(2-(4-phenylethyl-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy) 
benzothiazol-2-imine (160c, 0.12 g, 0.28 mmol, 47 %) as an off-white solid; Rf 0.13 (100 % 
EtOAc), m.p. 153 - 157 °C 
 
IR νmax/cm
-1 3263, 3030, 2971, 1614, 1585, 1484, 1260; 1H NMR (500MHz, CDCl3) δ; 7.25 
(2H, appt, J = 7.5 Hz, ArH), 7.19 (1H, t, J = 6.0 Hz, ArH), 7.11 (1H, s, H-7), 7.07 (2H, d, J = 
7.0 Hz, ArH), 7.03 (1H, bs, NH), 6.96 - 6.94 (2H, m, H-5 and H-5ʼʼ), 6.39 (1H, d, J = 9.0 Hz, H-
4), 4.69 (2H, t, J = 5.5 Hz, H-1ʼ), 4.39 (2H, t, J = 6.0 Hz, H-2ʼ), 2.89 (2H, t, J = 7.5 Hz, H-2ʼʼʼ), 
2.77 (2H, t, J = 8.5 Hz, H-1ʼʼʼ); 13C NMR (125MHz, CDCl3) δ; 26.1 (C-2ʼʼʼ), 34.4 (C-1ʼʼʼ), 42.8 
(C-2ʼ), 45.8 (C-1ʼ), 107.9 (C-4), 114.1 (C-7), 118.1 (ArC), 118.8 (C-5), 122.1 (C-5ʼʼ), 123.2 
(ArC), 125.1 (ArCH), 127.3 (ArCH), 127.4 (ArCH), 137.7 (ArC), 140.0 (ArC), 142.7 (Ar(OCF3)) 
146.6 (ArC), 159.67 (ArC); MS m/z [M+H]+ C20H19F3N5OS requires 434.13 found 434.13.  
 
3-(2-(4-(p-Toly)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160d 
 
Using the general procedure; to a solution of azide 223 (0.31 g, 1.02 mmol, 1.0 equiv.) and 4-
ethynyltoluene (0.1 mL, 1.07 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF heated to 20 
°C was added 0.7 mL CuSO4 (aq) and 1.4 mL freshly prepared 1M sodium ascorbate (aq) 
dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was column purified 
using 100 % EtOAc to yield 3-(2-(4-(p-toly)-1,2,3-triazolyl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160d, 0.17 g, 0.40 mmol, 56 %) as a pale yellow 
solid; Rf 0.27 (100 % EtOAc), m.p. 199 - 203 °C 
 
IR νmax/cm
-1 3273, 3014, 2943, 1626, 1586, 1479, 1386, 1252; 1H NMR (400MHz, CDCl3); 
7.57 (1H, s, H-5ʼʼ), 7.54 (2H, d, J = 8.0 Hz, ArH), 7.19 (2H, d, J = 8.0 Hz, ArH), 7.09 (2H, bs, 
H-7 and NH), 6.94  (1H, d, J = 8.5 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.8 (2H, t, J = 6.0 
Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 2.36 (3H, s, Ar(CH3)); 
13
C NMR (100MHz, CDCl3); 
20.2 (Ar(CH3)), 42.6 (C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-4), 114.2 (C-7), 118.1 (ArC), 118.8 (ArC),  
119.4 (C-5), 120.6 (C-5ʼʼ), 122.2 (ArC), 124.6 (ArCH), 126.3 (ArC), 128.4 (ArCH), 137.1 (ArC), 
142.8 (Ar(OCF3)), 147.2 (ArC), 159.8 (ArC); MS m/z [M+H]
+ C19H17F3N5OS requires 420.11, 
found 420.11. 
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3-(2-(4-(m-Toly)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160e 
 
Using the general procedure; to a solution of azide 223 (0.18 g, 0.60 mmol, 1.0 equiv.) and 3-
ethynyltoluene (0.1 mL, 0.90 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF heated to 20 
°C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 1M sodium ascorbate (aq) 
dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was column purified 
using 100 % EtOAc to yield 3-(2-(4-(m-toly)-1,2,3-triazolyl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160e, 0.15 g, 0.36 mmol, 59 %) as a pale yellow 
solid; Rf  (100 % EtOAc), m.p. 178 - 182 °C 
 
IR νmax/cm
-1 3280, 3029, 2954, 1625, 1586, 1480, 1384, 1267; 1H NMR (400MHz, CDCl3) δ; 
7.60 (1H, s, ArH), 7.52 (1H, s, H-5ʼʼ), 7.41 (1H, d, J = 7.5 Hz, ArH), 7.26 (1H, appt, J = 6.5 Hz, 
ArH), 7.13 (1H, d, J = 7.5 Hz, ArH), 7.09 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 
6.53 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ), 2.37 
(3H, s, Ar(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 20.3 (Ar(CH3)), 42.6 (C-2ʼ), 46.9 (C-1ʼ), 108.0 
(C-4), 114.2 (C-7), 118.1 (ArC), 118.8 (ArC), 119.7 (C-5), 120.6 (C-5ʼʼ), 122.2 (ArCH), 123.2 
(ArC) 125.4 (ArCH), 127.6 (ArCH), 128.0 (ArCH), 129.0 (ArC), 137.5 (ArC), 142.8 (Ar(OCF3)), 
147.2 (ArC), 159.8 (ArC); MS m/z [M+H]+ C19H17F3N5OS requires 420.11, found 420.11.  
 
3-(2-(4-(o-Toly)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160f 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.22 g, 0.73 mmol, 1.0 
equiv.) and 2-ethynyltoluene (0.1 mL, 1.09 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 and 1.5 mL freshly prepared 1M sodium 
ascorbate dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was column 
purified using 100 % EtOAc to yield 3-(2-(4-(o-toly)-1,2,3-triazolyl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160f, 0.11 g, 0.27 mmol, 37 %) as an off white solid; 
Rf 0.15 (100 % EtOAc), m.p. 165 - 170 °C 
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IR νmax/cm
-1 3227, 3077, 2960, 1601, 1581, 1484, 1382, 1260; 1H NMR (400MHz, CDCl3) δ; 
7.45 - 7.42 (2H, m, ArH and H-5ʼʼ), 7.24 - 7.19 (3H, m, ArH), 7.09 (2H, bs, H -7 and NH), 6.92 
(1H, d, J = 8.5 Hz, H-5), 6.44 (1H, d, J = 9.0 Hz, H-4), 4.86 (2H, t, J = 5.5 Hz, H-1ʼ), 4.47 (2H, 
t, H-2ʼ, J = 5.5 Hz), 2.16 (3H, s, Ar(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 19.6 (Ar(CH3)), 42.9 
(C-2ʼ), 45.9 (C-1ʼ), 107.8 (C-4), 114.2 (C-7), 118.07 (ArC), 118.9 (C-5), 120.6 (ArC), 121.9 (C-
5ʼʼ), 122.1 (ArC),  125.0 (ArCH), 127.3 (ArCH), 128.0 (ArCH), 128.5 (ArC), 129.6 (ArCH), 
134.6 (ArC), 137.66 (ArC), 142.8 (Ar(OCF3)), 146.4 (ArC); MS m/z [M+H]
+ C19H17F3N5OS 
requires 420.11, found 420.11.  
 
3-(2-(4-(Pyridin-2-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160g 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.67 mmol, 1.0 
equiv.) and 2-ethynylpyridine (0.1 mL, 1.01 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using a gradient solvent system from 100 % EtOAc to 100 % MeOH to 
yield 3-(2-(4-(pyridin-2-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
(160g, 0.15 g, 0.36 mmol, 53 %) a pale yellow solid; Rf 0.07 (100 % EtOAc), m.p. 156 - 160 
°C 
 
IR νmax/cm
-1 3206, 3056, 2950, 1602, 1581, 1484, 1260; 1H NMR (400MHz, CDCl3) δ; 8.52 
(1H, d, J = 4.5 Hz, CH(Py.)), 8.08 (1H, d, J = 8.0 Hz, CH(Py.)), 8.02 (1H, s, H-5ʼʼ), 7.75 (1H, t, 
J = 7.5 Hz, CH(Py.)), 7.21 (1H, t, J = 5.0 Hz, CH(Py.)), 7.11 (1H, bs, NH), 7.07 (1H, s, H-7), 
6.91 (1H, d, J = 9.0 Hz, H-5), 6.54 (1H, d, J = 9.0 Hz, H-4), 4.83 (2H, d, J = 6.0 Hz, H-1ʼ), 4.49 
(2H, d, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.5 (C-2ʼ), 46.0 (C-1ʼ), 107.8 (C-4), 
114.3 (C-7), 119.1 (C-5), 121.9 (CH(Py.)), 122.2 (CH(Py.)), 122.4 (C-5ʼʼ), 135.8 (CH(Py.)), 
137.6 (ArC), 142.7 (Ar(OCF3)), 144.4 (ArC), 147.6 (ArC), 148.3 (CH(Py.)), 148.8 (ArC), 149.8 
(ArC), 159.8 (ArC); MS m/z [M+H]+ C17H14F3N6OS requires 407.09, found 407.09. 
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3-(2-(4-(Pyridin-3-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160h 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.51 mmol, 1.0 
equiv.) and 3-ethynylpyridine (0.08 g, 0.77 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2.5 h.  After work-up the crude 
was column purified using a gradient solvent system from 100 % EtOAc to 100 % MeOH to 
yield 3-(2-(4-(pyridin-3-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
(160h, 0.13 g, 0.32 mmol, 64 %) as a pale yellow solid; Rf 0.08 (100 % EtOAc), m.p. 195 - 
197 °C 
 
IR νmax/cm
-1 3217, 3035, 2971, 1618, 1585, 1482, 1262; 1H NMR (400MHz, CDCl3) δ; 8.82 
(1H, s, CH(Py.)), 8.56 (1H, d, J = 4.0 Hz, CH(Py.)), 8.04 (1H, d, J = 8.0 Hz, CH(Py.)), 7.69 
(1H, s, H-5ʼʼ), 7.33 (1H, q, J = 5.0 Hz, CH(Py.)), 7.09 (1H, s, H-7), 6.94 (1H, d, J = 8.5 Hz, H-
5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.84 (2H, t, J = 6.0 Hz, H-1ʼ), 4.48 (2H, t, J = 6.0 Hz, H-2ʼ); 
13
C NMR (100MHz, CDCl3) δ; 42.4 (C-2ʼ), 45.9 (C-1ʼ), 107.8 (C-4), 114.3 (C-7), 118.8 (C-5), 
120.1 (C-5ʼʼ), 120.6 (ArC), 122.2 (ArC), 122.7 (ArC), 125.3 (CH(Py.)), 132.0 (CH(Py.)), 137.4 
(ArC), 142.8 (Ar(OCF3)), 144.0 (ArC), 145.9 (CH(Py.)), 148.3 (CH(Py.)), 159.8 (ArC); MS m/z 
[M+H]+ C17H14F3N6OS requires 407.09, found 407.09. 
 
3-(2-(4-(Pyridin-4-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160i 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.25 g, 0.82 mmol, 1.0 
equiv.) and 4-ethynylpyridine (0.17 g, 1.23 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.6 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 9:1 DCM:MeOH to yield 3-(2-(4-(pyridin-4-yl)-1,2,3-triazol-1-
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yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160i, 0.15 g, 0.38 mmol, 46 %) as an off 
white solid; Rf 0.21 (9:1 DCM:MeOH), m.p. 209 - 211 °C 
 
IR νmax/cm
-1 3221, 3028, 2971, 1604, 1583, 1482, 1266; 1H NMR (400MHz, CDCl3) δ; 8.63 
(2H, bs, CH(Py.)), 7.77 (1H, s, H-5ʼʼ), 7.57 (2H, d, J = 5.0 Hz, CH(Py.)), 7.10 (1H, s, H-7), 6.91 
(1H, d, J = 9.0 Hz, H-5), 6.54 (1H, d, J = 9.0 Hz, H-4), 4.85 (2H, t, J = 6.0 Hz, H-1ʼ), 4.48 (2H, 
t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.4 (C-2ʼ), 46.0 (C-1ʼ), 107.8 (C-4), 114.3 
(C-7), 118.0 (ArC), 118.8 (C-5), 120.6 (ArC), 121.2 (CH(Py.)), 122.2 (C-5ʼʼ), 136.4 (ArC), 
137.4 (ArC), 142.8 (Ar(OCF3)), 144.6 (ArC), 149.4 (CH(Py.)), 159.8 (ArC); MS m/z [M+H]
+ 
C17H14F3N6OS requires 407.09, found 407.09. 
 
3-(2-(4-(2,4-Difluorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160j 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.31 g, 1.02 mmol, 1.0 
equiv.) and 1-ethynyl-2,4-difluorobenzene (0.2 mL, 1.53 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 1.0 mL 1M CuSO4 (aq) and 2.0 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  The crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(2,4-difluorophenyl)-1,2,3-triazol-1-
yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160j, 0.22 g, 0.51 mmol, 50 %) as an off-
white solid; Rf 0.33 (100 % EtOAc), m.p. 194 - 200 °C 
 
IR νmax/cm
-1 3234, 3028, 2957, 1601, 1578, 1483, 1257; 1H NMR (400MHz, CDCl3) δ; 8.16 
(1H, td, J = 5.0 Hz and 9.0 Hz, ArH), 7.71 (1H, d, J = 3.5 Hz, H-5ʼʼ), 7.09 (2H, bs, H-7 and 
NH), 6.97 (1H, td, J = 3.0 Hz and 9.0 Hz, ArH), 6.91 (1H, d, J = 7.0 Hz, H-5), 6.83 (1H, ddd, J 
= 2.5 Hz, 9.0 Hz and 11.0 Hz, ArH), 6.49 (1H, d, J = 9.0 Hz, H-4), 4.83 (2H, t, J = 6.0 Hz, H-
1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.5 (C-2ʼ), 46.9 (C-1ʼ), 103.8 
(ArC), 104.0 (ArCH), 104.3 (ArC), 108.8 (C-4), 111.9 (ArCH), 112.1 (ArC), 114.6 (ArC), 115.3 
(C-7), 119.1 (ArC), 119.8 (C-5), 123.3 (C-5ʼʼ), 123.4 (ArC), 128.8 (ArCH), 138.5 (ArC), 140.8 
(ArC), 143.8 (Ar(OCF3)); MS m/z [M+H]
+ C18H13F5N5OS requires 442.08, found 442.08. 
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3-(2-(4-(3,4-Difluorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160k 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.15 g, 0.51 mmol, 1.0 
equiv.) and 3,4-difluorophenylacetylene (0.1 mL, 0.76 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(3,4-difluorophenyl)-1,2,3-
triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160k, 0.10 g, 0.23 mmol, 44 %) as 
an off-white solid; Rf  0.17 (100 % EtOAc), m.p. 179 - 184 °C 
 
IR νmax/cm
-1 3227, 3043, 1580, 1483, 1266; 1H NMR (400MHz, CDCl3) δ; 7.57 (1H, s, H-5ʼʼ), 
7.50 (1H, dddd, J = 2.0 Hz, 7.5 Hz and 10.0 Hz, ArH), 7.36 - 7.33 (1H, m, ArH), 7.16 (1H, q, J 
= 8.5 Hz, ArH), 7.10 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 6.51 (1H, d, J = 9.0 
Hz, H-4), 4.82 (2H, t, J = 6.0 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, 
CDCl3) δ; 42.4 (C-2ʼ), 45.9 (C-1ʼ), 107.8 (C-4), 113.9 (ArC), 114.3 (ArCH), 116.6 (C-7), 116.7 
(ArCH), 118.8 (C-5), 119.9 (C-5ʼʼ), 120.7 (ArC), 122.2 (ArCH), 126.2 (ArC), 137.5 (ArC), 142.8 
(Ar(OCF3)), 145.3 (ArC), 148.2 (ArC), 150.6 (ArC), 159.7 (ArC); MS m/z [M+H]
+ 
C18H13F5N5OS requires 442.08, found 442.07. 
 
3-(2-(4-(2,4-Difluorophenyl)-1,2,3-triazol-1-ly)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160l 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.19 g, 0.61 mmol, 1.0 
equiv.) and 1-ethynyl-3,5-difluorobenzene (0.1 mL, 0.92 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 0.6 mL CuSO4 (aq) and 1.2 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-
up the crude was column purified using 100 % EtOAc to yield 3-(2-(4-(2,4-difluorophenyl)-
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1,2,3-triazol-1-ly)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160l, 0.11 g, 0.25 mmol, 41 
%) as an off-white solid; Rf  0.23 (100 % EtOAc), m.p. 183 - 185 °C 
 
IR νmax/cm
-1 3259, 3087, 2954, 1617, 1588, 1484, 1262; 1H NMR (400MHz, CDCl3) δ; 7.62 
(1H, s, H-5ʼʼ), 7.19 (2H, d, J = 6.5 Hz, ArH), 7.10 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 8.5 
Hz, H-5), 6.75 (1H, tt, J = 2.0 Hz and 9.0 Hz, ArH), 6.51 (1H, d, J = 9.0 Hz, H-4), 4.83 (2H, t, J 
= 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.4 (C-2ʼ), 46.0 
(C-1ʼ), 102.5 (ArCH), 107.4 (ArCH), 107.6 (ArC), 107.8 (C-4), 114.3 (C-7), 118.8 (C-5), 120.4 
(C-5ʼʼ), 122.2 (ArC), 132.1 (ArC), 137.4 (ArC), 142.8 (Ar(OCF3)), 145.1 (ArC), 161.1 (ArC), 
163.5 (ArC); MS m/z [M+H]+ C18H13F5N5OS requires 442.08, found 442.07. 
 
3-(2-(4-(4-Fluorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine 
160m 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.21 g, 0.70 mmol, 1.0 
equiv.) and 1-ethynyl-4-fluorobenzene (0.1 mL, 1.05 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-fluorophenyl)-1,2,3-triazol-1-
yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160m, 0.16 g, 0.39 mmol, 56 %) as an off-
white solid; Rf 0.15 (100 % EtOAc), m.p. 193 - 197 °C 
 
IR νmax/cm
-1 3230, 3014, 1601, 1582, 1484, 1261; 1H NMR (400MHz, CDCl3) δ; 7.61 (2H, dd, 
J = 5.5 Hz and 8.5 Hz, ArH), 7.56 (1H, s, H-5ʼʼ), 7.09 (2H, bs, H-7 and NH), 7.06 (2H, appt, J 
= 8.5 Hz, ArH), 6.93 (1H, d, J = 8.5 Hz, H-5), 6.52 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 
Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.5 (C-2ʼ), 45.9 (C-1ʼ), 
107.9 (C-4), 114.2 (C-7), 114.7 (ArCH), 114.9 (ArCH), 118.8 (C-5), 119.5 (C-5ʼʼ), 122.2 (ArC), 
126.4 (ArC), 126.5 (ArC), 137.5 (ArC), 142.8 (Ar(OCF3)), 146.3 (ArC), 159.8 (ArC), 162.9 
(ArC); MS m/z [M+H]+ C18H14F4N5OS requires 424.09, found 424.08. 
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3-(2-(4-(3-Fluorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine 
160n 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.26 g, 0.84 mmol, 1.0 
equiv.) and 1-ethynyl-3-fluorobenzene (0.2 mL, 1.27 mmol, 1.5 equiv.) in 15.0 mL H2O and 
15.0 mL THF heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.7 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(3-fluorophenyl)-1,2,3-triazol-1-
yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160n, 0.16 g, 0.37 mmol, 44 %) as an off-
white solid; Rf 0.19 (100 % EtOAc), m.p. 185 - 190 °C 
 
IR νmax/cm
-1 3242, 3079, 2953, 1614, 1583, 1482, 1257; 1H NMR (400MHz, CDCl3) δ; 7.61 
(1H, s, H-5ʼʼ), 7.40 (2H, appt, J = 7.5 Hz, ArH), 7.34 (1H, appq, J = 8.0 Hz, ArH), 7.09 (2H, bs, 
H-7 and NH), 7.01 (1H, t, J = 8.5 Hz, ArH), 6.94 (1H, d, J = 9.5 Hz, H-5), 6.52 (1H, d, J = 9.0 
Hz, H-4), 4.82 (2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, 
CDCl3) δ; 43.5 (C-2ʼ), 47.0 (C-1ʼ), 108.9 (C-4), 112.6 (ArC), 112.8 (ArCH), 115.0 (ArCH), 
115.2 (ArC), 115.3 (C-7), 119.9 (C-5), 121.1 (C-5ʼʼ), 121.3 (ArCH), 123.2 (ArC), 130.4 (ArCH), 
132.2 (ArC), 138.5 (ArC), 143.9 (Ar(OCF3)), 147.1 (ArC), 160.8 (ArC); MS m/z [M+H]
+ 
C18H14F4N5OS requires 424.09, found 424.08.  
 
3-(2-(4-(2-Fluorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine 
160o 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.28 g, 0.93 mmol, 1.0 
equiv.) and 1-ethynyl-2-fluorobenzene (0.2 mL, 1.39 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.9 mL 1M CuSO4 (aq) and 1.9 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(2-fluorophenyl)-1,2,3-triazol-1-
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yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160o, 0.21 g, 0.49 mmol, 52 %) as an off-
white solid; Rf 0.33 (100 % EtOAc), m.p. 172 - 175 °C 
 
IR νmax/cm
-1 3243, 3068, 2958, 1576, 1483, 1254; 1H NMR (400MHz, CDCl3) δ; 8.17 (1H, td, J 
= 1.5 Hz and 7.5 Hz, ArH), 7.77 (1H, d, J = 3.5 Hz, H-5ʼʼ), 7.31 - 7.28 (1H, m, ArH), 7.22 (1H, 
t, J = 7.5 Hz, ArH), 7.09 - 7.00 (3H, m, ArH, NH, and H-7), 6.91 (1H, d, J = 8.5 Hz, H-5), 6.50 
(1H, d, J = 9.0 Hz, H-4), 4.84 (2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR 
(100MHz, CDCl3) δ; 42.5 (C-2ʼ), 45.8 (C-1ʼ), 107.8 (C-4), 114.2 (C-7), 114.5 (ArCH), 117.1 
(ArC), 118.7 (C-5), 122.2 (ArC), 122.8 (C-5ʼʼ), 123.5 (ArCH), 126.7 (ArCH), 128.4 (ArCH), 
137.5 (ArC), 140.4 (ArC), 142.7 (Ar(OCF3)), 156.8 (ArC), 159.8 (ArC), 159.8 (ArC); MS m/z 
[M+H]+ C18H14F4N5OS requires 424.09, found 424.08. 
 
3-(2-(4-(2-Methoxyphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160p 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.67 mmol, 1.0 
equiv.) and 2-ethynylanisole (0.1 mL, 1.01 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(2-methoxyphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160p, 0.22 g, 0.52 mmol, 77 %) as a 
pale yellow solid; Rf 0.20 (100 % EtOAc), m.p. 155 - 160 °C 
 
IR νmax/cm
-1 3287, 3011, 2835, 1632, 1585, 1481, 1245; 1H NMR (400MHz, CDCl3) δ; 8.21 
(1H, d, J = 7.5 Hz, ArH), 7.86 (1H, s, H-5ʼʼ), 7.29 (1H, appt, J = 8.0 Hz, ArH), 7.08 (2H, bs, C-
7 and NH), 7.05 (1H, appt, J = 7.5 Hz, ArH), 6.92 (2H, d, J = 8.5 Hz, ArH and C-5), 6.51 (1H, 
d, J = 9.0 Hz, C-4), 4.81 (2H, t, J = 6.0 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 3.82 (3H, s, 
Ar(OCH3)); 
13
C NMR (100MHz, CDCl3) δ; 42.6 (C-2ʼ), 45.7 (C-1ʼ), 54.2 (Ar(OCH3)), 108.0 (C-
4), 109.7 (ArCH), 114.0 (C-7), 118.0 (ArC), 118.8 (C-5), 120.0 (ArCH), 120.6 (ArC), 122.1 
(ArC), 123.1 (C-5ʼʼ), 126.6 (ArCH), 128.0 (ArCH), 137.7 (ArC), 142.4 (ArC), 142.7 (Ar(OCF3)), 
154.5 (ArC), 159.9 (ArC); MS m/z [M+H]+ C19H17F3N5O2S requires 436.11, found 436.10. 
 
 
6
N3
S
NH
O
F3C
1'
2'
N
5''
4''
N
N
MeO
160 p
CHAPTER 5: EXPERIMENTAL 
103 
3-(2-(4-(3-Methoxyphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160q 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.18 g, 0.58 mmol, 1.0 
equiv.) and 3-ethynylanisole (0.1 mL, 0.87 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(3-methoxyphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160q, 0.17 g, 0.39 mmol, 67 %) as 
an off white solid; Rf 0.18 (100 % EtOAc), m.p. 170 - 174 °C 
 
IR νmax/cm
-1 3253, 3097, 2835, 1606, 1584, 1485, 1364, 1258; 1H NMR (400MHz, CDCl3) δ; 
7.61 (1H, s, H-5ʼʼ), 7.28 (2H, d, J = 5.0 Hz, ArH), 7.17 (1H, d, J = 7.5 Hz, ArH), 7.09 (2H, bs, 
C-7 and NH), 6.94 (1H, d, J = 8.5 Hz, C-5), 6.86 (1H, d, J = 7.0 Hz, ArH), 6.54 (1H, d, J = 9.0 
Hz, C-4), 4.82 (2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ), 3.85 (3H, s, Ar(OCH3)); 
13
C NMR (100MHz, CDCl3) δ; 42.5 (C-2ʼ), 45.9 (C-1ʼ), 54.3 (Ar(OCH3)), 108.0 (C-4), 109.8 
(ArCH), 113.3 (ArCH), 114.2 (C-7), 117.1 (ArCH), 118.1 (ArC), 118.8 (C-5), 120.0 (C-5ʼʼ), 
120.6 (ArC), 122.2 (ArC), 128.8 (ArCH), 130.4 (ArC), 137.5 (ArC), 142.8 (Ar(OCF3)) 147.0 
(ArC), 158.9 (ArC); MS m/z [M+H]+ C19H17F3N5O2S requires 436.11, found 436.11. 
 
3-(2-(4-(4-Methoxyphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160r 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.14 g, 0.46 mmol, 1.0 
equiv.) and 4-ethynylanisole (0.1 mL, 0.69 mmol, 1.5 equiv.) in 5.0 mL H2O and 5.0 mL THF 
heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 0.9 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield 3-(2-(4-(4-methoxyphenyl)-1,2,3-triazolyl)ethyl)-6-
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(trifluoromethoxy)benzothiazol-2-imine (160r, 0.09 g, 0.21 mmol, 47 %) an off white solid; Rf 
0.21 (100 % EtOAc), m.p. 187 - 197 °C 
 
IR νmax/cm
-1 3262, 3029, 2835, 1619, 1584, 1485, 1362, 1265; 1H NMR (400MHz, CDCl3) δ; 
7.57 (2H, d, J = 9.0 Hz, ArH), 7.52 (1H, s, H-5ʼʼ), 7.09 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 
8.0 Hz, H-5), 6.91 (2H, d, J = 9.0 Hz, ArH), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.80 (2H, t, J = 6.0 
Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 3.83 (3H, s, Ar(OCH3)); 
13
C NMR (100MHz, CDCl3) δ; 
42.6 (C-2ʼ), 45.8 (C-1ʼ), 54.3 (Ar(OCH3)), 108.0 (C-4), 113.2 (ArCH), 114.2 (C-7), 118.1 (ArC), 
118.8 (C-5), 119.0 (C-5ʼʼ), 121.8 (ArC), 122.2 (ArC), 126.0 (ArCH), 137.6 (ArC), 142.8 
(Ar(OCF3)), 147.0 (ArC), 158.6 (ArC), 159.8 (ArC); MS m/z [M+H]
+ C19H17F3N5O2S requires 
436.11, found 436.10.  
 
4-(1-(2-(2-Imino-6-trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)aniline 
160s 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.24 g, 0.78 mmol, 1.0 
equiv.) and 4-ethynylaniline (0.14 g, 1.17 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF 
heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.6 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield 4-(1-(2-(2-imino-6-trifluoromethoxy)benzothiazol-
3-yl)ethyl)-1,2,3-triazol-4-yl)aniline (160s, 0.09 g, 0.21 mmol, 27 %) as a pale yellow solid; Rf 
0.10 (100 % EtOAc), m.p. 196 - 200 °C 
 
IR νmax/cm
-1 3373, 3318, 3028, 2962, 1609, 1585, 1484, 1252; 1H NMR (400MHz, CDCl3) δ; 
7.47 (1H, s, H-5ʼ), 7.44 (2H, d, J = 8.5 Hz, ArH), 7.09 (2H, bs, H-7ʼʼʼ and NH), 6.94 (1H, d, J = 
9.0 Hz, H-5ʼʼʼ) 6.68 (2H, d, J = 8.5 Hz, ArH), 6.53 (1H, d, J = 9.0 Hz, H-4ʼʼʼ), 4.78 (2H, t, J = 
6.0 Hz, H-1ʼʼ), 4.45 (2H, t, J = 6.0 Hz, H-2ʼʼ), 3.74 (2H, bs, Ar(NH2)); 
13
C NMR (100MHz, 
CDCl3) δ; 43.6 (C-2ʼʼ), 46.8 (C-1ʼʼ), 109.1 (C-4ʼʼʼ), 115.2 (ArCH and C-7ʼʼʼ), 119.6 (C-5ʼ), 119.9 
(C-5ʼʼʼ), 120.6 (ArC), 121.7 (ArC), 123.2 (ArC), 127.0 (ArCH), 138.6 (ArC), 143.8 (Ar(OCF3)), 
146.6 (ArC), 148.5 (ArC), 160.9 (ArC); MS m/z [M+H]+ C18H16F3N6OS requires 421.11, found 
421.11. 
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3-(1-(2-(2-Imino-6-trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)aniline 160t 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.25 g, 0.82 mmol, 1.0 
equiv.) and 3-ethynylaniline (0.1 mL, 1.23 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF 
heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.6 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield 3-(1-(2-(2-imino-6-trifluoromethoxy)benzothiazol-
3-yl)ethyl)-1,2,3-triazol-4-yl)aniline (160t, 0.15 g, 0.37 mmol, 45 %) as a pale yellow solid; Rf 
0.10 (100 % EtOAc), m.p. 196 - 199 °C 
 
IR νmax/cm
-1 3461, 3295, 3036, 2919, 1620, 1586, 1481, 1262; 1H NMR (400MHz, CDCl3) δ; 
7.60 (1H, s, H-5ʼ), 7.14 (1H, t, J = 7.5 Hz, ArH), 7.10 (2H, s, H-7ʼʼʼ and ArH), 6.95 (2H, d, J = 
8.0 Hz, H-5ʼʼʼ and ArH), 6.64 (1H, dd, J = 1.5 Hz and 8.0 Hz, ArH), 6.56 (1H, d, J = 9.0 Hz, H-
4ʼʼʼ), 5.30 (2H, s. Ar(NH2)), 4.80 (2H, t, J = 6.0 Hz, H-1ʼʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼʼ); 
13
C 
NMR (100MHz, CDCl3) δ; 42.5 (C-2ʼʼ), 45.8 (C-1ʼʼ), 108.0 (C-4ʼʼʼ), 111.2 (ArCH), 114.0 (ArCH), 
114.2 (C-7ʼʼʼ), 115.0 (ArCH), 118.8 (C-5ʼʼʼ), 119.8 (C-5ʼ), 120.6 (ArC), 122.2 (ArC), 128.7 
(ArCH), 130.1 (ArC), 137.5 (ArC), 142.8 (Ar(OCF3)), 145.8 (ArC), 147.2 (ArC), 160.0 (ArC); 
MS m/z [M+H]+ C18H16F3N6OS requires 421.11, found 421.11. 
 
2-(1-(2-(2-Imino-6-trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)aniline 
160u 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.65 mmol, 1.0 
equiv.) and 2-ethynylaniline (0.1 mL, 0.97 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF 
heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield 2-(1-(2-(2-imino-6-trifluoromethoxy)benzothiazol-
3-yl)ethyl)-1,2,3-triazol-4-yl)aniline (160u, 0.13 g, 0.32 mmol, 49 %) as a pale yellow solid; Rf 
0.20 (100 % EtOAc), m.p. 193 - 195 °C 
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IR νmax/cm
-1 3345, 3278, 3029, 2971, 1610, 1585, 1484, 1255; 1H NMR (400MHz, CDCl3) δ; 
7.63 (1H, s, H-5ʼ), 7.12 - 7.08 (4H, m, H-7ʼʼʼ, ArH and NH), 6.96 (1H, d, J = 8.5 Hz, H-5ʼʼʼ), 
6.73 (1H, d, J = 8.0 Hz, ArH), 6.67 (1H, t, J = 7.5 Hz, ArH), 6.53 (1H, d, J = 9.0 Hz, H-4ʼʼʼ), 
5.24 (2H, bs, Ar(NH2)), 4.83 (2H, t, J = 6.0 Hz, H-1ʼʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼʼ); 
13
C NMR 
(100MHz, CDCl3) δ; 43.5 (C-2ʼʼ), 46.9 (C-1ʼʼ), 108.9 (C-4ʼʼʼ), 113.4 (ArC), 115.3 (C-7ʼʼʼ), 116.6 
(ArCH), 117.4 (ArCH), 119.9 (C-5ʼʼʼ), 121.1 (C-5ʼ), 123.3 (ArC), 127.8 (ArCH), 129.2 (ArCH), 
138.6 (ArC), 143.9 (Ar(OCF3)), 148.7 (ArC), 154.1 (ArC), 157.9 (ArC), 160.1 (ArC); MS m/z 
[M+H]+ C18H16F3N6OS requires 421.11, found 421.11. 
 
3-(2-(4-(4-Chlorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-
imine 160v 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.25 g, 0.81 mmol, 1.0 
equiv.) and 1-chloro-4-ethynylbenzene (0.17 g, 1.21 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.6 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-chlorophenyl)-1,2,3-triazol-
1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160v, 0.19 g, 0.44 mmol, 55 %) as an off-
white solid; Rf 0.18 (100 % EtOAc), m.p. 206 -209 °C 
 
IR νmax/cm
-1 3255, 3086, 2958, 1617, 1586, 1484, 1237, 827; 1H NMR (400MHz, CDCl3) δ; 
7.60 (1H, s, H-5ʼʼ), 7.58 (2H, d, J = 5.0 Hz, ArH), 7.35 (2H, d, J = 8.5 Hz, ArH), 7.09 (2H, bs, 
H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.82 (2H, t, J = 6.0 
Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.5 (C-2ʼ), 46.9 (C-1ʼ), 
108.9 (C-4), 115.3 (C-7), 119.9 (C-5), 120.8 (C-5ʼʼ), 123.2 (ArC), 127.0 (ArCH), 129.0 (ArCH), 
132.9 (ArC), 134.0 (ArC), 138.5 (ArC), 143.9 (Ar(OCF3)), 147.1 (ArC), 154.7 (ArC), 160.9 
(ArC); MS m/z [M+H]+ C18H14ClF3N5OS requires 440.06, found 440.05.  
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3-(2-(4-(3-Chlorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-
imine 160w 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.30 g, 0.98 mmol, 1.0 
equiv.) and 3-chloro-1-ethynylbenzene (0.2 mL, 1.47 mmol, 1.5 equiv.) in 15.0 mL H2O and 
15.0 mL THF heated to 20 °C was added 1.0 mL 1M CuSO4 (aq) and 2.0 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(3-chlorophenyl)-1,2,3-triazol-
1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160w, 0.25 g, 0.57 mmol, 58 %) as an off-
white solid; Rf 0.23 (100 % EtOAc), m.p. 183 - 187 °C 
 
IR νmax/cm
-1 3242, 3043, 2953, 1612, 1581, 1481, 1254, 794; 1H NMR (400MHz, CDCl3) δ; 
7.67 (1H, s, ArH), 7.63 (1H, s, H-5ʼʼ), 7.53 (1H, d, J = 7.0 Hz, ArH), 7.33 - 7.26 (2H, m, ArH), 
7.10 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.82 
(2H, t, J = 6.0 Hz, H-1ʼ), 4.47 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.5 (C-
2ʼ), 47.0 (C-1ʼ), 108.9 (C-4), 115.3 (C-7), 119.9 (C-4), 121.1 (C-5ʼʼ), 123.2 (ArC), 123.8 
(ArCH), 125.8 (ArCH), 128.3 (ArCH), 130.1 (ArCH), 131.9 (ArC), 134.8 (ArC), 138.5 (ArC), 
143.8 (Ar(OCF3)), 146.9 (ArC), 156.6 (ArC), 160.8 (ArC); MS m/z [M+H]
+ C18H14ClF3N5OS 
requires 440.06, found 440.05. 
 
3-(2-(4-(2-Chlorophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-
imine 160x 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.17 g, 0.56 mmol, 1.0 
equiv.) and 1-chloro-2-ethynylbenzene (0.1 mL, 0.84 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(2-chlorophenyl)-1,2,3-triazol-
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1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160x, 0.13 g, 0.30 mmol, 53 %) as a pale 
yellow solid; Rf 0.30 (100 % EtOAc), m.p. 154 - 157 °C 
 
IR νmax/cm
-1 3245, 3093, 2955, 1614, 1584, 1484, 1253, 757; 1H NMR (400MHz, CDCl3) δ; 
8.03 (1H, d, J = 8.0 Hz, ArH), 7.94 (1H, s, H-5ʼʼ), 7.37 (1H, d, J = 8.0 Hz, ArH), 7.33 (1H, t, J = 
7.0 Hz, ArH), 7.26 -7.23 (1H, m, ArH), 7.08 (2H, bs H-7 and NH), 6.90 (1H, d, J = 9.0 Hz, H-
5), 6.42 (1H, d, J = 9.0 Hz), 4.86 (2H, d, J = 5.5 Hz, H-1ʼ), 4.46 (2H, d, J = 6.0 Hz, H-2ʼ); 13C 
NMR (100MHz, CDCl3) δ; 42.6 (C-2ʼ), 45.9 (C-1ʼ), 107.7 (C-4), 114.2 (C-7), 118.8 (C-4), 120.6 
(ArC), 122.2 (ArC), 123.3 (C-5ʼʼ), 126.1 (ArCH), 127.8 (ArC), 128.1 (ArCH), 128.8 (ArCH), 
129.0 (ArCH), 130.2 (ArC), 137.6 (ArC), 142.8 (Ar(OCF3)), 143.3 (ArC), 159.8 (ArC); MS m/z 
[M+H]+ C18H14ClF3N5OS requires 440.06, found 440.05. 
 
4-(1-(2-(2-Imino-6-(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl) 
benzonitrile 160y 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.21 g, 0.70 mmol, 1.0 
equiv.) and 4-ethynylbenzonitrile (0.13 g, 1.05 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 4-(1-(2-(2-imino-6-
(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl) benzonitrile4 (160y, 0.18 g, 0.32 
mmol, 59 %) as an off-white solid; Rf 0.12 (100 % EtOAc), m.p. 193 - 198 °C 
 
IR νmax/cm
-1 3320, 3048, 2938, 2222, 1612, 1584, 1483, 1252; 1H NMR (400MHz, CDCl3) δ; 
7.77 (2H, d, J = 8.0 Hz, ArH), 7.71 (1H, s, H-5ʼ), 7.67 (2H, d, J = 8.0 Hz, ArH), 7.10 (2H, bs, 
H-7ʼʼʼ and NH), 6.93 (1H, d, J = 8.5 Hz, H-5ʼʼʼ), 6.53 (1H, d, J = 9.0 Hz, H-4ʼʼʼ), 4.85 (2H, t, J = 
6.0 Hz, H-1ʼʼ), 4.48 (2H, t, J = 6.0 Hz, H-2ʼʼ); 13C NMR (100MHz, CDCl3) δ; 43.4 (C-2ʼʼ), 47.0 
(C-1ʼʼ), 108.8 (C-4ʼʼʼ), 111.7 (ArC), 115.4 (C-7ʼʼʼ), 118.7 (Ar(CN)), 119.1 (ArC), 119.9 (C-5ʼʼʼ), 
121.9 (C-5ʼ), 123.3 (ArC), 126.1 (ArCH), 132.7 (ArCH), 134.5 (ArC), 138.5 (ArC), 143.8 
(Ar(OCF3)), 146.3 (ArC), 160.8 (ArC); MS m/z [M+H]
+ C19H14F3N6OS requires 431.09, found 
431.09. 
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3-(2-(4-(4-Nitrophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine 
160z 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.15 g, 0.48 mmol, 1.0 
equiv.) and 1-ethynyl-4-nitrobenzene (0.11 g, 0.72 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 
mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(4-nitrophenyl)-1,2,3-triazol-1-
yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160z, 0.14 g, 0.30 mmol, 63 %) as a pale 
yellow solid; Rf 0.15 (100 % EtOAc), m.p. 181 - 186 °C 
 
IR νmax/cm
-1 3322, 3077, 2950, 1605, 1581, 1514, 1484, 1331, 1257; 1H NMR (400MHz, 
CDCl3) δ; 8.25 (2H, d, J = 8.5 Hz, ArH), 7.84 (2H, d, J = 8.5 Hz, ArH), 7.77 (1H, s, H-5ʼʼ), 7.10 
(2H, bs, H-7 and NH), 6.94 (1H, d, J = 9.0 Hz, H-5), 6.55 (1H, d, J = 9.0 Hz, H-4), 4.86 (2H, t, 
J = 6.0 Hz, H-1ʼ), 4.49 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.3 (C-2ʼ), 46.0 
(C-1ʼ), 107.8 (C-4), 114.5 (C-7), 118.8 (C-5), 120.6 (ArC), 121.3 (C-5ʼʼ), 122.3 (ArC), 123.2 
(ArCH), 125.1 (ArC), 135.4 (ArC), 137.4 (ArC), 142.8 (Ar(OCF3)), 144.8 (ArC), 146.3 (ArC), 
159.7 (ArC); MS m/z [M+H]+ C18H14F3N6O3S requires 451.08, found 451.08.  
 
3-(2-(4-(4-Hexylphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160aa 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.18 g, 0.61 mmol, 1.0 
equiv.) and 1-ethynyl-4-hexylbenzene (0.2 mL, 0.91 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-hexylphenyl)-1,2,3-
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triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160aa, 0.21 g, 0.44 mmol, 72 %) as 
a pale yellow solid; Rf 0.24 (100 % EtOAc), m.p. 175 - 180 °C 
 
IR νmax/cm
-1 3276, 3044, 2926, 1626, 1585, 1481, 1381, 1255; 1H NMR (400MHz, CDCl3) δ; 
7.57 (1H, s, H-5ʼʼ), 7.55 (2H, d, J = 8.0 Hz, ArH), 7.19 (2H, d, J = 8.0 Hz, ArH), 7.09 (2H, bs, 
H-7 and NH), 6.94 (1H, d, J = 9.0 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, d, J = 6.0 
Hz, H-1ʼ), 4.45 (2H, t, J = 6.0 Hz, H-2ʼ), 2.60 (2H, t, J = 7.5 Hz, H-1ʼʼʼʼ), 1.59 (2H, quin, H-2ʼʼʼʼ), 
1.34 - 1.30 (6H, m, H-3ʼʼʼʼ, H-4ʼʼʼʼ and H-5ʼʼʼʼ), 0.88 (3H, t, J = 6.5 Hz, H-6ʼʼʼʼ); 13C NMR 
(100MHz, CDCl3) δ; 13.1 (C-6ʼʼʼʼ), 21.6 (C-5ʼʼʼʼ), 27.9 (C-3ʼʼʼʼ), 30.3 (C-2ʼʼʼʼ), 30.7 (C-4ʼʼʼʼ), 34.7 
(C-1ʼʼʼʼ), 42.6 (C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-4), 114.2 (C-7), 118.8 (C-5), 119.4 (C-5ʼʼ), 120.6 
(ArC), 122.2 (ArC), 124.6 (ArCH), 126.5 (ArC), 127.8 (ArCH), 137.6 (ArC), 142.2 (ArC), 142.8 
(Ar(OCF3)), 147.2 (ArC), 159.8 (ArC); MS m/z [M+H]
+ C24H27F3N5OS requires 490.19, found 
490.19.  
 
3-(2-(4-(4-Pentylphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ab 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.17 g, 0.55 mmol, 1.0 
equiv.) and 1-ethynyl-4-pentylbenzene (0.2 mL, 0.82 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-pentylphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ab, 0.18 g, 0.38 mmol, 68 %) as 
a pale yellow solid; Rf 0.21 (100 % EtOAc), m.p. 184 - 187 °C 
 
IR νmax/cm
-1 3276, 3044, 2926, 1626, 1585, 1481, 1382, 1256; 1H NMR (400MHz, CDCl3) δ; 
7.59 (1H, s, H-5ʼʼ), 7.56 (2H, d, J = 8.0 Hz, ArH), 7.19 (2H, d, J = 8.0 Hz, ArH), 7.10 (2H, bs, 
H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 6.55 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 
Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 2.60 (2H, t, J = 7.5 Hz, H-1ʼʼʼʼ), 1.65 - 1.58 (2H, m, H-
2ʼʼʼʼ), 1.33 - 1.32 (4H, m, H-3ʼʼʼʼ and H-4ʼʼʼʼ) 0.89 (3H, t, J = 6.5 Hz, H-5ʼʼʼʼ); 13C NMR (100MHz, 
CDCl3) δ; 13.2 (C-5ʼʼʼʼ), 21.5 (C-4ʼʼʼʼ), 30.0 (C-2ʼʼʼʼ), 30.4 (C-3ʼʼʼʼ), 34.7 (C-1ʼʼʼʼ), 42.6 (C-2ʼ), 45.8 
(C-1ʼ), 108.0 (C-4), 114.2 (C-7), 118.8 (C-5), 119.4 (C-5ʼʼ), 120.6 (ArC), 123.2 (ArC), 124.6 
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(ArCH), 126.5 (ArC), 127.8 (ArCH), 137.6 (ArC), 142.2 (ArC), 142.8 (Ar(OCF3)), 147.2 (ArC), 
159.9 (ArC); MS m/z [M+H]+ C23H25F3N5OS requires 476.18, found 476.17. 
 
3-(2-(4-(4-Butylphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ac 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.15 g, 0.49 mmol, 1.0 
equiv.) and 1-butyl-4-ethynylbenzene (0.1 mL, 0.74 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-butylphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ac, 0.16 g, 0.35 mmol, 72 %) as 
a pale yellow solid; Rf 0.21 (100 % EtOAc), m.p. 183 - 186 °C 
 
IR νmax/cm
-1 3230, 3048, 2967, 1617, 1581, 1484, 1257; 1H NMR (400MHz, CDCl3) δ; 7.58 
(1H, s, H-5ʼʼ), 7.56 (2H, d, J = 7.5 Hz, ArH), 7.19 (2H, d, J = 7.5 Hz, ArH), 7.09 (2H, bs, H-7 
and NH), 6.94 (1H, d, J = 7.5 Hz, H-5), 6.54 (1H, d, J = 8.5 Hz, H-4), 4.81 (2H, bs, H-1ʼ), 4.48 
(2H, bs, H-2ʼ), 2.61 (2H, t, J = 7.5 Hz, H-1ʼʼʼʼ), 1.60 (2H, quin, J = 7.5 Hz, H-2ʼʼʼʼ), 1.36 (2H, 
sext, J = 7.5 Hz, H-3ʼʼʼʼ), 0.92 (3H, t, J = 7.5 Hz, H-4ʼʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 12.9 (C-
4ʼʼʼʼ), 21.3 (C-3ʼʼʼʼ), 32.5 (C-2ʼʼʼʼ), 34.4 (C-1ʼʼʼʼ), 42.6 (C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-4), 114.2 (C-
7), 118.8 (C-5), 119.5 (C-5ʼʼ), 120.6 (ArC), 122.2 (ArC), 124.6 (ArCH), 126.5 (ArC), 127.8 
(ArCH), 137.6 (ArC), 142.2 (ArC), 142.8 (Ar(OCF3)), 147.3 (ArC), 160.3 (ArC); MS m/z [M+H]
+ 
C22H23F3N5OS requires 462.16, found 462.16. 
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3-(2-(4-(4-Propylphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ad 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.18 g, 0.56 mmol, 1.0 
equiv.) and 1-ethynyl-4-propylbenzene (0.1 mL, 0.87 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-propylphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ad, 0.19 g, 0.42 mmol, 75 %) as 
an off-white solid; Rf 0.23 (100 % EtOAc), m.p. 190 - 196 °C 
 
IR νmax/cm
-1 3274, 3043, 2931, 1626, 1585, 1480, 1380, 1252; 1H NMR (400MHz, CDCl3) δ; 
7.59 (3H, d, J = 8.0 Hz, H-5ʼʼ and ArH), 7.19 (2H, d, J = 8.0 Hz, ArH), 7.09 (2H, bs, H-7 and 
NH), 6.93 (1H, d, J = 9.0 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 Hz, H-1ʼ), 
4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 2.59 (2H, t, J = 7.5 Hz, H-1ʼʼʼʼ), 1.63 (2H, sext, J = 7.5 Hz, H-
2ʼʼʼʼ), 0.94 (3H, t, J = 7.5 Hz, H-3ʼʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 12.7 (C-3ʼʼʼʼ), 23.4 (C-2ʼʼʼʼ), 
36.8 (C-1ʼʼʼʼ), 42.6 (C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-4), 114.2 (C-7), 118.8 (C-5), 119.5 (C-5ʼʼ), 
120.6 (ArC), 122.2 (ArC), 124.6 (ArCH), 126.6 (ArC), 127.8 (ArCH), 137.6 (ArC), 141.9 (ArC), 
142.8 (Ar(OCF3)), 147.2 (ArC), 159.9 (ArC); MS m/z [M+H]
+ C21H21F3N5OS requires 448,14, 
found 448.14. 
 
3-(2-(4-(4-Ethylphenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ae 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.19 g, 0.62 mmol, 1.0 
equiv.) and 1-ethyl-4-ethynylbenzene (0.1 mL, 0.93 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly prepared 
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1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-ethylphenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ae, 0.17 g, 0.40 mmol, 67 %) as 
an off-white solid; Rf 0.20 (100 % EtOAc), m.p. 189 - 193 °C 
 
IR νmax/cm
-1 3278, 3044, 2930, 1626, 1585, 1481, 1382, 1256; 1H NMR (400MHz, CDCl3) δ; 
7.57  (3H, d, J = 7.0 Hz, H-5ʼʼ and ArH), 7.21 (2H, d, J = 8.0 Hz, ArH), 7.09 (2H, bs, H-7 and 
NH), 6.93 (1H, d, J = 8.5 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 Hz, H-1ʼ), 
4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 2.66 (2H, q, J = 7.5 Hz, H-1ʼʼʼʼ), 1.24 (3H, t, J = 7.5 Hz, H-2ʼʼʼʼ); 
13
C NMR (100MHz, CDCl3) δ; 14.5 (C-2ʼʼʼʼ), 27.6 (C-1ʼʼʼʼ), 42.6 (C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-7), 
114.2 (C-4), 118.8 (C-5), 119.5 (C-5ʼʼ), 120.6 (ArC), 122.2 (ArC), 124.7 (ArCH), 126.5 (ArC), 
127.3 (ArCH), 137.6 (ArC), 142.8 (Ar(OCF3)), 143.5 (ArC), 147.2 (ArC), 159.8 (ArC); MS m/z 
[M+H]+ C20H19F3N5OS requires 434.13, found 434.12. 
 
3-(2-(4-(Napthalen-1-yl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160af 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.17 g, 0.55 mmol, 1.0 
equiv.) and 1-ethynylnapthalene (0.1 mL, 0.83 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(napthalen-1-yl)-1,2,3-triazolyl)ethyl)-
6-(trifluoromethoxy)benzothiazol-2-imine (160af, 0.15 g, 0.34 mmol, 61 %) as a red solid; Rf 
0.20 (100 % EtOAc), m.p. 161 - 163 °C 
 
IR νmax/cm
-1 3273, 3014, 2939, 1632, 1582, 1481, 1254; 1H NMR (400MHz, CDCl3) δ; 7.87 - 
7.84 (3H, m, ArH), 7.60 (1H, s, H-5ʼʼ), 7.52 - 7.39 (4H, m, ArH), 7.12 (2H, bs, H-7 and NH), 
6.95 (1H, d, J = 8.5 Hz, H-5), 6.49 (1H, d, J = 9.0 Hz, H-4), 4.93 (2H, t, J = 5.5 Hz, H-1ʼ), 4.52 
(2H, t, J = 5.5 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.9 (C-2ʼ), 46.0 (C-1ʼ), 107.8 (C-4), 
114.2 (C-7), 118.8 (C-4), 120.6 (ArC), 122.2 (ArC), 122.8 (C-5ʼʼ), 123.9 (ArCH), 124.2 (ArCH), 
125.0 (ArCH), 125.5 (ArCH), 126.2 (ArCH), 126.6 (ArC), 127.3 (ArCH), 127.9 (ArCH), 130.0 
(ArC), 132.7 (ArC), 138.6 (ArC), 142.8 (Ar(OCF3)), 146.0 (ArC), 159.7 (ArC); MS m/z [M+H]
+ 
C22H17F3N5OS requires 456.11, found 456.11. 
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3-(2-(4-(4-(tert-Butyl)phenyl)-1,2,3-triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-
imine 160ag 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.21 g, 0.68 mmol, 1.0 
equiv.) and 4-tert-butylphenylacetylene (0.2 mL, 1.01 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-(tert-butyl)phenyl)-1,2,3-
triazolyl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ag, 0.23 g, 0.50 mmol, 73 %) as 
a pale yellow solid; Rf 0.24 (100 % EtOAc), m.p. 176 - 180 °C 
 
IR νmax/cm
-1 3321, 3007, 2953, 1604, 1583, 1483, 1361, 1256; 1H NMR (400MHz, CDCl3) δ; 
7.58 (3H, d, J = 7.0 Hz, ArH and H-5ʼʼ), 7.40 (2H, d, J = 8.0 Hz, ArH), 7.09 (2H, bs, H-7 and 
NH), 6.93 (1H, d, J = 9.0 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.81 (2H, t, J = 6.0 Hz, H-1ʼ), 
4.46 (2H, t, J = 6.0 Hz, H-2ʼ), 1.32 (9H, s, ArC(CH3)3); 
13
C NMR (100MHz, CDCl3) δ; 30.2 
(ArC(CH3)3), 33.6 (ArC), 42.6 (C-2ʼ), 45.9 (C-1ʼ), 107.8 (C-4), 114.2 (C-7), 118.8 (C-5), 119.5 
(C-5ʼʼ), 120.6 (ArC), 122.2 (ArC), 124.5 (ArCH), 124.7 (ArCH), 126.3 (ArC), 137.6 (ArC), 
142.8 (Ar(OCF3)), 147.1 (ArC), 150.4 (ArC), 159.8 (ArC); MS m/z [M+H]
+ C22H23F3N5OS 
requires 462.16, found 462.16. 
 
3-(2-(4-(Thiophen-2-yl)-1,2,3-triazol-1-ly)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ah 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.21 g, 0.70 mmol, 1.0 
equiv.) and 2-ethynylthiophene (0.1 mL, 1.05 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
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was column purified using 100 % EtOAc to yield 3-(2-(4-(thiophen-2-yl)-1,2,3-triazol-1-
ly)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ah, 0.15 g, 0.37 mmol, 53 %) as a pale 
yellow solid; Rf 0.19 (100 % EtOAc), m.p. 172 - 176 °C 
 
IR νmax/cm
-1 3245, 3068, 2954, 1605, 1583, 1483, 1256; 1H NMR (400MHz, CDCl3) δ; 7.54 
(1H, s, H-5ʼʼ), 7.28 - 7.26 (1H, m, ArH), 7.23 (1H, d, J = 3.0 Hz, ArH), 7.10 (2H, bs, H-7 and 
NH), 7.03 (1H, t, J = 4.0 Hz, ArH), 6.96 (1H, d, J = 8.5 Hz, H-5), 6.54 (1H, d, J = 9.0 Hz, H-4), 
4.80 (2H, t, J = 6.0 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.4 
(C-2ʼ), 45.9 (C-1ʼ), 107.9 (C-4), 114.2 (C-7), 118.8 (C-5), 119.3 (C-5ʼʼ), 120.6 (ArC), 122.2 
(ArC), 123.3 (ArCH), 124.2 (ArCH), 126.5 (ArCH), 131.3 (ArC), 137.5 (ArC), 142.0 (ArC), 
142.8 (Ar(OCF3)), 159.8 (ArC); MS m/z [M+H]
+ C16H13F3N5OS2 requires 412.05, found 412.05. 
 
3-(2-(4-(Thiophen-3-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ai 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.67 mmol, 1.0 
equiv.) and 3-ethynylthiophene (0.1 mL, 1.00 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(thiophen-3-yl)-1,2,3-triazol-1-
yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160ai, 0.15 g, 0.37 mmol, 55 %) as an off 
white solid; Rf 0.17 (100 % EtOAc), m.p. 185 - 188 °C 
 
IR νmax/cm
-1 3246, 3081, 2954, 1615, 1585, 1483, 1258; 1H NMR (400MHz, CDCl3) δ; 7.55 
(1H, d, J = 2.0 Hz, ArH), 7.53 (1H, s, H-5ʼʼ), 7.35 - 7.33 (1H, m, ArH), 7.30 (1H, d, J = 5.0 Hz, 
ArH), 7.09 (2H, bs, H-7 and NH), 6.95 (1H, d, J = 8.5 Hz, H-5), 6.55 (1H, d, J = 9.0 Hz, H-4), 
4.80 (2H, t, J = 6.0 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.5 
(C-2ʼ), 45.8 (C-1ʼ), 108.0 (C-4), 114.2 (C-7), 118.8 (C-5), 119.6 (C-5ʼʼ), 120.2 (ArCH), 120.6 
(ArC), 122.2 (ArC), 124.7 (ArCH), 125.3 (ArCH), 130.3 (ArC), 137.5 (ArC), 142.8 (Ar(OCF3)), 
143.2 (ArC), 159.8 (ArC); MS m/z [M+H]+ C16H13F3N5OS2 requires 412.05, found 412.05. 
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3-(2-(4-Cyclopropyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160aj 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.66 mmol, 1.0 
equiv.) and cyclopropylacetylene (0.1 mL, 0.99 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-cyclopropyl-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160aj, 0.16 g, 0.44 mmol, 67 %) as a pale yellow 
solid; Rf 0.10 (100 % EtOAc), m.p. 149 - 152 °C 
 
IR νmax/cm
-1 3220, 3089, 2950, 1601, 1580, 1484, 1256; 1H NMR (400MHz, CDCl3) δ; 7.10 
(1H, s, H-7), 7.01 (1H, s, H-5ʼʼ), 6.93 (1H, d, J = 9.0 Hz, H-5), 6.33 (1H, d, J = 9.0 Hz, H-4), 
4.70 (2H, t, J = 5.5 Hz, H-1ʼ), 4.37 (2H, t, J = 6.0 Hz, H-2ʼ), 1.78 (1H, tt, J = 5.0 Hz and 13.5 
Hz, H-1ʼʼʼ), 0.83 (2H, dt, J = 4.5 Hz and 15.0 Hz, H-2ʼʼʼ and H-3ʼʼʼ), 0.57 (2H, dt, J = 4.5 Hz and 
11.0 Hz, H-2ʼʼʼ and H-3ʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 5.3 (C-1ʼʼʼ), 6.5 (C-2ʼʼʼ and C-3ʼʼʼʼ), 
42.7 (C-2ʼ), 45.7 (C-1ʼ), 107.8 (C-4), 114.1 (C-7), 118.5 (C-5), 119.8 (C-5ʼʼ), 120.7 (ArC), 
122.0 (ArC), 137.6 (ArC), 142.7 (Ar(OCF3)), 149.7 (ArC), 159.6 (ArC); MS m/z [M+H]
+ 
C15H15F3N5OS requires 370.10, found 370.10. 
 
3-(2-(4-Cyclopentyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160ak 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.21 g, 0.68 mmol, 1.0 
equiv.) and cyclopentylacetylene (0.1 mL, 1.02 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-cyclopentyl-1,2,3-triazol-1-yl)ethyl)-6-
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(trifluoromethoxy)benzothiazol-2-imine (160ak, 0.16 g, 0.40 mmol, 59 %) as an off white solid; 
Rf 0.13 (100 % EtOAc), m.p. 174 - 179 °C 
 
IR νmax/cm
-1 3248, 3078, 2948, 1600, 1579, 1484, 1261; 1H NMR (400MHz, CDCl3) δ; 7.09 
(1H, s, H-7), 7.06 (1H, bs, NH), 7.01 (1H, s, H-5ʼʼ), 6.91 (1H, dd, J = 1.5 Hz and 9.0 Hz, H-5). 
6.29 (1H, d, J = 9.0 Hz, H-4), 4.73 (2H, t, J 5.5 Hz, H-1ʼ), 4.37 (2H, t, J = 6.0 Hz, H-2ʼ), 3.01 
(1H, quin, J = 8.0 Hz, H-1ʼʼʼ), 1.94 - 1.86 (2H, m, H-2ʼʼʼ and H-5ʼʼʼ), 1.63 - 1.53 (4H, m, H-3ʼʼʼ 
and H-4ʼʼʼ), 1.44 - 1.32 (2H, m, H-2ʼʼʼ and H-5ʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 23.9 (C-3ʼʼʼ and 
C-4ʼʼʼ), 32.1 (C-2ʼʼʼ and C-5ʼʼʼ), 35.4 (C-1ʼʼʼ), 42.9 (C-2ʼ), 45.7 (C-1ʼ), 107.8 (C-4), 114.0 (C-7), 
118.8 (C-5), 119.8 (C-5ʼʼ), 120.7 (ArC), 121.9 (ArC), 137.7 (ArC), 142.7 (Ar(OCF3)), 152.2 
(ArC), 159.6 (ArC); MS m/z [M+H]+ C17H19F3N5Os requires 398.13, found 198.13. 
 
3-(2-(4-Cyclohexyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160al  
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.23 g, 0.75 mmol, 1.0 
equiv.) and cyclohexylacetylene (0.2 mL, 1.12 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.8 mL 1M CuSO4 (aq) and 1.5 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-cyclohexyl-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160al, 0.17 g, 0.41 mmol, 55 %) as a pale yellow 
solid; Rf 0.15 (100 % EtOAc), m.p. 178 - 182 °C 
 
IR νmax/cm
-1 3220, 3028, 2925, 1581, 1483, 1254; 1H NMR (400MHz, CDCl3) δ; 7.09 (2H, bs, 
H-7 and NH), 6.99 (1H, s, H-5ʼʼ), 6.90 (1H, d, J = 9.0 Hz, H-5), 6.27 (1H, d, J = 9.0 Hz, H-4), 
4.74 (2H, t, J = 5.5 Hz, H-1ʼ), 4.37 (2H, t, J = 5.5 Hz, H-2ʼ), 2.58 (1H, ttt, J = 3.5 Hz and 11.5 
Hz, H-1ʼʼʼ), 1.78 - 1.75 (2H, m, H-2ʼʼʼ and H-6ʼʼʼ), 1.70 -1.64 (3H, m, H-3ʼʼʼ, H-4ʼʼʼ and H-5ʼʼʼ), 
1.35 - 1.25 (2H, m, H-2ʼʼʼ and H-6ʼʼʼ), 1.20 - 1.06 (3H, m, H-3ʼʼʼ, H-4ʼʼʼ and H-5ʼʼʼ); 13C NMR 
(100MHz, CDCl3) δ; 25.1 (C-3ʼʼʼ, C-4ʼʼʼ and C-5ʼʼʼ), 31.9 (C-2ʼʼʼ and C-6ʼʼʼ), 34.0 (C-1ʼʼʼ), 42.9 
(C-2ʼ), 45.7 (C-1ʼ), 107.8 (C-4), 114.0 (C-7), 118.1 (ArC), 118.8 (C-5), 119.6 (C-5ʼʼ), 120.6 
(ArC), 121.9 (ArC), 137.7 (ArC), 142.6 (Ar(OCF3)), 153.1 (ArC), 159.6 (ArC); MS m/z [M+H]
+ 
C18H21F3N5OS requires 412.14, found 412.14. 
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3-(2-(4-(tert-Butyl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 
160am 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.53 mmol, 1.0 
equiv.) and 3,3-dimethyl-1-butyne (0.1 mL, 0.80 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 
mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-(tert-butyl)-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160am, 0.13 g, 0.34 mmol, 64 %) as a pale yellow 
solid; Rf 0.13 (100 % EtOAc), m.p. 150 - 154 °C 
 
IR νmax/cm
-1 3256, 3068, 2979, 1605, 1580, 1484, 1384, 1258; 1H NMR (400MHz, CDCl3) δ; 
7.09 (1H, s, H-7), 7.07 (1H, bs, NH), 6.98 (1H, s, H-5ʼʼ), 6.89 (1H, d, J = 9.0 Hz, H-5), 6.25 
(1H, d, J = 9.0 Hz, H-4), 4.74 (2H, t, J = 5.5 Hz, H-1ʼ), 4.36 (2H, t, J = 5.5 Hz, H-2ʼ), 1.12 (9H, 
s, ArC(CH3)3); 
13
C NMR (100MHz, CDCl3) δ; 29.1 (ArC(CH3)3), 42.9 (C-2ʼ), 45.6 (C-1ʼ), 107.7 
(C-4), 114.0 (C-7), 118.1 (ArC), 118.7 (C-5), 118.8 (C-5ʼʼ), 120.7 (ArC), 123.2 (ArC), 137.7 
(ArC), 142.6 (Ar(OCF3)), 157.1 (ArC), 159.6 (ArC); MS m/z [M+H]
+ C16H19F3N5OS requires 
386.13, found 386.13. 
 
Ethyl 1-(2-(2-Imino-6-(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazole-4-
carboxylate 160an 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.15 g, 0.48 mmol, 1.0 
equiv.) and ethyl propiolate (0.1 mL, 0.72 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF 
heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield ethyl 1-(2-(2-imino-6-
(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazole-4-carboxylate (160an, 0.12 g, 0.29 
mmol, 61 %) as a pale yellow solid; Rf 0.15 (100 % EtOAc), m.p. 159 - 163 °C 
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IR νmax/cm
-1 3276, 3043, 2979, 1721, 1631, 1583, 1485, 1377, 1261; 1H NMR (400MHz, 
CDCl3); 7.95 (1H, s, H-5ʼ), 7.11 (1H, s, H-7ʼʼʼ), 7.09 (1H, bs, NH), 6.97 (1H, d, J = 8.5 Hz, H-
5ʼʼʼ), 6.49 (1H, d, J = 9.0 Hz, H-4ʼʼʼ), 4.84 (2H, t, J = 6.0 Hz, H-1ʼʼ), 4.46 (2H, t, J = 6.0 Hz, H-
2ʼʼ), 4.37 (2H, q, J = 7.0 Hz, H-3), 1.37 (3H, t, J = 7.0 Hz, H-4); 13C NMR (100MHz, CDCl3); 
14.2 (C-4), 43.3 (C-2ʼʼ), 47.2 (C-1ʼʼ), 61.4 (C-3), 108.7 (C-4ʼʼʼ), 115.4 (C-7ʼʼʼ), 119.9 (C-5ʼʼʼ), 
121.7 (ArC), 123.4 (ArC), 128.6 (C-5ʼ), 138.4 (ArC), 140.4 (ArC), 143.9 (Ar(OCF3)), 160.4 
(ArC), 160.8 (ArC); MS m/z [M+H]+ C15H15F3N5O3S requires 402.09, found 402.08. 
 
3-(2-(4-Isopentyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160ao 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.54 mmol, 1.0 
equiv.) and 5-methyl-1-hexyne (0.1 mL, 0.81 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-isopentyl-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160ao, 0.14 g, 0.34 mmol, 63 %) as a pale yellow 
solid; Rf 0.11 (100 % EtOAc), m.p. 126 - 129 °C 
 
IR νmax/cm
-1 3232, 3072, 2958, 1602, 1581, 1484, 1384, 1257; 1H NMR (400MHz, CDCl3) δ; 
7.09 (2H, bs, H-7 and NH), 7.07 (1H, s, H-5ʼʼ), 6.92 (1H, d, J = 9.0 Hz, H-5), 6.36 (1H, d, J = 
9.0 Hz, H-4), 4.73 (2H, t, J = 5.5 Hz, H-1ʼ), 4.39 (2H, t, J = 6.0 Hz, H-2ʼ), 2.54 (2H, t, J = 8.0 
Hz, H-1ʼʼʼ), 1.46 - 1.36 (1H, m, H-3ʼʼʼ), 1.34 - 1.28 (2H, m, H-2ʼʼʼ), 0.85 (6H, d, J = 6.5 Hz, H-4ʼʼʼ 
and H-1ʼʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 22.2 (C-4ʼʼʼ and C-1ʼʼʼʼ), 26.3 (C-1ʼʼʼ), 37.4 (C-2ʼʼʼ 
and C-3ʼʼʼ), 42.8 (C-2ʼ), 45.7 (C-1ʼ), 107.9 (C-4), 114.0 (C-7), 118.1 (ArC), 118.7 (C-5), 120.7 
(C-5ʼʼ), 122.1 (ArC), 137.6 (ArC), 142.7 (Ar(OCF3)), 147.9 (ArC), 159.7 (ArC); MS m/z [M+H]
+ 
C17H21F3N5OS requires 400.14, found 400.14. 
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6-(Trifluoromethoxy)-3-(2-(4-(4-(trifluoromethyl)phenyl)-1,2,3-triazol-1-
yl)ethyl)benzothiazol-2-imine 160ap 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.22 g, 0.72 mmol, 1.0 
equiv.) and 4-ethynyl-α,α,α-trifluorotoluene (0.2 mL, 1.09 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.4 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-
up the crude was column purified using 100 % EtOAc to yield 6-(trifluoromethoxy)-3-(2-(4-(4-
(trifluoromethyl)phenyl)-1,2,3-triazol-1-yl)ethyl)benzothiazol-2-imine (160ap, 0.12 g, 0.25 
mmol, 35 %) as a pale yellow solid; Rf 0.17 (100 % EtOAc), m.p. 218 - 221 °C 
 
IR νmax/cm
-1 3253, 3021, 2953, 1613, 1584, 1484, 1326, 1234; 1H NMR (400MHz, CDCl3) δ; 
7.78 (2H, d, J = 8.0 Hz, ArH), 7.69 (1H, s, H-5ʼʼ), 7.63 (2H, d, J = 8.0 Hz, ArH), 7.10 (2H, d, J 
= 1.5 Hz, H-7 and NH), 6.94 (1H, d, J = 8.5 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.84 (2H, 
t, J = 5.5 Hz, H-1ʼ), 4.48 (2H, t, J = 5.5 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 43.5 (C-2ʼ), 
47.0 (C-1ʼ), 108.9 (C-4), 115.5 (C-7), 119.9 (C-5), 121.6 (C-5ʼʼ), 122.7 (ArC), 123.3 (Ar(CF3)), 
123.7 (ArC), 125.8 (ArCH), 129.7 (ArC), 130.0 (ArC), 130.3 (ArC), 133.6 (ArC), 138.6 
(Ar(OCF3)), 143.9 (ArC), 146.8 (ArC); MS m/z [M+H]
+ C19H14F6N5OS requires 474.08, found 
474.08. 
 
6-(Trifluoromethoxy)-3-(2-(4-(3-(trifluoromethyl)phenyl)-1,2,3-triazol-1-
yl)ethyl)benzothiazol-2-imine 160aq 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.18 g, 0.59 mmol, 1.0 
equiv.) and 3-ethynyl-α,α,α-trifluorotoluene (0.1 mL, 0.88 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.2 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-
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up the crude was column purified using 100 % EtOAc to yield 6-(trifluoromethoxy)-3-(2-(4-(3-
(trifluoromethyl)phenyl)-1,2,3-triazol-1-yl)ethyl)benzothiazol-2-imine (160aq, 0.18 g, 0.39 
mmol, 66 %) as a yellow/green solid; Rf 0.21 (100 % EtOAc), m.p. 145 - 149 °C 
 
IR νmax/cm
-1 3246, 3071, 2958, 1578, 1483, 1322, 1253; 1H NMR (400MHz, CDCl3) δ; 7.91 
(1H, s, ArH), 7.85 (1H, d, J = 7.5 Hz, ArH), 7.70 (1H, s, H-5ʼʼ), 7.57 (1H, d, J = 8.0 Hz, ArH), 
7.50 (1H, t, J = 7.5 Hz, ArH), 7.10 (2H, bs, H-7 and NH), 6.94 (1H, d, J = 8.0 Hz, H-5), 6.54 
(1H, d, J = 9.0 Hz, H-4), 4.84 (2H, bs, H-1ʼ), 4.48 (2H, bs, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 
42.4 (C-2ʼ), 45.9 (C-1ʼ), 107.8 (C-4), 114.3 (C-7), 118.8 (C-5), 120.3 (C-5ʼʼ), 120.6 (ArC), 
121.4 (ArCH), 121.6 (ArC), 122.2 (Ar(CF3), 123.8 (ArCH), 124.3 (ArC), 127.8 (ArCH), 128.3 
(ArCH), 130.1 (ArC), 130.4 (ArC), 137.5 (Ar(OCF3)), 142.8 (ArC), 145.8 (ArC); MS m/z [M+H]
+ 
C19H14F6N5OS requires 474.08, found 474.08. 
 
6-(Trifluoromethoxy)-3-(2-(4-(2-(trifluoromethyl)phenyl)-1,2,3-triazol-1-
yl)ethyl)benzothiazol-2-imine 160ar 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.22 g, 0.74 mmol, 1.0 
equiv.) and 2-ethynyl-α,α,α-trifluorotoluene (0.2 mL, 1.11 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.5 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-
up the crude was column purified using 100 % EtOAc to yield 6-(trifluoromethoxy)-3-(2-(4-(2-
(trifluoromethyl)phenyl)-1,2,3-triazol-1-yl)ethyl)benzothiazol-2-imine (160ar, 0.21 g, 0.43 
mmol, 59 %) as an off white solid; Rf 0.32 (100 % EtOAc), m.p. 186 - 190 °C 
 
IR νmax/cm
-1 3245, 3081, 2954, 1616, 1585, 1485, 1318, 1256; 1H NMR (400MHz, CDCl3) δ; 
7.69 (2H, t, J = 7.5 Hz, ArH), 7.57 (2H, t, J = 9.5 Hz, ArH and H-5ʼʼ), 7.45 (1H, t, J = 7.5 Hz, 
ArH), 7.08 (2H, bs, H-7 and NH), 6.93 (1H, d, J = 9.0 Hz, H-5), 6.45 (1H, d, J = 9.0 Hz, H-4), 
4.87 (2H, t, J = 5.5 Hz, H-1ʼ), 4.47 (2H, t, J = 5.5 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.8 
(C-2ʼ), 46.0 (C-1ʼ), 107.7 (C-4), 114.2 (C-7), 118.7 (C-4), 122.2 (ArC), 123.0 (Ar(CF3)), 124.2 
(C-5ʼʼ), 125.0 (ArC), 126.2 (ArCH), 126.5 (ArC), 127.3 (ArC), 128.0 (ArCH), 130.6 (ArCH), 
130.9 (ArCH), 137.6 (Ar(OCF3)), 142.7 (ArC), 143.6 (ArC), 159.8 (ArC); MS m/z [M+H]
+ 
C19H14F6N5OS requires 474.08, found 474.08. 
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6-(Trifluoromethoxy)-3-(2-(4-(3,4,5-trifluorophenyl)-1,2,3-triazol-1yl)ethyl)benzothiazol-
2-imine 160as 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.14 g, 0.46 mmol, 1.0 
equiv.) and 3,4,5-trifluorophenylacetylene (0.11 g, 0.69 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 0.9 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 6-(trifluoromethoxy)-3-(2-(4-(3,4,5-
trifluorophenyl)-1,2,3-triazol-1yl)ethyl)benzothiazol-2-imine (160as, 0.16 g, 0.34 mmol, 74 %) 
as a pale yellow solid; Rf 0.21 (100 % EtOAc), m.p. 166 - 170 °C 
 
IR νmax/cm
-1 3229, 3077, 2958, 1607, 1518, 1483, 1257; 1H NMR (400MHz, CDCl3) δ; 7.59 
(1H, s, H-5ʼʼ), 7.32 - 7.24 (2H, m, ArH), 7.11 (2H, d, J = 1.5 Hz, H-7 and NH), 6.94 (1H, d, J = 
8.5 Hz, H-5), 6.51 (1H, d, J = 9.0 Hz, H-4), 4.82 (2H, t, J = 6.0 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 
Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.4 (C-2ʼ), 46.0 (C-1ʼ), 107.8 (C-4), 108.6 (ArCH), 
108.9 (ArCH), 114.4 (C-7), 118.8 (C-5), 120.2 (C-5ʼʼ), 122.2 (ArC), 137.4 (ArC), 139.8 
(Ar(CF)), 142.8 (Ar(OCF3)), 144.4 (ArC), 149.3 (ArC), 151.8 (Ar(CF)), 159.8 (ArC); MS m/z 
[M+H]+ C18H12F6N5OS requires 460.07, found 460.07. 
 
6-(Trifluoromethyoxy)-3-(2-(4-(3,5-bis(trifluoromethyl)phenyl)-1,2,3-triazol-1-
ly)ethyl)benzothiazol-2-imine 160at 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.14 g, 0.47 mmol, 1.0 
equiv.) and 1-ethynyl-3,5-bis(trifluoromethyl) benzene (0.1 mL, 0.71 mmol, 1.5 equiv.) in 10.0 
mL H2O and 10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 0.9 mL 
freshly prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After 
work-up the crude was column purified using 100 % EtOAc to yield 6-(trifluoromethyoxy)-3-(2-
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(4-(3,5-bis(trifluoromethyl)phenyl)-1,2,3-triazol-1-ly)ethyl)benzothiazol-2-imine (160at, 0.22 g, 
0.41 mmol, 87 %) as a pale yellow solid; Rf 0.31 (100 % EtOAc), m.p. 184 - 188 °C 
 
IR νmax/cm
-1 3217, 3043, 2954, 1624, 1587, 1484, 1324, 1275; 1H NMR (400MHz, CDCl3) δ; 
8.12 (2H, s, ArH), 7.81 (1H, s, ArH), 7.79 (1H, s, H-5ʼʼ), 7.10 (2H, d, J = 1.5 Hz, H-7 and NH), 
6.95 (1H, d, J = 8.5 Hz, H-5), 6.55 (1H, d, J = 9.0 Hz, H-4), 4.87 (2H, t, J = 6.0 Hz, H-1ʼ), 4.49 
(2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, CDCl3) δ; 42.4 (C-2ʼ), 46.1 (C-1ʼ), 107.8 (C-4), 
114.4 (C-7), 118.9 (C-5), 121.8 (C-5ʼʼ), 120.7 (Ar(CF3)), 120.9 (ArCH), 123.5 (ArC), 124.5 
(ArCH), 131.1 (ArC), 131.2 (ArC), 131.4 (ArC), 137.4 (Ar(OCF3)), 143.9 (ArC), 144.4 (ArC), 
155.6 (ArC); MS m/z [M+H]+ C20H13F9N5OS requires 542.07, found 542.07. 
 
3-(2-(4-(4-Bromophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-
imine 160au 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.17 g, 0.55 mmol, 1.0 
equiv.) and 1-bromo-4-ethynylbenzene (0.15 g, 0.82 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.6 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(4-bromophenyl)-1,2,3-triazol-
1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160au, 0.18 g, 0.38 mmol, 69 %) as an 
off-white solid; Rf 0.17 (100 % EtOAc), m.p. 213 - 215 °C 
 
IR νmax/cm
-1 3240, 3087, 2950, 1614, 1584, 1484, 1254, 757; 1H NMR (400MHz, CDCl3) δ; 
7.61 (1H, s, H-5ʼʼ), 7.54 - 7.49 (4H, m, ArH), 7.10 (2H, d, J = 1.5 Hz, H-7 and NH), 6.94 (1H, 
dd, J = 1.5 Hz and 9.0 Hz, H-5), 6.53 (1H, d, J = 9.0 Hz, H-4), 4.82 (2H, t, J = 6.0 Hz, H-1ʼ), 
4.46 (2H, t, J = 6.0 Hz, H-1ʼ); 13C NMR (100MHz, CDCl3) δ; 43.5 (C-1ʼ), 46.9 (C-2ʼ), 108.9 (C-
4), 115.3 (C-7), 119.8 (C-5), 120.9 (C-5ʼʼ), 121.7 (ArC), 122.2 (ArC), 123.2 (ArC), 127.2 
(ArCH), 129.1 (ArC), 132.0 (ArCH), 138.5 (ArC), 143.9 (Ar(OCF3)), 147.1 (ArC), 160.8 (ArC); 
MS m/z [M+H]+ C18H14BrF3N5OS requires 484.01, found 484.00. 
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3-(2-(4-(2-Bromophenyl)-1,2,3-triazol-1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-
imine 160av 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.53 mmol, 1.0 
equiv.) and 1-bromo-2-ethynylbenzene (0.1 mL, 0.80 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was left to stir at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 3-(2-(4-(2-bromophenyl)-1,2,3-triazol-
1-yl)ethyl)-6-trifluoromethoxy)benzothiazol-2-imine (160av, 0.13 g, 0.26 mmol, 50 %) as a 
pale yellow solid; Rf 0.25 (100 % EtOAc), m.p. 169 - 174 °C 
 
IR νmax/cm
-1 3254, 3083, 2961, 1616, 1585, 1484, 1234; 1H NMR (400MHz, CDCl3) δ; 7.97 
(1H, s, H-5ʼʼ), 7.87 (1H, dd, J = 1.5 Hz and 8.0 Hz, ArH), 7.57 (1H, dd, J = 1.0 Hz and 8.0 Hz, 
ArH), 7.36 (1H, td, J = 1.0 Hz and 7.5 Hz, ArH), 7.17 (1H, td, J = 1.5 Hz and 8.0 Hz, ArH), 
7.08 (2H, d, J = 1.5 Hz, H-7 and NH), 6.90 (1H, dd, J = 1.5 Hz and 9.0 Hz, H-5), 6.41 (1H, d, J 
= 9.0 Hz, H-4), 4.87 (2H, t, J = 5.5 Hz, H-1ʼ), 4.46 (2H, t, J = 6.0 Hz, H-2ʼ); 13C NMR (100MHz, 
CDCl3) δ; 42.8 (C-2ʼ), 46.0 (C-1ʼ), 107.8 (C-4), 114.2 (C-7), 118.8 (C-5), 120.2 (ArC), 120.6 
(ArC), 122.2 (ArC), 123.2 (C-5ʼʼ), 126.6 (ArCH), 128.4 (ArCH), 129.5 (ArCH), 129.8 (ArC), 
132.3 (ArCH), 137.6 (ArC), 142.8 (Ar(OCF3)), 144.7 (ArC), 159.8 (ArC); MS m/z [M+H]
+ 
C18H14BrF3N5OS requires 484.01, found 484.00. 
 
Methyl 4-(1-(2-(2-imino-6-(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-
yl)benzoate 160aw 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.14 g, 0.45 mmol, 1.0 
equiv.) and methyl-4-ethynylbenzoate (0.11 g, 0.67 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 0.9 mL freshly prepared 
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1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield methyl 4-(1-(2-(2-imino-6-
(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)benzoate (160aw, 0.12 g, 0.26 
mmol, 59 %) as an off white solid; Rf 0.19 (100 % EtOAc), m.p. 196 - 199 °C 
 
IR νmax/cm
-1 3276, 3099, 2955, 1721, 1604, 1582, 1485, 1366, 1261; 1H NMR (400MHz, 
CDCl3) δ; 8.05 (2H, d, J = 8.5 Hz, ArH), 7.74 (2H, d, J = 8.5 Hz, ArH), 7.71 (1H, s, H-5ʼ), 7.10 
(2H, d, J = 1.5 Hz, H-7ʼʼʼ and NH), 6.94 (1H, d, J = 8.5 Hz, H-5ʼʼʼ), 6.55 (1H, d, J = 9.0 Hz, H-
4ʼʼʼ), 4.84 (2H, t, J = 6.0 Hz, H-1ʼʼ), 4.48 (2H, t, J = 6.0 Hz, H-2ʼʼ), 3.93 (3H, s, H-3ʼʼʼʼ); 13C NMR 
(100MHz, CDCl3) δ; 43.5 (C-2ʼʼ), 47.0 (C-1ʼʼ), 52.2 (C-3ʼʼʼʼ), 109.0 (C-4ʼʼʼ), 115.3 (C-7ʼʼʼ), 119.1 
(ArC), 120.0 (C-5ʼʼʼ), 121.7 (C-5ʼ), 123.3 (ArC), 125.5 (ArCH), 129.7 (ArC), 130.2 (ArCH), 
134.4 (ArC), 138.5 (ArC), 143.9 (Ar(OCF3)), 147.1 (ArC), 161.0 (ArC), 166.7 (ArC); MS m/z 
[M+H]+ C20H17F3N5O3S requires 464.10, found 464.10. 
 
4-(1-(2-(2-Imino-6-(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)benzoic 
acid 160ax 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.53 mmol, 1.0 
equiv.) and 4-ethynylbenzoic acid (0.12 g, 0.79 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 
mL THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  Once washed with brine a 
precipitate formed.  This was filtered to yield 4-(1-(2-(2-imino-6-
(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)benzoic acid (160ax, 0.14 g, 0.31 
mmol, 59 %) as an off-white solid; m.p. 380 - 384 °C 
 
IR νmax/cm
-1 3238, 2974, 1585, 1484, 1262; 1H NMR (500MHz, MeOD) δ; 8.32 (1H, s, H-5ʼ), 
8.00 (2H, d, J = 10.0 Hz, ArH), 7.71 (2H, d, J = 5.0 Hz, ArH), 7.33 (1H, s, H-7ʼʼʼ), 6.99 (1H, d, 
J = 10.0 Hz, H-5ʼʼʼ), 6.77 (1H, d, J = 10.0 Hz, H-4ʼʼʼ), 4.88 (2H, t, J = 5.0 Hz, H-1ʼʼ), 4.52 (2H, t, 
J = 5.0 Hz, H-2ʼʼ); 13C NMR (125MHz, MeOD) δ; 42.7 (C-2ʼʼ), 46.7 (C-1ʼʼ), 109.2 (C-4ʼʼʼ), 115.1 
(C-7ʼʼʼ), 119.1 (C-5ʼʼʼ), 119.6 (ArC), 122.3 (C-5ʼ), 123.9 (ArC), 124.6 (ArCH), 129.6 (ArCH), 
132.0 (ArC), 138.7 (Ar(OCF3)), 143.7 (ArC), 147.4 (ArC), 157.9 (ArC), 162.3 (ArC), 173.0 
(ArC); MS m/z [M+H]+ C19H15F3N5O3S requires 450.09, found 450.08. 
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4-(1-(2-(2-Imino-6-(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)-N,N-
dimethylaniline 160ay 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.67 mmol, 1.0 
equiv.) and 4-ethynyl-N,N-dimethylaniline (0.15 g, 1.01 mmol, 1.5 equiv.) in 10.0 mL H2O and 
10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly prepared 
1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the 
crude was column purified using 100 % EtOAc to yield 4-(1-(2-(2-imino-6-
(trifluoromethoxy)benzothiazol-3-yl)ethyl)-1,2,3-triazol-4-yl)-N,N-dimethylaniline (160ay, 0.17 
g, 0.39 mmol, 58 %) as a pale yellow solid; Rf 0.17 (100 % EtOAc), m.p. 214 - 217 °C 
 
IR νmax/cm
-1 3246, 3014, 2945, 1614, 1584, 1483, 1352, 1251; 1H NMR (400MHz, CDCl3) δ; 
7.53 (2H, d, J = 9.0 Hz, ArH), 7.49 (1H, s, H-5ʼ), 7.09 (2H, d, J = 1.5 Hz, H-7ʼʼʼ and NH), 6.94 
(1H, d, J = 9.0 Hz, H-5ʼʼʼ), 6.72 (2H, d, J = 9.0 Hz, ArH), 6.55 (1H, d, J = 9.0 Hz, H-4ʼʼʼ), 4.80 
(2H, t, J = 6.0 Hz, H-1ʼʼ), 4.45 (2H, t, J = 6.0 Hz, H-2ʼʼ), 2.99 (6H, s, ArN(CH3)2); 
13
C NMR 
(100MHz, CDCl3) δ; 40.4 (ArN(CH3)2), 43.6 (C-2ʼʼ), 46.8 (C-1ʼʼ), 109.1 (C-4ʼʼʼ), 112.4 (ArCH), 
115.2 (C-7ʼʼʼ), 118.4 (ArC), 119.3 (C-5ʼ), 119.8 (C-5ʼʼʼ), 121.7 (ArC), 123.2 (ArC), 126.7 
(ArCH), 138.6 (ArC), 143.8 (Ar(OCF3)), 148.7 (ArC), 150.5 (ArC), 160.9 (ArC); MS m/z [M+H]
+ 
C20H20F3N6OS requires 449.14, found 449.14. 
 
3-(2-(4-(1-Methyl-1H-imidazol-5-yl)-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine 160az 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.20 g, 0.66 mmol, 1.0 
equiv.) and 5-ethynyl-1-methyl-1H-imidazole (0.1 mL, 0.99 mmol, 1.5 equiv.) in 10.0 mL H2O 
and 10.0 mL THF heated to 20 °C was added 0.7 mL 1M CuSO4 (aq) and 1.3 mL freshly 
prepared 1M sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-
up the crude was column purified using 9:1 DCM:MeOH to yield 3-(2-(4-(1-methyl-1H-
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imidazol-5-yl)-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine (160az, 0.18 g, 
0.44 mmol, 67 %) as an off white solid; Rf 0.52 (9:1 DCM:MeOH), m.p. 220 - 225 °C 
  
IR νmax/cm
-1 3161, 2958, 1626, 1585, 1484, 1386, 1267; 1H NMR (400MHz, CDCl3) δ; 7.52 
(1H, s, H-5ʼʼ), 7.48 (1H, bs, H-2ʼʼʼ), 7.11 (1H, d, J =1.5 Hz, H-7), 7.06 (1H, bs, H-5ʼʼʼ), 6.94 (1H, 
dd, J = 1.5 Hz and 9.0 Hz, H-5), 6.51 (1H, d, J = 9.0 Hz, H-4), 4.84 (2H, t, J = 5.5 Hz, H-1ʼ), 
4.47 (2H, t, J = 6.0 Hz, H-2ʼ), 3.73 (3H, s, N(CH3)); 
13
C NMR (100MHz, CDCl3) δ; 32.2 
(N(CH3)), 42.5 (C-2ʼ), 45.8 (C-1ʼ), 107.7 (C-4), 114.3 (C-7), 118.1 (ArC), 118.6 (C-5), 120.7 
(ArC), 121.4 (C-5ʼʼ), 122.4 (ArC), 123.2 (ArC), 129.1 (C-5ʼʼʼ), 137.5 (C-2ʼʼʼ), 137.6 (ArC), 142.8 
(Ar(OCF3)), 159.6 (ArC); MS m/z [M+H]
+ C16H15F3N7OS requires 410.10, found 410.10. 
 
3-(2-(4-Isobutyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160ba 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.14 g, 0.48 mmol, 1.0 
equiv.) and 4-methyl-1-pentyne (0.1 mL, 0.72 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL 
THF heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.0 mL freshly prepared 1M 
sodium ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude 
was column purified using 100 % EtOAc to yield 3-(2-(4-isobutyl-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160ba, 0.18 g, 0.47 mmol, 98 %) as an off-white 
solid; Rf 0.19 (100 % EtOAc), m.p. 165 -170 °C 
 
IR νmax/cm
-1 3237, 3065, 2955, 1580, 1485, 1383, 1263; 1H NMR (400MHz, CDCl3) δ; 7.07 
(3H, bs, H-7, H-5ʼʼ and NH), 6.91 (1H, dd, J = 1.5 Hz and 9.0 Hz, H-5), 6.38 (1H, d, J = 9.0 
Hz, H-4), 4.76 (2H, t, J = 5.5 Hz, H-1ʼ), 4.40 (2H, t, J = 6.0 Hz, H-2ʼ), 2.42 (2H, d, J = 6.0 Hz, 
H-1ʼʼʼ), 1.70 (1H, sept, J = 6.5 Hz, H-2ʼʼʼ), 0.72 (6H, d, J = 6.5 Hz, H-3ʼʼʼ and H-1ʼʼʼʼ); 13C NMR 
(100MHz, CDCl3) δ; 20.9 (C-1ʼʼʼʼ and C-3ʼʼʼ), 27.5 (C-2ʼʼʼ), 33.4 (C-1ʼʼʼ), 42.9 (C-2ʼ), 45.7 (C-1ʼ), 
107.9 (C-4), 114.1 (C-7), 118.8 (C-5), 120.7 (ArC), 121.4 (C-5ʼʼ), 122.1 (ArC), 137.7 (ArC), 
142.7 (Ar(OCF3)), 146.4 (ArC), 159.7 (ArC); MS m/z [M+H]
+ C16H18F3N5OS requires 386.13, 
found 386.13. 
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3-(2-(4-Propyl-1,2,3-triazol-1-yl)ethyl)-6-(trifluoromethoxy)benzothiazol-2-imine 160bb 
 
Using the general procedure; to a solution of ring-cyclised azide 223 (0.16 g, 0.53 mmol, 1.0 
equiv.) and 1-pentyne (0.1 mL, 0.79 mmol, 1.5 equiv.) in 10.0 mL H2O and 10.0 mL THF 
heated to 20 °C was added 0.5 mL 1M CuSO4 (aq) and 1.1 mL freshly prepared 1M sodium 
ascorbate (aq) dropwise.  This was stirred at 20 °C for 2 h.  After work-up the crude was 
column purified using 100 % EtOAc to yield 3-(2-(4-propyl-1,2,3-triazol-1-yl)ethyl)-6-
(trifluoromethoxy)benzothiazol-2-imine (160bb, 0.09 g, 0.23 mmol, 44 %) as a pale yellow 
solid; Rf 0.14 (100 % EtOAc), m.p. 134 - 138 °C 
 
IR νmax/cm
-1 3334, 3072, 2961, 1602, 1580, 1484, 1383, 1257; 1H NMR (400MHz, CDCl3) δ; 
7.09 (2H, d, J = 1.5 Hz, H-7 and NH), 7.06 (1H, s, H-5ʼʼ), 6.92 (1H, dd, J = 1.5 Hz and 9.0 Hz, 
H-5), 6.35 (1H, d, J = 9.0 Hz, H-4), 4.74 (2H, t, J = 5.5 Hz, H-1ʼ), 4.39 (2H, t, J = 6.0 Hz, H-2ʼ), 
2.52 (2H, t, J = 7.5 Hz, H-1ʼʼʼ), 1.44 (2H, sext, J = 7.5 Hz, H-2ʼʼʼ), 0.78 (3H, t, J = 7.5 Hz, H-
3ʼʼʼ); 13C NMR (100MHz, CDCl3) δ; 12.4 (C-3ʼʼʼ), 21.6 (C-2ʼʼʼ), 26.3 (C-1ʼʼʼ), 42.9 (C-2ʼ), 45.7 (C-
1ʼ), 107.8 (C-4), 114.1 (C-7), 118.8 (C-5), 120.7 (ArC), 120.9 (C-5ʼʼ), 122.0 (ArC), 137.7 (ArC), 
142.7 (Ar(OCF3)), 147.5 (ArC), 159.7 (ArC); MS m/z [M+H]
+ C15H16F3N5OS requires 372.11, 
found 372.11. 
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